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ABSTRACT 
The role of dendritic cells (DCs) in directing the immune response as they are a 
source of cytokines which can promote T cell survival and T helper cell 
differentiation..While it has become evident that soluble-N-ethylmaleimide-
sensitive-factor accessory-protein receptors (SNARE) are involved in membrane 
fusion and ultimately cytokine release, little is known about which members of this 
family facilitate the secretion of specific cytokines from DCs. The importance of 
research into SNAREs was highlighted by the 2013 Nobel Prize for Physiology and 
Medicine to the researchers involved in discovery of these essential proteins.  
We established a cell model of cytokine and chemokine secretion from DCs using 
the cell line JAWSII DCs and primary bone marrow-derived DCs (BMDCs) which 
were stimulated with a panel of TLR ligands that we correlated with differential 
SNAREs expression. We also examined SNARE expression, in vivo, in two models 
of experimental colitis was examined and we identified two candidate SNAREs, 
STX3 and STX11, to investigate further.  
 
We showed that STX3 mRNA levels correlated with IL-6 and MIP-1α release from 
JAWSII DCs.  Abolishment of STX3 from DCs, by two separate means, RNAi and a 
neutralising antibody, resulted in attenuation of IL-6 levels and to some extent MIP-
1α levels. Analysis of subcellular location showed translocation of STX3 to the cell 
membrane only in DCs secreting IL-6 or MIP-1α, indicating a role for it in 
trafficking of these immune mediators. We also investigated the role of STX11 using 
DCs from STX11 deficient mice. These cells portrayed a more mature phenotype 
compared with wildtype (WT) BMDCs, with increased production of the IL-12 
family of cytokines, increased expression of co-stimulatory surface markers and 
reduced levels of CD11c in unstimulated cells. We established that this phenotype 
was due to uncontrolled production of IFN-γ, a known DC maturation stimulus, and 
identified STX11 as a regulator of IFN-γ secretion. These findings may lead to a 
better understanding of the pathogenesis of the autosomal recessive disorder of 
immune dysregulation, familial hemophagocyticlymphohistiocytosis type-4 (FHL-
4), which is characterised by over production of cytokines and higher number of 
activated lymphocytes due to STX11 deficiency.  
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1.0 THE IMMUNE SYSTEM 
The immune system is composed of a network of lymphoid organs, cells, humoral 
factors and cytokines which can be divided into the innate and the adaptive immune 
response. The innate, how we sense infection and the adaptive, how we eradicate 
infection. Although separate, these “arms” of the immune system act 
interdependently.  
 
1.1 OVERVIEW OF INNATE AND ADAPTIVE IMMUNITY 
The innate immune response is our first line of defence against pathogens. It is a 
non-specific response and does not give long lasting immunity. It includes physical, 
chemical and microbiological barriers and also provides immediate host defence by 
way of neutrophils, monocytes, macrophages, complement, cytokines and acute 
phase proteins. It is a rapid but non specific response and can sometimes cause tissue 
damage as a result. It is a highly conserved response and can be seen in the simplest 
of animals confirming its importance for host survival (Parkin and Cohen 2001).  
 
The adaptive immune system is controlled and assisted by the innate immune system 
.It is a characteristic of higher animals and is extremely specific and precise and  can 
take several days to weeks to mount a response. This response is mediated by 
antigen-specific lymphocytes, in particular, T cells which express a vast array of 
recombinant receptors. These receptors are capable of recognising every pathogen 
that a host may encounter. Cells with the appropriate receptor required for the 
scenario, proliferate, in a process called clonal expansion or are eliminated to induce 
tolerance through the process called clonal elimination (Kimbrell and Beutler 2001). 
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1.2 LINKING THE INNATE AND ADAPTIVE: THE DENDRITIC 
CELL 
Dendritic cells (DCs), were first described by Ralph Steinman and Zanvil Cohn, as a 
rare murine spleen cell which had dendrite like protrusions with phagocytic ability 
(Steinman and Cohn 1973). Since then, technological advances have progressed 
cellular immunology research, coupled with the fact that dendritic cells can now be 
readily obtained in sufficient quantities, has allowed the role of DCs in immunity to 
be understood.  
DCs are cells of the hematopoietic immune system and are referred to as immature 
cells before they undergo maturation. Immature DCs, present in the peripheral 
tissues, are characterised by a high capacity for antigen capture and processing by 
phagocytosis, chemokine receptor expression, chemokine responsiveness and low T 
cell stimulatory capability (Banchereau and Steinman 1998b).  
The ability of DCs to regulate immunity is dependant on DC maturation. During 
maturation, which is induced by the interaction of a variety of factors such as 
pathogens, which are converted into immunogens and subsequently presented to T 
cells, DCs express molecules such as cytokines, chemokines and co-stimulatory 
molecules.  
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1.3 ENGAGEMENT OF PATHOGEN RECOGNITION RECEPTORS 
(PRRS) IN DCS IS A CRITICAL STEP IN THE INDUCTION OF THE 
ADAPTIVE IMMUNE RESPONSE. 
Cells of the innate immune system, in particular DCs, are activated when pathogen-
associated molecular patterns (PAMPs) or endogenous damage-associated molecular 
patterns (DAMPs) engage pattern recognition receptors (PPRs). These PPRs can be 
divided into Toll-like receptors (TLRs), nucleotide-binding domain and leucine-rich 
repeat containing receptors (NLRs) and retinoic acid-inducible gene-I (RIG)-like 
receptors (RLRs) (Creagh and O'Neill 2006). Once these PRRs are engaged, it 
results in the activation of signalling cascades that induce the production of pro-
inflammatory cytokines. These signalling cascades include nuclear factor Κ-light-
chain-enhancer of activated B cells (NFκB), interferon (IFN) response factors 
(IRFs), activator protein-1 (AP-1) and mitogen-activated protein kinases (MAPK) 
(Rakoff-Nahoum et al. 2004). 
1.3.1 Toll-like Receptors (TLRs) 
Toll-like receptors (TLRs) have emerged over the past decade as the crucial sensors 
of PAMPs from microorganisms or DAMPs from damaged tissue. The TLR family 
consists of at least 10 members in human and 13 in mice (Kawai and Akira 2006). 
TLR proteins are type 1 transmembrane receptors that are composed of a ligand 
binding domain of leucine rich repeats and a signalling Toll-IL-1 receptor (TIR) 
domain that interacts with TIR domain containing adaptor molecules, of which there 
are five: myeloid differentiation primary response 88 (MyD88), MyD88-adaptor-like 
(Mal), TIR-domain-containing adaptor-inducing interferon-β (TRIF), TRIF-related 
adaptor molecule (TRAM) and sterile-α and Armadillo motif containing protein 
(SARM) (McGettrick and O'Neill 2004). Engagement of these different adaptors is 
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dependent on the TLR utilising them and results in the induction of the 
aforementioned signalling cascades to ultimately produce pro-inflammatory 
mediators, cytokines and chemokines, see Figure 1.1 (Kenny and O'Neill 2008). 
 
1.3.2 TLR location – Critical to their Function 
The TLRs are located on the cell surface, recognise markers on the surface of 
pathogens. These include TLR1, 2, 4, 5 and 6, present of the surface of the 
cell,which recognise lipid structures and in the case of TLR5, the protein Flagellin. 
TLRs located within the cell are classed as endosomal. These include TLR3, 7, 8 and 
9 and reside intracellularly to be able to recognise nucleic acids derived from the 
genome of viruses and bacteria (Lavelle et al. 2010).  
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Figure 1.1: A detailed overview of the mammalian TLR signalling pathways. 
This includes the location of TLRs, surface or endosomal, the structure of the TIR 
domain containing the adaptor molecules which induce signalling cascades which 
ultimately produce pro-inflammatory mediators, cytokines and chemokines (O'Neill, 
Golenbock and Bowie 2013).  
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1.4 MATURE DCS – POTENT INDUCERS OF EFFECTOR T CELL 
RESPONSES 
 
Following PRR ligation and subsequent DC maturation, the DC becomes an antigen 
presenting cell (APC) that migrate to secondary lymphoid tissue selecting antigen-
specific lymphocytes to which they present the processed antigen initiating clonal 
immunity.  
 
1.4.1 Migration to Lymphoid Organs – A Role for Chemokines 
 
Migration to areas of inflammation and subsequently to lymphoid organs from the 
peripheral tissues is an important function of DCs. Essential components of 
migration are chemokines and their subsequent receptors. Immature DCs express 
chemokine receptors C-C chemokine receptor-1 (CCR1), CCR2, CCR5, CCR6 and 
CXCR1 and are attracted to inflamed areas by Macrophage Inflammatory Protein 
(MIP)-3α (Hartgers, Figdor and Adema 2000). Following maturation DCs lose 
responsiveness to MIP-3α and lose their cell surface expression of CCR1 CCR5 and 
CCR6 (Sallusto et al. 1999). The mature DC becomes responsive to chemokines 
such as MIP-3β and secondary lymphoid-tissue chemokine (SLC). SLC attracts DC 
and T cells which aids in their colocalisation (Chan et al. 1999). With the arrival of 
the DC at the lymphoid organs the mature DC primes a naive T cell to become an 
effector T cell. To do this three signals are required, antigen presentation, up-
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regulation of co-stimulatory markers and secretion of cytokines, Figure 1.2.  
 
 
 
Figure 1.2: Overview of the Three Signals Required to Polarise Naive T-Cells. 
Signal 1 is delivered by MHC/peptide complex stimulation of the TCR, signal 2 is 
the co-stimulatory surface expression on the APC and CD28 on the T cell and signal 
3 involves secretion of the cytokines that polarise T cells into the different T cell 
subsets (De Koker et al. 2011).  
 
1.4.2 Signal 1 - Antigen Presentation - MHC Class I and II 
 
DCs are potent T cell activators and this is related to the constitutive expression of 
both major histocompatibility complex (MHC) class I/II. To prime a naive T cell to 
become an effector T cell, T helper (Th) or a cytotoxic T lymphocyte (CTL), the 
antigen needs to be presented via the MHC molecule by the APC, to the cognate T-
cell receptor (TCR) (Ni and ONeill 1997). 
 
Antigen presentation via MHCI to Cluster of Differentiation 8 (CD8) T cells enables 
them to recognise and kill transformed and virally infected cells. The MHCI pathway 
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is present in almost all cell types. Peptides that have originated from proteins 
degraded in the cytosol by the proteasome which have been transported to the ER are 
loaded on the MHCI molecule (Villadangos and Schnorrer 2007). However MHCII 
presents antigen to CD4 T cells and is only present in professional APCs such as B-
cells, macrophages, basophils and DCs. MHCII presents peptides from endocytosed 
antigens also via the ER and transported to the cell surface (De Koker et al. 2011). 
 
 
1.4.3 Signal 2 – Co-Stimulation molecules CD80/CD86  
Surface molecules CD80 and CD86 on APCs, such as DCs, mediate co-stimulation 
through interaction with the CD28 receptor on T cells. Maturation of the DC results 
in up-regulation of these surface molecules and immature DCs generally have low 
expression, making them weak APCs. However, these immature DCs can undergo a 
functional maturation which induces migration to lymphoid organs, presentation of 
self antigen and expression of these co-stimulatory markers. Instead of an immune 
response, it results in important mechanisms of tolerance to self antigens by the 
means of T cell anergy, clonal deletion or development of immunosuppressive T 
regulatory (TREG) (Luckashenak et al. 2008).  
 
1.4.4 Signal 3 – Cytokine polarisation  
Cytokines are classified into interleukins (IL), colony-stimulating factors, interferons 
(IFNs). Different cytokines secreted from DCs can polarise the naïve T cells into 
different subsets of T cells. These differential cytokine secretion patterns are 
dependant on the PRR activation and as a result this shapes the Th response. 
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Subsequently certain pathogens have associated Th subsets in immune activation 
against them (Pulendran 2004). Secretion of IL-12 from DCs is triggered by 
generally by intracellular bacteria and viruses and drives T helper 1 (Th1) cell 
differentiation.  Following activation of the DC with a helminth, secretion of IL-4 is 
triggered which induces Th2 phenotype. IL-6 and IL-23 are associated with Th17 
differentiation following PRR recognition of bacteria and fungi and IL-10 secretion 
promotes TREG response, see Figure 1.3 (Mills 2011). 
 
 
Figure 1.3: TLR4 stimulation of a dendritic cell leads to cytokine production that 
promotes the activation of T-cells (Mills 2011). 
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1.5 CYTOKINES AND CHEMOKINES AS TARGETS IN 
INFLAMMATORY DISEASE 
Cytokines have been implicated in inflammatory diseases as critical mediators either 
though production and/or as maturation stimuli of cells such as DCs which then can 
become APCs which can select autoreactive lymphocytes (Blanco et al. 2008). This 
makes their secretion an attractive option to study to possibly target blocking their 
secretion in inflammatory diseases. The advantages of this include inhibition of the 
“critical cytokine” which is acting as a master regulator and so there is the possibility 
to switch off inflammation without any detrimental side effects (Macdonald 2011). 
For example, IL-23, a cytokine important for the development of Th17 polarisation, 
has been shown to be important in the pathogenesis of experimental autoimmune 
encephalitis (EAE), collagen-induced arthritis (CIA) and inflammatory bowel 
disease (IBD). This has been established through the inhibition of disease using IL-
23 knockout mouse models or subjecting wild-type mice to anti-IL-23 treatment 
(Cua et al. 2003, Murphy et al. 2003, Hue et al. 2006). Blockade of IL-6, another 
cytokine important in driving the Th17 subset, has been shown to be successful in 
autoimmune diseases and the use of a humanized anti-IL-6 receptor antibody in 
patients with RA and systemic-onset juvenile chronic arthritis (JCA) was 
demonstrated to have remarkable clinical effects (Yoshizaki 2009). These are just 
some of the numerous studies that demonstrate the benefits of blocking cytokines in 
disease and provide a solid rationale for us attempting to uncover which SNARE 
proteins control the secretion of such cytokines in DCs.  
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1.6 PROTEIN TRAFFICKING 
The presence of biochemically distinct intracellular compartments is an outstanding 
feature of eukaryotic cells. Membrane carriers, often vesicles, mediate trafficking 
between these compartments to and from the cell surface. Budding, target selection 
and fusion of these carriers require a large array of proteins (Stow and Murray 2013) 
 
 1.6.1 Cytokine Secretion 
While the functions of cytokines and chemokine are well documented, how these 
immune mediators are secreted is not as well understood. There are several secretory 
pathways reported in eukaryotic cells (Stow et al. 2009). Firstly newly synthesised 
protein precursors are loaded onto the endoplasmic reticulum (ER). They are then 
folded, checked for quality and glycosylated and loaded into vesicles for transport to 
the Golgi complex for post-translational processing and further glycosylation. The 
final step in the Golgi complex is the trans Golgi network (TGN) and beyond this the 
secretory pathways differ and diverge in their routes, vesicles and organelles 
(Farquhar and Palade 1998). These can be broadly divided into constitutive, 
regulated and unconventional. Constitutive secretion is present in nearly all cells, 
regulated secretion, is required in specialized cells to secrete a large dose of stored 
cytokine in response to a specific stimulus and unconventional, in which a number of 
immune mediators are synthesized in the cytoplasm, are released from the cell 
without passing through the ER and Golgi complex (Stow and Murray 2013). It 
seems that cytokines can employ any of these pathways for secretion across the 
various cells of the immune system. However how these cytokines are released 
through these secretion pathways is relatively unknown. We do know there is an 
integral family of proteins that are involved in this trafficking. These proteins are 
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called members of the soluble N-ethylmaleimide-sensitive-factor attachment protein 
receptor (SNARE) family (Hay 2001).   
 
1.7 SNARES 
Since SNAREs were identified almost two decades ago they have since been 
identified as key elements in membrane fusion. The significance of SNARE 
discovery was recognised in 2013 as the Nobel Prize was awarded to instrumental 
researchers in the trafficking field, James Rothman, Randy Schekman and Thomas 
Südhof.  
Their research has led to the characterisation of key elements and mechanisms of 
eukaryotic cell trafficking which in turn can contribute to many diseases, including 
those of the immune system. These researchers Nobel Prize winning work was 
ignited when Schekman discovered a set of genes involved in secretion in yeast and 
mammalian cells, while at the same time Rothman purified two soluble proteins with 
these that developed an in vitro trafficking assay which reconstituted efficient 
transport (Schekman and Orci 1996, Balchet al. 1984). These proteins were later 
identified to be N-ethylmaleimide sensitive factor (NSF) and an adaptor protein 
called soluble NSF attachment protein (SNAP), which act in many intracellular 
pathways (Block et al. 1988, Clary, Griff and Rothman 1990). Subsequently the NSF 
attachment protein receptor; SNARE hypothesis was born. Südhof identified key 
regulators of SNARE membrane fusion such as the mammalian uncoordinated 
(MUNC) protein, which enforce precise timing and coordination that is required to 
fuse membranes. This group also identified targets for SNARE inactivation in the 
form of bacterial toxins derived from tetanus and botulinum (Sudhof 1995).  
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1.7.1 SNARE Structure 
There are currently 38 identified members of the SNARE family. SNARE proteins 
have a simple structure, which is characterised by the presence of a SNARE motif 
approximately 60-70 amino acids in length, arranged in heptad repeats (Stow and 
Murray 2013, Weimbs et al. 1997). The SNARE motif is also found in all SNAREs 
and contains the crucial 16 residues and polar layer. Most SNAREs contain a single 
SNARE motif which is connected by a short linker to the transmembrane domain 
located at the C-terminal end. The SNARE N-terminal domain is not as conserved as 
SNARE motifs or C-terminals, however they provide variation which allows for 
distinction between subsets of SNAREs, see Figure 1.4. The SNARE family are 
classed into R-SNAREs (generally on vesicles) and Qa-, Qb-, Qc-, Qb,c- (usually at 
the target membrane). This classification is based on whether the central functional 
residue in the motif is arginine (R) or glutamine (Q) and sub-classification of Q-
SNAREs is based on where their SNARE domains would sit in an assembled trans-
SNARE complex (Jahn and Scheller 2006). 
 
 
Figure 1.4: The Domain Structure and Classification of SNAREs Proteins:The 
distinguishing feature of SNARE protein is the SNARE motif. However most also 
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contain a transmembrane domain and a N-terminal domain and are classified into R-
SNARES and Q-SNAREs according to whether the central functional residue in the 
motif is arginine (R) or glutamine (Q) [Taken with adaptations from (Jahn and 
Scheller 2006)].  
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1.7.2 SNARE Functions 
 
SNARE proteins are present on opposing membranes that drive fusion using the free 
energy which is released from the formation of a central coiled coil SNARE motifs. 
The crystal structure of this “coiled coil” SNARE complex was first solved by 
Sutton et al., who analysed a complex involved during the process of exocytosis. 
This was measured to a resolution of 2.4Å and from this discovered that the SNARE 
complex assumes a 4 α-helix bundle structure with a cylindrical shape. The complex 
is 120Å in length with a circular cross section with all four helices arranging 
themselves so that their C-termini are at the anchor end while the rest of the protein 
is available for a two-helix interaction. The high stability of these bonds within the 
SNARE complex makes them resistant to treatments with detergents such as Sodium 
dodecyl sulphate (SDS) (Sutton et al. 1998). Thus fusion of the two membranes 
generally requires four SNAREs, an R-SNARE, for example a vesicle associated 
membrane protein (VAMP), and three Q-SNAREs, such as Syntaxin (STX) or 
synaptosome-associated protein of 23 (SNAP-23). Firstly Q-SNAREs assemble with 
the aid of SM (Sec1/Munc18-related proteins) which R-SNAREs interact with 
through the N-terminal end of the SNARE motifs forming the four-helical trans-
complex. This results in a trans-SNARE complex, which forms to pull the vesicle 
and target membranes together. Once this has happened the trans complex converts 
to a cis complex allowing all the SNAREs associate in the same membrane allowing 
for transport of the contents from the vesicle, see Figure 1.5. Specialized chaperone 
machinery is in place for the disassembly of cis-SNARE complexes due to its 
extreme kinetic and thermodynamic stability. These chaperones, previously 
mentioned NSF and SNAP, utilise Adenosine Triphosphate (ATP) hydrolysis to 
dissemble cis-SNARE complexes releasing SNAREs for trans-SNARE complex 
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assembly and allowing recycling of these previously used SNAREs for another 
round of membrane fusion (Ungar and Hughson 2003).  
 
 
Figure 1.5 SNARE Mediated Fusion: This mechanism is identical in all cells but 
SNARE partners differ. Generally there are three Q-SNAREs on the acceptor 
membrane and one R-SNARE on the vesicle. Assembly of the acceptor complexes is 
composed by clusters of Q-SNAREs with the possible aid of SM proteins. R-
SNAREs interact with the acceptor complex through the N-terminal end of the 
SNARE motifs forming the four-helical trans-complex.  The transition from a loose 
trans-complex to a tight trans-complex is due to the “zippering” of just one N-
terminal portion of the SNARE motifs to where this is almost completed. When the 
strained trans-complex relaxes into a cis-complex, a fusion pore develops. 
Chaperone NSF and co-chaperone SNAP disassemble the cis-complex with the 
energy of ATP hydrolysis allowing for the recycling of SNAREs the have already 
performed a membrane fusion [Taken from (Jahn and Scheller 2006)].   
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1.8 SNARES AND THEIR ROLE IN DISEASE 
SNAREs have been implicated in many human diseases which have defective 
membrane fusion, such as familial hemophagocyticlymphohistiocytosis type-4 
(FHL-4), Hermansky-Pudlak syndrome, Griscelli syndrome, Chediak-Higashi 
syndrome and Early-onset mycocardial infarction (zur Stadt et al. 2005, Huizing, 
Anikster and Gahl 2000, Shirakawa et al. 2004, Tchernev et al. 2002, Shiffman et al. 
2006). Genetic mutations in SNARE proteins can result in these diseases and 
symptoms include high levels of pro-inflammatory cytokines in serum levels of 
patients (IFN-γ, IL-6, Tumour necrosis factor alpha (TNF-α)) or impaired leukocyte 
degranulation (Offenhaeuser et al. 2011, Stow, Manderson and Murray 2006b). 
Therefore it indicates the importance of regulation of SNAREs during immune 
activation. 
 
1.9 SNARES IN IMMUNE CELLS 
As the immune system is composed of a large quantity of cell types all with different 
specific functions, the mechanism of trafficking is extremely important for secretion 
of immune mediators, such as cytokines and chemokines.  
 
 1.9.1.NEUTROPHILS 
 
Neutrophils are critical cells of the innate immune system and make up the majority 
of circulating lymphocytes (40-80% in healthy individuals). Post their speedy 
recruitment to sites of inflammation; they exert protective or pathogenic effects 
depending on the inflammatory signal (Lacy 2006). Neutrophils store a wide range 
of immune mediators (including cytokines such as TNF-α and IL-12) and factors 
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(such as antimicrobial products) in pre-formed granules (Beil et al., 1995, Denkers et 
al., 2003). There are four different types of these granules: primary (azurophilic), 
secondary (specific), tertiary (gelatinase) and secretory vesicles with each granule 
having an associated set of SNARE proteins (Stow, Manderson and Murray 2006a). 
mRNA levels of STX1a, 3, 4, 5, 6, 7, 9, 11 and 16 have been identified byReverse 
transcription- polymerase chain reaction (RT-PCR) in human neutrophils and a 
neutrophil-differentiated cell line (HL-60). Subsequently STX4 was identified as a 
functional SNARE in two trans complexes, STX4-SNAP-23-VAMP-2 and STX4-
SNAP-23-VAMP-1, that are involved in the secretion of specific and gelatinase 
granules (Martin-Martin et al. 1999, Mollinedo et al. 2006). STX11 has been 
described to be highly expressed in human neutrophils, which is interesting given the 
role for STX11 in FHL-4 (Xie et al. 2009). Recently a role for STX11 has been 
indicated in activated neutrophils. Degranulation of activated neutrophils from 
STX11 deficient mice was impaired, indicating that STX11 controls neutrophil 
degranulation (D'Orlando et al. 2013).  
 
 1.9.1 MAST CELLS 
Like DCs, mast cells are also cells of the hematopoietic-immune system. They are 
critical effector cells in allergic disorders and when activated can secrete a large 
array of biologically active products, such as cytokines and chemokines that can 
facilitate in the development of the adaptive immune system (Galli et al. 2005). 
These inflammatory mediators are stored in secretory granules and secretory vesicles 
and their release is initiated by mast cell stimulation with IgE through the FcεRI 
receptor, through compound exocytosis. A cascade of granule-to granule fusion, 
commences with the primary fusion of a granule to the cell surface. This exocytosis 
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is mediated through R-SNAREs and Q-SNAREs present on the primary granule and 
cell membrane, but they are also present on the deeper lying granules within the cell 
to trigger secondary fusion of the granule-to-granule (Pickett and Edwardson 2006). 
Mast cells have been reported to express a large number of SNARE proteins, 
including SNAP-23, STX2, 3, 4, and 6 and VAMP2, 3, 4, 7 and 8, however SNARE 
functionality in these cells has only been somewhat explored (Lorentz et al. 2012). 
SNAREs were first indicated in mast cell degranulation in 1998, where SNAP-23 
was shown to be essential for exocytosis (Guo, Turner and Castle 1998). 
Subsequently STX4 was reported to have a role in degranulation. siRNA of STX4 
inhibited exocytosis and following stimulation with IgE, STX4 and SNAP23 were 
shown to localise at the mast cell membrane (Woska and Gillespie 2011, Wong et al. 
1998). These Q-SNAREs STX-4-SNAP23 complex with R-SNAREs VAMP2, 
VAMP3 and VAMP8 to form at least three trans-SNARE complexes (Puri et al. 
2003). In 2011, Frank et al, found that antibodies blocking STX3 and SNAP23 but 
not STX2 or VAMP3 inhibited release from all chemokines tested, although these Q-
SNAREs were previously indicated to form SNARE complexes with VAMP2, 
VAMP3 and VAMP8, it appeared that only VAMP8 was involved in the release of 
chemokines IL-8 (Frank et al. 2011). 
 1.9.2 NATURAL KILLER CELLS  
 
Natural Killer Cells (NK cells) are a cytotoxic lymphocyte which secrete cytolytic 
granules to kill virally infected or transformed cells and cytokines which have 
immunostimulatory effects, antimicrobial and antiviral effects (Hamerman, 
Ogasawara and Lanier 2005). The role of SNAREs has not yet been very well 
defined in these cells however SNAP23, STX4, STX6 and VAMP7 have all been 
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reported to be expressed at the mRNA level in a natural killer cell line and it has 
been elucidated that VAMP7 is essential for targeting cell killing (Marcet-Palacios et 
al. 2008). Recently STX11 has been implicated in the secretion of IFN-γ from NK 
cells, however more work is required to fully understand this (D'Orlando et al. 
2013).  
 1.9.3 MACROPHAGE 
 
TNF-α secretion from macrophage is one of the best researched and most understood 
pathways of cytokine secretion. These cells of the innate immune system are highly 
reliant on trafficking due to a large array of functions including sampling their 
environment and secretion of immune mediators, thus indicating a requirement for 
SNAREs to regulate this trafficking (Murray et al. 2005a). Resting macrophage, like 
most cells, sustain low levels of constitutive secretion to sustain “housekeeping” 
levels of protein transport. However upon macrophage activation cytokine secretion 
is up-regulated and subsequently so are SNARE proteins (Murray et al. 2005b). 
Stow and colleagues exploited these trends of up-regulation in the mRNA and/or 
protein levels of R- and Q- SNAREs following activation with Lipopolysaccharide 
(LPS) to correlate them with cytokine secretion. With this method they first 
identified STX4 as a regulator of TNF-α secretion which they confirmed by the cell-
surface localisation of STX4 and the ability of a mutant variant of STX4 to block 
TNF-α surface delivery and secretion. STX4 forms part of the Q SNARE complex 
with SNAP23 at the cell surface (Pagan et al. 2003). STX6-STX7-Vti1b Q-SNARE 
complex was also identified in this manner and facilitates transport of TNF from the 
trans-golgi-network (TGN) (Murray et al. 2005a).The R-SNARE required for fusion 
of these two Q-SNAREs was identified as VAMP3, which was present on the 
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recycling endosome (RE), which implies a possible role for a two step TNF secretion 
pathway (Murray et al. 2005b). The role of the RE in this secretion was later shown 
to be related to the membrane contribution from the RE to the plasma membrane to 
aid in phagocytosis and subsequently TNF-α secretion is linked to phagocytosis 
(Stow, Manderson and Murray 2006a). This pathway is overview in Figure 1.6.  
 
 
Figure 1.6-Overview of Macrophage SNARE-mediated pathway for TNF-α 
secretion: Newly synthesized TNF-α is transported from the Golgi complex in 
vesicles containing the Q-SNARE complex STX7–Vti1b–STX6. The vesicle then 
interacts with RE bearing the R-SNARE, VAMP3 which fuses the two vesicles 
together. The RE also contains the Q-SNARE complex STX4-SNAP23, which then 
translocates to the phagocytic cup. Interaction with VAMP3 results the membranes 
fusing and TNF-α being displayed on the cell surface. Once on the surface, TNF-α is 
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cleaved by TNF-converting enzyme (TACE) and released (Stow, Manderson and 
Murray 2006b).  
 
 
 1.9.4. Dendritic Cell 
As described in section 1.4, DCs are APCs that are capable of linking innate and 
adaptive immunity (Banchereau and Steinman 1998a). SNARE profiles in DCs are 
possibly one of the most neglected areas of SNARE research. VAMP8 has been 
reported to be involved in phagocytosis in dendritic cells. Over-expression of 
VAMP8 resulted in significant inhibition of phagocytosis and use of VAMP8
-/-
 DCs 
significantly increased phagocytic ability. This was a study on a SNARE protein 
reported to functionally inhibit phagocytosis from phagocytic cells (Ho et al. 2008). 
Cai et al., reported that SNARE expression of Vti1a, Vti1b, VAMP3, VAMP8 and 
STX8 in DCs are up-regulated in response to acetylsalicylic acid (ASA), the main 
ingredient in aspirin. This study stated that Vti1a and Vti1b localised to the 
phagosomes and that up-regulated expression of these SNAREs inhibited 
phagocytosis in DCs. As the cellular targets of aspirin are poorly understood this 
provides new insight to both immunopharmacology of aspirin and role of SNAREs 
in DCs (Cai et al. 2011).  
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1.10 PROJECT AIMS AND OBJECTIVES 
 
Although there are numerous reports of SNARE function in immune cells there are 
relatively few in DCs and none in DC secretion. This project aims to identify 
SNARE proteins involved in cytokine or chemokine secretion in these important 
immune cells. Our overall objectives were as follows: 
 
 To characterise BMDCs and JAWSII DCs in response to TLR stimulation, 
with respect to surface marker expression and cytokine/chemokine secretion 
and from this establish a cytokine/chemokine model of secretion from DCs  
 
 To assess if SNAREs have a role in vitro following TLR stimulation in DCs 
and in vivo in colitis models of disease and if so identify possible candidate 
SNAREs that play a role in DC  secretion 
 
 To determine the functional roles of SNAREs, STX3 and STX11 in DC 
secretion 
 
Defining the role of SNAREs in secretion of cytokines and chemokines provides a 
exciting new opportunity to target inflammatory mediators in disease even before 
they are secreted. 
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2.1 MATERIALS  
 2.1.1 Cell Culture Materials and Reagents 
 
TABLE 2.1: Tissue culture materials and reagents used including suppliers. 
 
Materials Source  
Tissue culture flasks 
T-25/T-75/T-175cm
2
 
Nunc
™ 
Sterile Petri Dishes Nunc
™
 
6, 24, 96-well tissue culture plates Nunc
™
 
96 round bottom plates Sarstedt 
Dimethyl sulphoxide (DMSO) Sigma
®
 
rGM-CSF Sigma
®
 
Trypan blue (0.4% v/v) Sigma
®
 
CellTiter 96
®
 Aqueous One Solution Pierce 
α-MEM Invitrogen
™
 
Foetal Bovine Serum (FBS) Invitrogen
™ 
Penicillin Streptomycin Invitrogen
™
 
Gentomycin Invitrogen
™
 
CpG Invitrogen
™
 
Flagellin Invitrogen
™
 
LPS (E.Coliserotype R515) Enzo Life Sciences 
PamC3S4 Invitrogen
™
 
PGN Invitrogen
™
 
Poly:IC Invitrogen
™
 
Zymosan Invitrogen
™
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2.1.2 Enzyme Linked ImmunoSorbent Assay Reagents 
 
TABLE 2.2: Materials and reagents used for ELISAs including suppliers. 
 
Materials Source 
96-well microtitre plate Nunc
™
 
3,3’,5,5’-tetramethyl-benzidine (TMB) BDOptEIA™ 
Tween
®
 20 Sigma
®
 
Bovine serum albumin (BSA) Sigma
®
 
DuoSet ELISA kits R&D Systems
®
 
1X PBS Invitrogen
™
 
  
 
2.1.3 Flow Cytometry Reagents 
 
TABLE 2.3: Antibody concentrations, suppliers and controls used for cell surface 
staining 
 
Antibody Fluorochrome Source Stock 
Concentration 
Isotype 
Control 
Working 
Concentration 
TLR4-MD-2 PE eBio 0.2mg/ml RatIgG2a κ 0.5 μg 
 
MHCII FITC BD 0.5mg/ml Rat IgG2a κ 0.5 μg 
CD80 PE BD 0.2mg/ml HamsterIgG κ 0.5 μg 
CD86 FITC BD 0.5mg/ml Rat IgG2aκ 0.5 μg 
CD40 PE BD 0.2mg/ml Rat IgG2aκ 0.5 μg 
CD14 FITC eBio 0.5mg/ml Rat IgG2aκ 0.5 μg 
CCR5 PE BD 0.2mg/ml Rat IgG2cκ 0.5 μg 
TLR2 FITC eBio 0.5mg/ml Rat IgG2aκ 0.5 μg 
CD11c APC BD 0.2mg/ml Hamster IgG1 0.5 μg 
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2.1.4 FACS Aria Reagents 
 
TABLE2.4: Reagents required for FACS Aria and corresponding suppliers 
Materials  Source 
FACS Clean BD 
FACS Flow BD 
FACS Rinse BD 
 
2.1.5 RNA Isolation and cDNA synthesis Reagents 
 
TABLE 2.6: Antibodies used for FACs analysis of cell surface markers; suppliers 
and concentrations used. 
 
Materials Source 
Nucleospin RNA II Columns Machinery Nagel 
2-Mercaptoethanol Sigma 
DEPC H2O Invitrogen 
High Capacity cDNA Reverse Transcription Kit Applied Biosciences 
 
2.1.6 Polymerase Reaction Chain Reaction Reagents 
 
TABLE 2.7: Reagents used for RT-PCR and qRT-PCR and corresponding supplier 
Material  Source 
GoTaq ® DNA polymerase Ladder Promega 
Fast Start Universal Sybr Green Roche 
MicroAmp Optical 96-well Plate Applied Biosystems 
MicroAmo Optical Adhesive Film  Applied Biosystems 
 
.
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2.1.7 Quantitative Reverse Transcriptase Polymerase Chain Primers 
TABLE 2.8: Primers used for PCR and their sequences. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Ref Seq ID Forward [5’ to 3’] Reverse [5’ to 3’] 
SNAP-23  NM_009222  GTTCTTGCTCAGGCTTCC CCAACCAACCAATACCAATAATG 
STX-2  NM_007941  GGTGGCAAAGGTGATGTT CAGGTATGGTCGGAGTCA 
STX-3 NM_001025307  CCACAACCACTAGCATCATAA CTCAAGAGATATTCCGCCTTAA 
STX-4  NM_009294  GGTGTCAAGTGTGAGAGAG AACCTCATCTTCATCGTCTG 
STX-5 NM_001167799.1 GCAAGTCCCTCTTTGATGAT TTCAGATTCTCAGTCCTCACT 
STX-6 NM_021433  CAAGGATTGTTTCAGAGATGGA CCTGACAATTTGCCGAGTA 
STX-7  NM_016797   CACAACGCATCTCCTCTAAC TAATCGGTCTTTCTGTATCTTTCTC 
STX-11 NM_001163591.1 ATCACGGCAAAATGAAGGA GGTCGGTCTCGAACACTA 
STX-12 NM_133887 CGCAAGAAGATGTGTATCCT CTCTGAGGCAAGCACTTC 
STX-16 NM_001102432.1   GAGCAGTACCAGAAGAAGAAC CAAGTCCTATCACCAATAATCCA 
Vti1a  NM_016862   GAATGTATAGCAACAGGATGAGA CCGTGTTATCCAGCAGATG 
Vti1b  NM_016862   TACCTTGGAGAACGAGCAT TGGACATTGAGCGAAGAATC 
VAMP-1  NM_001080557   CCCTCTGTTTGCTTTCTCA CGTTGTCTTCGGGTAGTG 
VAMP-2  NM_009497   CTCCTTCCCTTGGATTTAACC TGAAACAGACAGCGTATGC 
VAMP-3  NM_009498  TTGTTCTTGTTGTATATCACTCCTAA GGCTCGCTCTCACAGTAT 
VAMP-4  NM_016796  GTATGCCTCCCAAGTTCAAG TGTAGTTCATCCAGCCTCTC 
VAMP-7  NM_011515 GATGGAGACTCAAGCACAAG GACACAATGATATAGATGAACACAAT 
VAMP-8  NM_016794  GGCGAAGTTCTGCTTTGA CTTGACTCCCTCCACCTC 
Mip-1α/CCL3 NM_011337 CCTTGCTGTTCTTCTCTGTACC- CGATGAATTGGCGTGGAATC 
MIP-2/CXCL2 NM_009140 CAGAAGTCATAGCCACTCTCAAG CTTTCCAGGTCAGTTAGCCTT - 
MCP/CCL2 NM_011333 CATCCACGTGTTGGCTCA AACTACAGCTTCTTTGGGACA- 
TNF-α NM_013693 AGA CCCTCA CACTCA GAT CA TCT TTG AGATCC ATG CCGTTG 
IL-6 NM_031168 AGC CAG AGT CCT TCA GAG A TCC TTA GCC ACT CCT TCT GT 
IFN-γ NM_008337.3  ATGAACGCACACACTGCATC CCATCCTTTTGCCAGTTCCTC 
S18 NM_011296 CTGAGAAGTTCCAGCACATT GCTTTCCTCAACACCACAT 
2.1.8 Protein Purification Reagents 
 
TABLE 2.9: Reagents used for protein purification and corresponding suppliers. 
Material  Source 
Ammonium Persulphate (APS) Sigma® 
BCA Assay Pierce® 
Bis-Acrylamide 30% (w/v) Sigma® 
Complete Protease Inhibitor Roche 
Dithiothreitol (DTT) Sigma® 
Luminata HRP Solution Millipore 
N,N,N’,N’-Tetramethylethylenediamine (TEMED) Sigma® 
Nitrocellulose membranes, iBlot Invitrogen® 
PageRuler™Prestained Protein Ladder Plus Fermentas 
Complete Phosphatase Inhibitor Sigma® 
Potassium Chloride (KCl) Sigma® 
Potassium Phosphate (KH2PO4) Sigma® 
Propan-2-ol (isopropanol) VWR International Ltd. 
Protease Inhibitor Sigma® 
Re-Blot Plus Solution (10X) Millipore 
Sodium dodecylsulphate (SDS) Sigma® 
Sodium Phosphate Dibasic (Na2PHO) Sigma® 
Trizma Base Sigma® 
Tween ® 20 Sigma® 
 
 2.1.9 Antibodies used for Western and Immunofluorescence  
TABLE 2.10: Antibodies used for western blotting and immunofluorescence 
corresponding suppliers. 
Antibody Source  Species 
Anti –STX3 Abcam
®
 Rabbit 
Anti-β actin Sigma 
®
 Mouse 
 
2.1.10 Immunofluorescence Reagents 
TABLE 2.11: Reagents used for immunofluorescence and corresponding suppliers. 
Material  Source 
0.13-0.16mm Coverslips (RA 1.5) Harley and Davidson 
Paraformaldehyde  Fisher Scientific  
Ammunium Chloride Sigma 
Saponin Sigma 
Fish Gelatin Sigma  
SoduimAzide Sigma  
Propidium Iodide  Miltenyi Biotec 
DAKO Invivogen 
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2.1.11 Immunofluorescence Secondary antibodies 
 
TABLE 2.12: Reagents used for immunofluorescence straining and corresponding 
suppliers. 
Dye Absorption
 max. (nm) 
Emission 
max.(nm) 
Species Reactivity Isotype Source 
AlexaFluro 488 496 519 Donkey Anti-rat IgG Invivogen
®
 
AlexaFluro 488 496 519 Donkey Anti Goat IgG Invivogen
®
 
AlexaFluro 488 496 519 Donkey Anti Mouse IgG Invivogen
®
 
AlexaFluro 488 496 519 Donkey Anti Rabbit IgG Invivogen
®
 
AlexaFluro 546 556 573 Donkey Anti Mouse IgG Invivogen
®
 
AlexaFluro 546 556 573 Donkey Anti Rabbit IgG Invivogen
®
 
AlexaFluro 633 632 647 Donkey  Anti Goat IgG Invivogen
®
 
AlexaFluro 633 632 647 Goat Anti Rat IgG Invivogen
®
 
Strep Alexa 488 496 519 Goat Anti  Mouse IgG Invivogen
®
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2.2 METHODS 
 2.2.1 Stock Solutions and Buffers 
 
TABLE 2.13: Stock Solutions and recipes.  
Buffer Composition 
10 X Phosphate Buffered Saline (10 X PBS) 8 mM Na2HPO4, 1.5 M KH2PO4, 137 
mMNaCl, 2.7 mM KCL, pH 7.4 
PBS-Tween (PBS-T) 1 X PBS with 0.05% Tween
®
 20 
10 X Tris Buffered Saline (10 X TBS) 20 mM Trizma, 150 mM NaCl pH 7.2 – 
7.4 
TBS-Tween (TBS-T) 1 X TBS with 0.05% Tween
®
 20 
TAE Buffer (50X) 40mM Tris, 20mM acetic acid, 1mM 
EDTA pH 8.4 
 
 
2.3 CELL CULTURE TECHNIQUES 
 
All cell culturing techniques were carried out using aseptic technique in a class II 
laminar airflow unit (Holten 2010- ThermoElectron Corporation, USA). Cells were 
maintained in a 37
o
C incubator with 5% CO2 and 95% humidified air (Model 381 – 
ThermoElectron Corporation USA). Cells were cultured in α-Minimum Essential 
Medium (α-MEM) supplemented with 20% Non-heat inactivated fetal bovine serum 
(FBS), 100 μg/ml/100 μg/ml penicillin/streptomycin, 50 μg/ml gentamycin and 50 
μg/ml murine recombinant GMCSF and visualised with an inverted microscope 
(Olympus CKX31, Olympus Corporation, Toyko, Japan).   
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2.3.1 CELL ENUMERATION AND VIABILITY ASSESSMENT 
 
Counts and viability were assessed using a haemocytometer and trypan blue 
exclusion test. This test is based on the principle that viable cells with intact 
membranes are able to actively exclude the dye whereas dead cells are unable and 
appear blue when viewed under the microscope. A glass coverslip was mounted onto 
the moistened shoulders of a haemocytometer until the phenomenon of Newton’s 
rings was observed ensuring the coverslip had adhered and the depth of the chamber 
was correct. 100 μl of gentle agitated cell suspension was added to 150 μl of PBS 
and 250 μl of trypan blue solution (0.4% (v/v)). After ~2 minutes cells were gently 
applied to a Brightline™Neubauer haemocytometer (Sigma) and drawn out into the 
chamber by capillary action. Cells were counted under a 10X magnification using 
phase contrast microscope in one set of the 16 squares (equates to number of cells 
x10
4
/ml)[Figure 2.1], this was repeated four times and averaged. 
𝐶𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑚𝑙
= 𝑁  𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐶𝑒𝑙𝑙 𝑁𝑢𝑚𝑏𝑒𝑟 𝑥 5  𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑥 104 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡  
To assess cell viability, total cell number, (i.e. dead plus alive cells) is expressed as a 
fraction of alive cells as follows. 
% 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦
=  
𝑁 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑨𝒍𝒊𝒗𝒆 𝐶𝑒𝑙𝑙 𝑁𝑢𝑚𝑏𝑒𝑟 𝑥 5  𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑥 104(𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡)
𝑁 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑻𝒐𝒕𝒂𝒍 𝐶𝑒𝑙𝑙 𝑁𝑢𝑚𝑏𝑒𝑟 𝑥 5  𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑥 104(𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡)
 𝑥 100 
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FIGURE 2.1: Cell enumeration and viability assessment using the Neubauer 
haemocytometer. Inset indicating the 16 squares where viable (colourless) and non-
viable (blue stained) cells were counted. Cells touching the left or top boundary are 
counted however those that touch the lower or right hand boundary are not counted. 
[Adapted from 
http://www.cf.ac.uk/biosi/staffinfo/kille/Methods/Cellculture/HAEMO.html] 
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2.3.2 JAWS II DENDRITIC CELL LINE  
 
The murine dendritic cell line JAWS II (CRL-11904) was used extensively in this 
study and is referred to as JAWS II DCs throughout. The cell line was bought from 
ATCC and maintained in fully supplemented α-MEM [see Appendix] in T75cm2 
flasks. JAWS II DCs are an immature dendritic cell line derived from a p53 growth 
suppressor gene deficient C57BL/6 mice, which have been reported to be induced to 
become an activated dendritic cell line with the ability to stimulate T cells to 
proliferate (MacKay and Moore, 1997). JAWS II DCs are a mixed culture of 
attached and suspension cells thus for subculture, after seven days of growth, 
suspension cells were transferred to a 50ml falcon before adherent cells being 
washed with PBS and 0.25% trypsin-0.53mM EDTA being added. All cells were 
pooled, centrifuged at 1000 rpm for 10 minutes and subcultured at a 1:5 ratio and 
incubated at 37
o
C and 5% CO2.  
 
2.3.3 ISOLATION AND CULTURE OF BONE MARROW-
DERIVED DENDRITIC CELLS  
 
2.3.3.1 Day 1 – Bone Marrow Harvest 
 
Isolation of bone marrow-derived dendritic cells (BMDCs) was adapted from Lutz et 
al., 1999 (Lutz et al. 1999) Bone marrow was isolated aseptically from the tibiae and 
femurs of C57BL/6 mice (Charles River) aged 6-12 weeks which were housed in a 
Specific Pathogen Free (SPF) unit. This was done by flushing α-MEM through the 
cut bones using a 27.5g needle and syringe into a sterile 50ml falcon. Bone marrow, 
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still intact, was then gently broken up with a 19.5g needle and syringe. Cells were 
then centrifuged for five minutes at 1200 rpm, supernatant removed, pellet 
resuspended in α-MEM to allow for 1ml of cells per Petri dish required. To ensure 
an adequate number of viable cells had been harvested a cell count using the trypan 
blue exclusion method was performed. 9ml of α-MEM supplemented with 50 ng/ml 
rGMCSF and 1ml of cells were added to each Petri dish and incubated at 37
o
C and 
5% CO2.  
  2.3.3.2 Day 4 – Feeding Cells 
 
To visualise the monolayer of adherent cells, the Petri dish was tipped forward and 
using a transfer pipette ~6mls of media was gently removed without disturbing the 
cells. 10 mls of pre-warmed α-MEM with r-GMCSF was added to the Petri dish and 
incubated at 37
o
C and 5% CO2.  
  2.3.3.4 Day 7 – Counting and Plating Cells  
 
To remove the semi-adherent, i.e. the immature DCs, a transfer pipette with media 
was repeatedly pipetted onto the Petri dish surface before being collected in a 50ml 
falcon tube. Petri dishes were then examined under the microscope to ensure the 
majority of the cells were removed. Cells were centrifuged at 1200rpm for 5 
minutes, resuspended and counted using trypan blue exclusion method. The cell 
concentration was adjusted with α-MEM and generally cells were plated at 1x106/ml. 
2.3.4 Cryogenic Preservation of Cell Stocks 
 
To maintain reserves of cells, JAWS II DCs were cryogenically preserved in liquid 
nitrogen. JAWS II DCs were grown to a state of sub-confluency, counted and 
resuspended at 10x10
6cells/ml of complete α-MEM with 5% (v/v) DMSO. 1ml 
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aliquots were transferred to labelled and dated cryovials (Nalgene
®
) and placed in a 
Mr Frosty® in a -80
o
C freezer. Mr Frosty provides a 1
o
C/min cooling rate which is 
required for successful cryopreservation of cells. After three hours the cryovials were 
then transferred for storage to the liquid nitrogen vessel.  
 2.3.5 Revival of Frozen Stocks 
 
A cryovial was removed from liquid nitrogen, thawed rapidly (~2 minutes) by gentle 
agitation in a 37
o
C water bath. As soon as contents were thawed, the vial was 
sprayed with 70% ethanol and the contents were removed under aseptic conditions 
and transferred into 9 ml complete α-MEM. Cells were centrifuged for 5 minutes at 
1000rpm. The pellet was resuspended in 10 ml complete α-MEM and placed in a 
pre-warmed T25cm
2
 culture flask incubated at 37
o
C and 5% CO2.   
 2.3.6 Toll-Like Receptor Activation 
 
Cells were activated with TLR ligands outlined in the Table 2.14, and incubated for 
a period of time ranging from 1-24 hours before being used for the relevant 
experimental set up outlined.  
 
TABLE 2.14: Concentrations of TLR ligands used for the maturation of dendritic 
cells. 
TLR Ligand Stock Concentration Working Concentration 
2 PGN 200μg/ml 5μg/ml 
2/1 Pam3CSK4 1mg/ml 1μg/ml 
3 Poly IC HMW  1mg/ml 10μgml 
4 Rough LPS 1mg/ml 100ng/ml 
5 Flagellin 100μg/ml 5μg/ml 
7 Loxoribine 10mM 1mM 
9 CpG 500μM 2μM 
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 2.3.7 Cytotoxicity Assay 
 
To measure cytotoxicity a CellTiter 96
®
AQueousOne Solution Proliferation Assay 
(Promega) was employed. This reagent contains a novel tetrezolium compound [3-
4,5-dimethylthialzol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt; MTS] and an electron coupling reagent 
(phenazineethosulfate; PES). This is a colourimetric method for determining the 
number of viable cells in proliferation as the MTS is bioreduced by cells into a 
soluble coloured formazan product (figure 2.2). The quantity of formazan produced 
is measured at an absorbance of 490nm and is directly proportional to the number of 
living cells in culture.  
 
 
FIGURE2.2: MTS tetrazolium structure and its formazan product [adapted from 
http://worldwide.promega.com/resources/protocols/technical-bulletins/0/celltiter-96-
aqueous-one-solution-cell-proliferation-assay-system-protocol/]. 
JAWSII DCs were trypsinized, counted and plated at 0.1x10
6/100μl of complete α-
MEM in tissue culture treated 96-well plates and left to rest overnight. The following 
day cells were stimulated with TLR ligands (as outlined in section 2.3.6) for 24 
hours. A volume of 20μl of CellTiter 96®AQueousOne Solution was added to each 
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well, incubated for two hours at 37
o
C in 5% CO2 after which absorbance was read at 
490nm by plate reader. The cell viability of each sample was expressed as a 
percentage of the control cells (absorbance of control treated at 100%).  
2.4 ENZYME LINKED IMMUNOSORBANT ASSAY (ELISA) 
A sandwich ELISA can measure the amount of antigen, in this case cytokine or 
chemokine, between a capture and detection antibody, as indicated in figure 2.3. The 
antigen contains at least two antigenic sites for the capture and detection antibodies 
to bind to. Sandwich ELISAs offer higher sensitivity to that of direct or indirect 
ELISAs as samples do not have to be purified before analysis. 
 
 
FIGURE2.3: Illustration of the principles behind the sandwich ELISA [taken with 
adaptations fromhttp://www.epitomics.com]. 
 
An overview; using the ELISA Duoset from R&D Systems, a 96 well plate was 
coated with specific (to the target antigen) capture antibody diluted in buffer such as 
PBS. The plate was sealed and incubated overnight at RT. The following day 
blocking buffer such as 5% BSA/PBS was added to block any remaining protein 
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binding sites on the plate. A two-fold serial dilution of the top standard was 
prepared, along with the samples (containing unknown concentrations of antigen) 
were added to the plate and incubated overnight at 4
o
C to allow antigen to bind to the 
capture antibody. On day three the detection antibody specific to the target antigen, 
which is biotinylated, was added to the plate. Streptavidin-Horseradish peroxidase 
(HRP) was then added to the plate for 20 minutes at room temperature. Streptavidin 
binds to biotin with high affinity. The substrate 3, 3’, 5, 5’ - Tetramethylbenzidine 
(TMB) was added. HRP catalyzes TMB to form a coloured blue compound. The 
intensity of the blue colour formed is proportional to the concentration of antigen 
present in the sample or standard. The reaction was stopped with 2N H2SO4, which 
changes the blue colour to a yellow colour which was then read at 450nm on a 
spectrophotometer. 
 2.4.1 DETECTION OF CYTOKINES, IL-6, IL-10, TNF-ALPHA, 
IL-12P40, IL-12-70, IL-23 AND IL-27P28 
 
The cytokines IL-6, IL-10, TNF-α, IL-12p40, IL-12p70, IL-23 and IL-27p28 were 
quantified according to manufactures recommendations. 1% (w/v) BSA/PBS was 
used for blocking buffer and reagent diluent. Washing buffer consisted of 0.05% 
Tween-20 in PBS. 
2.4.2 DETECTION OF CYTOKINES, IL-1BETA AND IFN-
GAMMA   
The cytokines IL-1β and IFN-γ were quantified according to manufacturer’s 
recommendations. 1% (w/v) BSA/PBS was used for blocking buffer and 0.1% (w/v) 
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BSA/TBS +0.05% (v/v) Tween-20 was used for reagent diluent. Washing buffer 
consisted of 0.05% Tween-20 in PBS. 
  
2.4.3 DETECTION OF CHEMOKINES, MIP-1 AND MIP-2 
 
Cytokines MIP-1α and MIP-2 were quantified according to manufacturer’s 
recommendations. 1% (w/v) BSA/PBS was used for the blocking buffer and reagent 
diluent. Washing buffer consisted of 0.05% Tween-20 in PBS. 
 
2.5 FLOW CYTOMETRY  
 
Flow cytometry is a powerful technique for the analysis of multiple parameters of 
cells within a heterogeneous cell population. These include inherent cell 
characteristics such as size, shape, granularity and expression of cell surface markers 
and intracellular molecules. The flow cytometer does this by passing the cell 
suspension into a hydrodynamically focused, sheath fluid through a 100 μm nozzle, 
which allows one cells at a time past a laser light, see figure 2.4, (a). The light 
scattered and the fluorescence emitted (from positively stained cells) are read by 
detectors. The detector in front of the laser beam is called the Forward Scatter which 
determines cell size and the detectors to the side such as the Side Scatter determines 
the granularity. When a cell has been stained by a fluorochrome, it will emit light at 
a certain wavelength when excited by a laser at the corresponding excitation. The 
emitted light is detected by detectors called a photomultiplier tubes (PMTs) which 
convert the energy of a photon into an electrical signal called a voltage, see figure 
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2.4 b. Each voltage pulse equates to an “event” and 100,000 of these are recorded on 
average.  
 
 
FIGURE 2.4: (a) “single file” cells being passed through the nozzle (100 μm on the 
FACS Aria I) under hydrodynamic focusing into the path of the laser and (b) 
measurement of scattered light and fluorescence by PMTs. Take with amendments 
from http://www.abcam.com].  
A 
B 
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In order to investigate an antigen on the surface of a cell, the cell is incubated with a 
fluorescently labelled monoclonal antibody specific to the antigen of interest. These 
fluorochromes are excited by a laser and emit light at specific wavelengths. In this 
study we used three-colour polychromatic flow cytometery with Fluorescein 
isothiocyanate (FITC), excited at 495nm, emits at 520nm, Phycoerythrin (PE) 
465nm, emits at 578nm and Allophycocyanin(APC) excites at 635nm, emits at 
660nm the flurophores used through-out the study. See figure 2.5. 
 
 
Figure 2.5: Excitations, emissions, laser and bandpass filter used for FITC, PE and 
APC staining, taken with adaptations from (Baumgarth and Roederer 2000). 
2.5.1 CELL SURFACE STAINING 
 
Cells, either JAWS II DCs or BMDCs were trypsinized or scraped, counted and 
plated at 2 x 10
6
 cells per well on a six well plate, in a total of 2ml of media and left 
to rest overnight. Cells were then stimulated for the indicated period of time, 
generally 24 hours with an appropriate ligand (see section 2.3.6). Cells were then 
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scraped in media, transferred to a falcon tube with an equal amount of FCS, to block 
non specific binding, for 15 minutes. Following this, cells were centrifuged at 1200 
rpm for 5 minutes. The resulting pellet was resuspended in 1 ml of FACS buffer. 200 
μl of cells (~400,000 cells) were added per well of a 96-well round bottomed plate, 
spun at 1200 rpm for 5 minutes and stained with antibody (see Table 2.3) including 
separate wells for corresponding isotype matched controls. These plates were left in 
the dark at 4
o
C for 30 minutes, following which; cells were spun at 2000 rpm for 5 
minutes at 4
o
C and washed by being resuspended in 200 μl FACS buffer three times. 
Cells were then transferred to labelled FACS tubes and the volume was brought up 
to 500 μl with FACS buffer.  Samples were then acquired immediately on the Becton 
Dickinson (BD) FACSAria™ I Cell Sorter and analysed using FlowJo software 
(Tree Star) with cells gated on CD11
+
cells.  
 2.5.2 CELL VIABILITY 
 
To measure cell viability we employed the use of propidium iodide (PI), which 
serves as a dead cell indicator. It does this as PI is membrane impermeant, thus it 
does not enter viable cells with intact membranes. When cells are dead their 
membrane is compromised, PI can enter and intercalate with nucleic acids, see figure 
2.6. Fluorescence is then enhanced 20-30 fold, shifting its fluorescence excitation 
maximum ~30-40 nm to 535 nm and emission maximum is shifted ~15nm to 617nm.  
Cells were prepared as in 2.5.X, with two exceptions. Only antibodies that do not 
emit in the PI spectra were used for analysis of other surface markers in the 
incubation step and PI is added at the last step at a concentration of 1 μg/ml for 15 
minutes and read immediately. All FACS experiments included viability testing to 
ensure populations were comparable.  
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Figure 2.6: PI is a membrane impermeant that is generally excluded from viable 
cells. However when the membrane is compromised it binds to double stranded 
DNA by intercalating between base pairs, which is then excited at 488nm and emits 
at 617nm [Taken from http://www.rndsystems.com].  
 
2.6 QUANTITATIVE POLYMERASE CHAIN REACTION (QPCR) 
  
2.6.1  RNase Free Working Environment 
 
To ensure the quality of RNA, work was conducted in a ribonuclease (RNase) free 
environment. RNase is an enzyme that catalyzes the degradation of RNA into 
smaller compounds. They are found in both prokaryotes and eukaryokes. The human 
body uses RNases to defend against microorganisms hence they are present in flaked 
skin and hair that could fall into the bench destroying RNA samples. A dedicated 
RNase free bench was set up in the lab at which gloves were worn at all times and 
exchanged for fresh ones after touch any area outside of this. A dedicated set of 
pipettes were left in the RNase free area and only used with filter inserted RNase-
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free pipette tips. Diethylpyrocarbonate (DEPC) treated- H2O was used at all times as 
DEPC inactivates enzymatic activity of potential RNases in H2O.  
 2.6.2 RNA Isolation  
 
Cells, either JAWS II DCs or BMDCs were trypsinized or scraped, counted and 
plated at 2 x 10
6
 cells per well on a six well plate, in a total of 2ml and left to rest 
overnight. Cells were then stimulated with appropriate ligand with for the indicated 
period of time, between 1 and 12 hours with the appropriate ligand (see table 2.14). 
RNA was then extracted by NucleoSpin
®
RNA kit (Machiney Nagel) spin columns. 
Cells were lysed in a solution containing chaotropic ions, which inactive RNases and 
create appropriate binding conditions for absorption of the RNA to the silica 
membrane on the spin column. rDNase was added to the silica membrane to remove 
contaminating DNA which may also have bound. Two different buffers were used 
for washing steps which remove salts, metabolites and macromolecular cellular 
components. RNA was eluted under low ionic strength conditions with RNase free 
H2O. All RNA was stored at -80
o
C. 
 2.6.3 RNA Integrity Analysis and Quantification by Spectrometry 
 
The NanoDrop Spectrophotometer reads the absorbance spectra from 230nm to 600 
nm. As little as 1μl of sample, in this case nucleic acid, can give quantitative 
assessment and purity information. RNA should have a A260/A280 ratio of 2 (due to 
the absorbance of uracil to thymidine).  
Historically the A260/A280 ratio has been the primary measure of purity, however 
examining the entire absorbance spectra, including the A260/A230 can help you 
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identify problems such as contaminants. For example, phenol absorbance will lower 
the samples A260/A230 which should be around 1.8-2.2, see Figure 2.7. 
 
Figure 2.7:Readout from a Nanodrop and the corresponding ratios of pure RNA.  
 
2.6.4 RNA Integrity Analysis by Gel Electrophoresis 
 
To assess the integrity of the RNA, 1 μg of all RNA samples were made up in 
sample buffer containing formamide, heated to 65
o
C for 10 minutes and run on a 
denaturing agarose gel at 100V for 45 minutes. The gel was then visualised using the 
G-Box Gel Imagine System (Syngene). Intact total RNA will have two clear 
ribosomal RNA bands at 28S and 18S. The 28S rRNA band should be 2:1 the 
intensity as the 18S rRNA. This indicates the RNA is completely intact.  
 
2.6.5 Reverse Transcription (RT) – complementary DNA (cDNA) 
Synthesis 
 
cDNA was generated using the High Capacity cDNA Reverse Transcription kit 
(Applied Biosystems). In an RT reaction single-stranded RNA is reversely 
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transcribed into cDNA by using, in this case, total RNA, a reverse transcriptase 
enzyme, random primers, dNTPs and an RNase inhibitor. 1μg of mRNA was 
converted to cDNA as follows. 
 
TABLE 2.15: cDNA Reaction Components. 
Components Total 
10X RT Buffer 2μl 
10X Random Primers 2μl 
25X dNTP Mix (100mM) 0.8μl 
Reverse Transcriptase (50U/μl) 1μl 
Nuclease Free H20/RNA mix 14.2μl 
Total per reaction 20μl 
 
Samples were mixed and spun before being placed in a Thermocycler and set 
according to Table 2.16. cDNA was at -20
o
C until further use. 
 
TABLE 2.16:cDNA Cycling Settings. 
Steps Temperature Duration 
1 25
o
C 10 minutes 
2 37
o
C 120 minutes 
3 85
o
C 5 minutes 
4 4
o
C ∞ 
 
2.6.6 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
 
RT-PCR is a two step process, n the first step,RNA is transcribed into cDNA using a 
reverse transcriptase (“RT”) and this has been described in section 2.6.5. This cDNA 
is the template for subsequent PCR reactions using specific primers for one or more 
genes. Go-Taq
®
 Green (Promega) was used as the master mix and 500 ng of cDNA 
was amplified as outlined in Table 2.17 and PCR products run out on a 1% agarose 
gel and visualised then visualised using the G-Box Gel Imagine System (Syngene). 
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TABLE2.17: Constituents used for the 25μl RT-PCR reaction mixture. 
   
2X GoTaq
®
 Green Master Mix  12.5μl 
10μM Forward Primer 1μl 
10μM Reverse Primer 1μl 
H2O/cDNA Template 10.5μl 
 
Samples were mixed and spun before being placed in a Thermaoycler and amplified 
using the conditions as outlines in Table 2.18. 
TABLE 2.18: The conditions used for amplification of the cDNA. 
Steps Temperature Duration 
1 95
o
C 5 minutes 
2 95
o
C 15 seconds 
3 55-65
o
C 30 seconds 
4 72
o
C 15 seconds 
5 Steps 2-4 were repeated 60 times 
6 72
o
C 5 minutes 
7 4
o
C ∞ 
 
2.6.7 Temperature Gradients  
 
Primers (Sigma and IDT) were supplied with theoretical annealing temperatures. 
This temperature is generally calculated on the number of G’s, C’s, A’s and T’s in 
the primers sequence as follows;  
𝑇𝑚 = 4𝑜𝐶 𝑥 (𝑛𝑢𝑚𝑏𝑒𝑟𝑠 𝑎𝑛𝑑 𝐺’𝑠 𝑎𝑛𝑑 𝐶’𝑠 𝑖𝑛 𝑡𝑕𝑒 𝑝𝑟𝑖𝑚𝑒𝑟 𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒)
+ 2𝑜𝐶 𝑥 (𝑛𝑢𝑚𝑏𝑒𝑟𝑠 𝑜𝑓 𝐴’𝑠 𝑎𝑛𝑑 𝑇’𝑠 𝑖𝑛 𝑡𝑕𝑒 𝑝𝑟𝑖𝑚𝑒𝑟 𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒) 
As too low an annealing temperature can produce non-specific products and too high 
a temperature the PCR yield can be low product, annealing temperature optimisation 
was carried out. A thermacyler with a block gradient feature was used [Figure 2.8]. 
RT-PCR was performed as in section 2.6.6 with a temperature gradient between 55
o
c 
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and 65
o
C. PCR products run out on a 1% agarose gel and then visualised using the 
G-Box Gel Imagine System (Syngene) [See Appendix]. 
 
FIGURE2.8: Schematic representation of the thermacylcers temperature gradient 
across the 96-well block [taken from http://www.techne.com]. 
2.6.8 Primer Efficiency Curves 
 
To move on to quantitative PCR (qPCR) the assay efficiency had to be determined 
as it is critical to accurate data interpretation. A serial dilution of neat cDNA was 
generated; a standard curve plotting the log of the dilution factor against the Ct value 
obtained from the cDNA and the target of interest. The equation of the line was 
generated and the slope was used to calculate the efficiency based on the following 
equation;  
𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 = 10  
−1
𝑆𝑙𝑜𝑝𝑒
 − 1 
Ideally the efficiency of the assay should be 100%, indicating that PCR product is 
doubling during the logarithmic phase of the reaction. This means that the slope 
value would have to be -3.32, however slopes in the range of -3.60 to -3.10, equating 
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to efficiencies of 90% to 110% are considered acceptable. R
2
 value of the line was 
also taken into account and values of >0.950 were deemed acceptable.  
2.6.9 Quantitative Reverse Transcriptase Polymerase Chain Reaction 
(qRT-PCR) 
 
As all points of the PCR reaction were optimised qRT-PCR could then be carried 
out. The technology used for quantification. For this SYBR-Green based detection 
was employed. This method was chosen over probe-based detection as it is high 
throughput and we were taking a screening approach with the data. SYBR Green dye 
binds to double strained DNA produced during PCR reactions. SYBR Green has an 
excitation of 494 nm and emission maxima of 521 nm.   
An overview; in step one, denaturation, double-stranded DNA is heated to 94
o
C -
98
o
C, melting the DNA helix into two separate strands (step two). To anneal the 
single stranded DNA, step three, primers bind to the single stranded DNA template, 
the reaction is cooled to 45
o
C -65
o
C. Complimentary nucleotides, dATP, dCTP, 
dGTP and TTP are incorporated into the primed template with the aid of DNA 
polymerases. A slight raise in temperature during this extension cycle (65
o
C -75
o
C) 
as the optimal temperature of Taq DNA polymerase is 72
o
C, yields a double-
stranded DNA complex. As SYBR green is a double stranded DNA binding dye, it 
binds to newly synthesized double-stranded DNA helixes and fluoresces. The level 
of intensity of fluorescence of SYBR Green that is greater that background is 
measured and the amount of newly generated DNA strands is directly proportional to 
the amount of SYBR green fluorescence accumulated at the end of the PCR cycle. 
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FIGURE 2.9:Schematic representation of the steps involved inSYBR Green I based 
qPCR. Step 1&2 Denaturation; double-stranded complex denatures, target primers 
and complimentary nucleotides anneal with the aid of DNA polymerases resulting in 
Step 3; Extension of the new double-stranding DNA complex to which SYBR green 
binds and fluoresces [Taken with adaptions from http://www.sigmaaldrich.com]. 
 
TABLE 2.19: Constituents used for the 25μl qRT-PCR reaction mixture. 
Component  Total 
2X SYBR Green I
®
 Green Master Mix  12.5μl 
300nM Forward Primer 1μl 
300nM  Reverse Primer 1μl 
H2O/cDNA Template 10.5μl 
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TABLE 2.20: The conditions used for amplification of the cDNA in qRT-PCR. 
Steps Temperature Duration 
1 95
o
C 10 minutes 
2 95
o
C 15 seconds 
3 55-65
o
C 60 seconds 
4 72
o
C 15 seconds 
5 Steps 2-4 were repeated 50 times 
6 72
o
C 5 minutes 
7 4
o
C ∞ 
 
2.7 WESTERN BLOTTING  
2.7.1 Isolation of Whole cell Lysates 
 
JAWS II DCs were seeded at 1 x 10
6
 cell/ml in a 24-well plate and left overnight to 
rest. Cells were then transfected for 24 hours. Cells were washed with PBS and 
scraped in 200μl of NP-40 lysing buffer [see Appendix]. Protease and phophatase 
inhibitor cocktails were added just before use. Cells were scraped into pre-chilled 
tubes and inverted at 4ᴼC for 30 minutes. Lysates were then centrifuged at 12,000 x 
g for 10min at 4ºC and supernatants were transferred to new pre-chilled tubes. The 
protein concentration of the supernatants were then determined using the BCA assay 
and aliquots containing equal amounts of protein were mixed with 4X SDS sample 
buffer, boiled at 100ᴼC for 10 min and separated using SDS denaturing 
polyacrylamide gel electrophoresis. 
 
2.7.3 SDS Denaturing Polyacrylamide Gel Electrophoresis 
 
Sodium Dodecylsulphate-Polyacrylamide Electrophoresis (SDS-PAGE) resolution 
of protein lysates was carried out. Acrylamide gels (12 % (w/v)) [see Appendix] 
were cast between a pair of 10*100mm glass plates and affixed to the electrophoresis 
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unit using spring clamps. Running buffer [see Appendix] was added to the 
electrophoresis tank and 10μl (10μg) of protein lysate were loaded into the wells. A 
molecular weight protein ladder (Fermentas) ranging from 10-250kDa was added to 
lanes either side of the protein lysates. Gels were run at 30mA per gel for ~45 
minutes. 
2.74. Protein Transfer 
 
Transfer of the proteins from the gel onto a nitrocellulose membrane was done using 
the iBlot Dry Blotting System (Invitrogen™) [Figure 2.10]. The iBlot has a patented 
gel matrix technology that allows for transfer of the proteins from the gel onto the 
membrane in only seven minutes. It does this due to shortened distance between the 
electrodes, high field strength and high currents.  
 
 
FIGURE 2.10: Schematic of the transfer stack of the iBlot showing the flow of 
current which results in shortened transfer time. Taken from lifetechnologies.com. 
  
2.7.6 Immunoblotting and Detection 
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Post transfer, the membranes were incubated with 5 % (w/v) BSA/TBS-T for 1 hour 
on a rocker at RT to block non-specific protein binding. Membranes were then 
washed x 3 with TBS-T (wash buffer) for 5 minutes and incubated with the 
appropriate primary antibody in [see Table 2.1.8] 5 % (w/v) BSA/TBS-T overnight 
at 4
o
C. Following overnight incubation, membranes were washed three times for 5 
minutes in wash buffer. Membranes were then incubated with the appropriate Horse 
Radish Peroxidase (HRP)-conjugated secondary antibody [see Table 2.1.8] in 5% 
(w/v) BSA/TBS-T with gentle rocking at room temperature for 2 hours. The blots 
were then washed three times for 5 minutes in wash buffer. Luminata 
chemiluminescence substrate was then added to the membranes to detect HRP-
labelled antibody complexes. The intensity of signals was detected by the G-Box 
fluorescence gel analysis system (Syngene NJ USA) and exposed for a range of 
different times depending on the concentration of protein.  
 
2.8 INHIBITION OF INTRACELLULAR PROTEIN STX-3 
 
The STX-3 antibody [see Table 2.1.8] used in this study recognises the cytoplasmic 
NH2-terminal region required for SNARE binding. Bacterial-derived Streptolysin-O 
(SLO) toxin (Sigma) temporary permeablises cells to allow for delivery of the 
neutralising antibody which inhibits STX-3 activity.  
 
0.5x10
6
 JAWSII DCs were washed and resuspended with Hanks Balanced salt 
solution (HBSS) containing 30 mM HEPES. 20μg/ml Streptolysin-O (SLO) toxin 
and 20 μg/ml STX-3 antibody were added to the JAWS II DCs and were incubated 
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in a water bath for 15 minutes. Ice cold α-MEM was added (to allow pores in cells to 
close) for 1 hour on ice. Cells were centrifuged, resuspended in α-MEM and 
incubated for 4 hours at 37
o
C in 5% CO2. Supernatants were removed and analysed 
for the levels of IL-1β, IL-6, TNF-α and MIP-1α.  
 
2.9 RNAI 
RNAi is a biological process where gene expression is inhibited by RNA molecules 
which cause the destruction of specific mRNA molecules. We exploited this pathway 
to study the gene function of STX-3 in JAWS II DCs.  
 2.9.1 siRNA  
 
Small interfering (siRNAs) are a double-stranded RNA molecule, usually 20-25 base 
pairs in length. In this study we used a specific siRNA to STX-3 to interfere with the 
expression of this gene. We also used a scrambled RNA as a negative control and 
assessed transfection efficiency using fluorescently labelled Cy™3 labelled 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Invitrogen™) [See 
Appendix]. Genesilencer (Genelantis) is a cationic lipid formulation designed for 
delivery of siRNAs into cells.  
JAWSII DCs were plated at 1x 10
6
/ml on a 24-well plate and left to rest overnight. 
Genesilencer reagent and serum free media were added to one tube and siRNA 
diluent, specific siRNA (1nM) and serum free media were added to another tube and 
left to incubate at RT for 5 minutes. The two tubes were then mixed together and 
incubated for 10 minutes. This mixture was then added directly to the plate and left 
for 24 hours. Medium was then removed, replenished with fresh media and left 
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another 4 hours. Supernatants were removed and analysed for the levels of IL-1β, IL-
6, TNF-α and MIP-1α. 
 
2.10 IN VIVO MOUSE MODELS OF DISEASE 
 
2.10.1 DSS Model of Colitis  
 
In this model of colitis mice receive a chemical compound, dextran sulphate sodium 
(DSS) which, when given orally in the drinking water of mice, results in acute and 
chronic colitis resembling UC. During the acute phase, the mice develop colonic 
mucosal inflammation with ulcerations, loss to their body weight and bloody 
diarrhoea. In the chronic stages of disease the mice develop severe infiltration of 
mononuclear cells and regenerative changes in the epithelium (Melgar et al., 2005).  
 
The DSS colitis model was carried out in collaboration with Silvia Melgar in the 
Alimentary Pharmabiotic Centre, University College Cork. Isolation of the lamina 
propria, tissue sectioning and immunohistochemisty was performed by Maja Kristek 
and Dr Joseph DeCourcey.  
 
On arrival at the Biological Services Unit (BSU) at UCC 25 C57BL/6 female mice 
were weighed (18-20g). The mice were then split into one control group which 
contained 6 mice and 4 test groups with 6-8 mice. 3% DSS (Sigma) was prepared 
fresh daily and added to the drinking water of the mice for 5 days. Early acute, late 
acute and chronic mice were culled at 7, 12 and 26 days respectively post DSS 
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treatment for 5 days. Sections of the distal colon were homogenised and total RNA 
was extracted as described in Section 2.6.2. 
2.10.2 CITROBACTER RODENTIUM Model  
 
Citrobacter rodentium is a gram negative murine specific bacterium that causes a 
similar pathology in mice to that caused by enteropathogenic Escherichia coli in 
humans. This rare model offers the opportunity for understanding chronic 
inflammatory responses seen in genetically susceptible IBD patients following 
abnormal exposure to enteric bacteria of the intestinal mucosal immune system 
(Bhinder et al. 2013). 
 
The C. rodentium colitis model was also carried out in collaboration with Silvia 
Melgar in the Alimentary Pharmabiotic Centre, University College Cork. On arrival 
at the Biological Services Unit (BSU) at UCC 25 C57BL/6 female mice were 
divided into 5 groups of 6-8, one control and 4 infected groups. Mice were 
inoculated orally by a 200μl gavage of approximately 200x109 CFU C. rodentium. 
Mice were culled at 9, 14, 21 and 28 days post infection for tissue processing. Post 
removal and washing, colons were weighed and measured as an indication of gut 
inflammation. Sections of the distal colon were homogenised and total RNA was 
extracted as described in Section 2.6.2. 
 
2.11 IMMUNOFLUORESCENCE  
 
In order to investigate the sub-cellular location of STX-3 in JAWSII DCs we 
employed the use of confocal microscopy. Confocal microscopy has several 
advantages over conventional optical microscopy, including depth of field control, 
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elimination of out of focus light and collection of several optical sections to 
construct a 3-D image. Confocal microscopy is able to achieve this by its 
arrangement pinholes (at the source of the laser light and at the detection point) to 
exclude out of focus light not allowing it to reach the photomultiplier (PMT) detector 
[Figure 2.11].  
 
 
Figure2.11: Schematic representation of the components of a confocal microscope. 
[Taken from www.jic.ac.uk]. 
 
 2.11.1 Coverslips 
0.13-0.16 mm thick coverslips (Harly and Davidson) with a refractive index of 1.5 
were placed in 100%EtOH and sterilized through a Bunsen flame. These coverslips 
were then placed in a 6-well plate and exposed to Ultra-Violet (UV) light for 
30minutes. 0.5x10
5
 JAWSII DCs were added to the 6-well plate and left over-night 
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to adhere. Cells were then stimulated with the appropriate TLR ligand for 1 hour. 
Media was removed and coverslips were washed with 0.2 μM filtered PBS.  
 
 2.11.2 Fixation  
1 ml of 3% Paraformaldehyde (PAF) [See Appendix] was added to each well 
containing coverslips and left on ice for 20minutes. This reaction was then quenched 
with 50 mM Ammonium Chloride for 5 minutes. Cells were then permebilised with 
“perm-block” solution [See Appendix] for 20 minutes.  
 
2.11.3 Intracellular SNARE Staining 
The STX3 primary antibody was added to the coverslips and incubated overnight at 
4
o
C. Coverslips were then washed with perm-block solution 3 times and 
corresponding fluorescently conjugated secondary antibody [Table 2.12] was added 
to the coverslips and incubated for 1 hour at room temperature. Coverslips were then 
washed 3 times with perm-block and nucleus stained with PI for 10minutes. 
Coverslips were then washed again and DAKO (an anti-fading medium) was 
applied, coverslips inverted onto a slide, left at 4
o
C for 5 minutes and sealed with 
nail varnish to avoid drying out. Slides were then viewed using a Zeiss 710 confocal 
microscope and analysed using LSM software.  
 
2.12 STX11
-/-IN VITRO STUDY 
 
Wild Type (WT) and STX11
-/-
 mice on a C57BL/6 background were provided by 
Department of Immunology and Cell Biology, Research Centre Borstel, Germany in 
collaboration with Silvia Bulfone-Paus and Udo ZurStadt. Mice were used between 
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10-12 weeks old and maintained in specific pathogen-free conditions at University 
Medical Centre Hamburg Eppendorf animal facility. BMDCs were generated from 
WT and STX-11
-/-
 mice as previously described in section 2.3.2. Absence of STX-11 
gene from these mice was proven by RT-qPCR [See Appendix].  
 
2.13 STX11
-/-
 BMDC T-CELL CO-CULTURE  
2.13.1 Isolation of Splenocytes 
 
Spleens were removed aseptically from female C57BL/6 mice (Charles River) aged 
6-12 weeks which were housed in a Specific Pathogen Free (SPF) unit and collected 
in cRPMI [See Appendix] on ice. The spleens were pressed through a 40 μm cell 
strainer to achieve a single cell suspension.   
 
2.13.2 CD4+ T-Cell Magnetic Particle Isolation 
 
CD4
+
 T cells were isolated according to Stemcell technologies – Easysep© Mouse 
CD4
+
 T-cell isolation (19765) protocol. Splenocytes were prepared at a 
concentration of 1x10
6
 cells/ml and placed into a 5ml polystyrene falcon tube. 
50μl/ml of rat serum and 50μl/ml of antibody cocktail (Easysep™ mouse CD4+ T-
cell enrichment cocktail) was added to the splenocytes, mixed and left to incubate at 
RT for 10 minutes. This cocktail of antibodies target cell surface markers of all the 
cells excluding T-cells. To isolate CD4
+
 the antibody cocktail consisted of CD8, 
CD11b, CD11c, CD19, CD24, CD24, CD45r, CD49B, TCRγ/δ and TER119. 
Easysep™ streptavidin rapidspheres™ were vortexed for 30 seconds to ensure they 
were in a uniform suspension, added to the cell suspension at concentration of 75 
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μl/ml, mixed and left at RT for 2.5 minutes. The total cell suspension was mixed, 
brought up to 2.5 ml with cRPMI, capped and placed in the Easysep™ magnet for 
2.5 minutes at RT. In one sweeping motion the CD4
+
 T cells were poured off from 
the magnet and set aside for Section 2.13.3.  
 
 2.13.3 Proliferation Analysis using CFSE Dye 
 
To assess T-cell proliferation non-fluorescent 
carboxyfloresceindiacatatesuccinimidyl ester (CFDE-SE) was added to the T-cells. 
This compound contains acetate groups, which are highly permeable and toxic, 
however when it is added to cells it enters the cytoplasm of the cells and is highly 
stable. It loses the acetate groups and becomes the fluorescent molecule CFSE, 
which has an excitation at 494 nm and an emmision at 521 nm. When the cell 
divides, so does the CFSE fluorescence allowing proliferation to be monitored up to 
8 generations. CFSE-SE was added at a concentration of 5μM in a 5% FBS/PBS 
solution to buffer the toxic effects of the CD4
+
 T cells.  Cells were incubated for 5 
minutes, then washed twice with 5% FBS/PBS solution and resuspended in cRPMI. 
 
2.13.4 BMDC T-Cell Co-Culture 
 
CD4
+
 T-cells were isolated in section 2.13.2. STX11
-/-
 BMDCs were previously 
isolated [Section 2.12] from STX11 deficient mice which were obtained from Silvia 
Bulfone-Paus group in the Borstel Research Institute, Hamburg Germany. WT and 
STX11-/- BMDCs were stimulated with LPS (100 ng/ml) for 4 hours, washed and 
added to the CD4
+
 T-cells (CFSE stained, Section 2.13.3) at a 1:100 dilution 
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respectively onto a α-CD3 coated plate for 72 hours. Cells were scraped and 
analysed on FACS Aria while supernatants were removed and analysed for the levels 
of IFNγ, IL-2, IL-4 and TNF –α.  
 
2.14 STATISICAL ANALYSIS  
The parametric student’s T-test was used to determine significant differences 
between two samples. The level of statistical significance was indicated by *p≤0.05, 
**p≤0.01***p≤0.001. 
 
One-way analysis of variance (ANOVA) was used to determine significant 
differences between more than two samples. When this indicated significance 
(p≤0.05), post-hoc Student-Newmann-Keul test was used to determine which 
conditions were significantly different from each other. The level of statistical 
significance was indicated by *p≤0.05, **p≤0.01***p≤0.001. 
 
Parametric statistical test’s were used throughout this study. Sample size was not 
large enough to test distribution and thus it was assumed the data was normally 
distributed.  
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3.1 INTRODUCTION 
 
DCs are innate immune cells, originally identified by Steinman and Cohn which play 
a critical role in the initiation of the adaptive immune response (Steinman and Cohn 
1973). Maturation of DCs, which are antigen presenting cells, by immunogenic 
agents such as microbes, triggers an immune response. These microbes contain 
PAMPs which signal through a variety of PRRs, such as toll like receptors TLRs, 
allowing the DC to present antigen (Blanco et al. 2008). These DCs then activate T 
cells by presenting the processed antigen to naïve T cells in an immunogenic form. 
The subsquent activation of these naïve T cells not only requires antigen presentation 
but also the secretion of immune mediators called cytokines. Different cytokines 
polarise the naïve T cells into different subsets of T cells. IL-12 drives T helper 1 
(TH1) cell differentiation, IL-4 drives TH2 phenotype, IL-10 promotes a T regulatory 
(TREG) and IL-1, IL-6 and IL-23 are associated with TH17 differentiation (Mills 
2011). 
 
These cytokines and others have also been shown to play a role in the pathogenesis 
of many inflammatory and autoimmune diseases (Taylor and Feldmann 2009). 
Blockade of TNF-α has been clinically successful in a number of immune mediated 
pathologies such as rheumatoid arthritis, Crohn’s disease and psoriasis, however it is 
not successful in all patients or autoimmune diseases (Williams, Paleolog and 
Feldmann 2007). Abolishment of IL-23 by either utilising IL-23 knockout mouse 
models or subjecting wild-type mice to anti-IL-23 treatment has been shown to 
render mice resistant to certain inflammatory and autoimmune diseases such as 
experimental autoimmune encephalitis (EAE), collagen-induced arthritis (CIA) and 
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inflammatory bowel disease (IBD) (Cua et al. 2003, Murphy et al. 2003, Hue et al. 
2006). As DCs act as a link between innate and adaptive immunity and secrete 
cytokines which are important in inflammatory diseases, investigating how DCs 
secrete these cytokines may provide us with new therapeutic targets in these 
diseases.  
 
Mechanisms that control the release of cytokines from different cell have not been 
well studied in comparison to the numerous studies describing the detailed signalling 
pathways induced by cytokines. However SNARE family members have been 
implicated at each step of membrane fusion in intracellular trafficking pathway 
including that of cytokine release (Stow, Manderson and Murray 2006a). Indeed a 
novel SNARE complex, STX6 and Vti1b, has been reported to be involved in the 
secretion of TNF-α in macrophage. STX6 and Vti1b were shown to be up-regulated 
in parallel with increasing cytokine secretion and have been shown to have rate 
limiting roles in TNF-α trafficking and secretion. This study indicates the specific 
role for SNAREs in intracellular trafficking of cytokines secretion (Murray et al. 
2005a). Therefore we wanted to examine the role of these proteins in DCs. 
 
In order to investigate the role of SNAREs in DCs we first determined whether we 
could use a DC cell line. Research in DC biology most commonly uses primary 
derived DCs, however a cell line would have significant advantages, including the 
provision of a pure population to study the expression of SNARE proteins in DCs, 
which could be later validated in primary DCs. There are two types of DC cell lines 
available; an immortalised DC cell line and a growth factor-dependent DC line 
(Pinchuk, Lee and Filipov 2007). A DC cell line that closely mimics behaviour in 
vivo is preferred and which can also be easily matured in vitro. (Girolomoni et al. 
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1995) Thus in this study we chose JAWS II, a C57BL/6 immature DC line, derived 
from p53
-/-
 mice, which is grown in the presence of the differentiating factor GM-
CSF. JAWSII DCs have previously been reported to be able to be matured and 
subsequently have T-cell stimulatory abilities (MacKay and Moore, 1997).  
 
JAWS II, a C57BL/6 murine DC line, was used in this study. Previously JAWS II 
DCs have been used for immunobiological studies of Chlamydia muridarum (Jiang 
et al. 2008), to examine the expression of nicotinic acetylcholine receptor during cell 
maturation (Kondo et al. 2010), to assess the role of CD40 in activation of naïve T 
cells (Haase, Michelsen and Jorgensen 2004), to assess the transduction of IL-12 
genes (Pajtasz-Piasecka et al. 2007) and the genetic modification to express 
immunomodulatory molecule CTLA4Ig to prolong antigen-specific skin graft 
survival (Ierino et al. 2010). The latter studies indicate this cell line as an attractive 
option for in vitro studies of intracellular pathways through RNA interference 
(RNAi). 
 
The objective of this chapter was to examine the cytokine and chemokine profile of 
the JAWS II DC in response to a panel of TLR ligands in order to characterise the 
cell line.  
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3.2 RESULTS 
3.2.1 THE DOSES OF THE TLR LIGANDS USED ON JAWSII DCS 
HAVE NO SIGNIFICANT EFFECT ON CELL VIABILITY 
 
To compare the cytokine production and surface marker expression from JAWS II 
DCs following stimulation with a panel of TLR ligands, we firstly had to examine 
the potential toxicity of the ligands to the cells by exposing them to the JAWS II 
DCs. Following stimulation with 5 µg/ml peptidoglycan (PGN), 10 µg/ml 
Polyinosinic-polycytidylic acid (Poly (I:C)), 100 ng/ml Lipopolysaccharide (LPS) 
(E. coli serotype R515), 5 µg/ml Flagellin, 10 µg/ml Zymozan, 1 mM Loxoribine or 
2 µM CpG oligodeoxynucleotides (CpG ODN) for 24 h, the cell viability was 
assessed using Cell Titer 96 Aqueous One Solution (Promega, WI, USA) according 
to the manufacturer’s instructions. These doses did not exhibit any significant 
cytotoxic effect on JAWS II DCs in vitro and thus were used at these concentrations 
for all subsequent experiments [Figure 3.1]. 
 
3.2.2 JAWSII DCS TIME DEPENDENTLY SECRETE PRO-
INFLAMMATORY CYTOKINES IN RESPONSE TO THE TLR4 
LIGAND, LIPOPOLYSACCHARIDE (LPS) 
 
JAWS II DCs were cultured for seven days in the presence of murine recombinant 
GM-CSF (r-GM-CSF ) (Sigma ®) and plated at 1 x 10
6
 cell/ml. Cells were then 
stimulated with 100 ng/ml LPS (E. coli serotype R515) for 1 h, 2 h, 4 h, 6 h, 12 h 
and 24 h time-points. Supernatants were removed and analysed for the levels of IL-
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1β, IL-6, TNF-α and IL-27p28 [Figure 3.2] using specific immunoassays. A time 
dependent secretion of the pro-inflammatory cytokines IL-1β, IL-6, TNF-α and IL-
27p28 was observed [Figure 3.2].  All the cytokines examined were secreted at 
significant levels at 24 h (p≤0.01, p≤0.001), this was the time point used for 
subsequent experiments.   
3.2.3 COMPARISON OF CYTOKINE AND CHEMOKINE 
SECRETION FROM JAWSII DCS AND BMDCS FOLLOWING 
ACTIVATION WITH THE TLR2 LIGAND, PEPTIDOGLYCAN (PGN)  
 
In order to characterise JAWS II DCs we compared them to well characterised Bone 
Marrow Dendritic Cells (BMDCs) following activation with a panel of TLR ligands. 
BMDCs harvested from C57BL/6 mice and JAWS II DCs were cultured for seven 
days in the presence of r-GM-CSF (Sigma ®) and plated at 1 x 10
6
 cell/ml. Cells 
were then stimulated with 5 µg/ml PGN for 24h. Supernatants were removed and 
analysed for the levels of, IL-12p40, IL-12p70, IL-23, IL-27p28 [Figure 3.3], IL-1β, 
IL-6, IL-10, TNF-α [Figure 3.4], Macrophage inflammatory protein-α (MIP-1 α) 
and MIP-2 [Figure 3.5] using specific immunoassays. 
  
Activation of BMDCs with PGN resulted in significant levels of IL-12p40 (p≤ 0.01) 
and high levels of IL-12p40, IL-23 and IL-27 (not statistically significant), however 
these cytokines were not secreted by JAWS II DCs when stimulated with PGN 
[Figure 3.3]. BMDCs significantly increased secretion of IL-6 and TNF-α (p≤ 0.05, 
p≤ 0.01) and produced high levels of IL-1β and IL-10 (not statistically significant) in 
response to PGN. JAWSII DCs also significantly increased secretion of IL-6 and 
TNF-α (p≤ 0.01, p≤ 0.001) and high levels of IL-10 in response to PGN (not 
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statistically significant) however the levels were lower than BMDCs [Figure 3.4]. 
PGN stimulation induced significant secretion of MIP-2 from both BMDCs and 
JAWSII DCs (p≤ 0.01) and induced significant secretion of MIP-1α from JAWSII 
DCs (p≤ 0.01) with small levels from BMDCs [Figure 3.5].  
 
3.2.4 COMPARISON OF CYTOKINE AND CHEMOKINE 
SECRETION FROM JAWSII DCS AND BMDCS FOLLOWING 
ACTIVATION WITH THE TLR3 LIGAND, POLYINOSINIC-
POLYCYTIDYLIC ACID (POLY (I:C))  
 
BMDCs harvested from C57BL/6 mice and JAWS II DCs were cultured for seven 
days in the presence of r-GM-CSF (Sigma ®) and plated at 1 x 10
6
 cell/ml. Cells 
were then stimulated with 10 µg/ml Poly (I:C) for 24h. Supernatants were removed 
and analysed for the levels of, IL-12p40, IL-12p70, IL-23, IL-27p28 [Figure 3.6], 
IL-1β, IL-6, IL-10, TNF-α [Figure 3.7], MIP-1α and MIP-2 [Figure 3.8] using 
specific immunoassays. 
As with TLR2 stimulation, TLR3 stimulation did not induce any secretion of IL-
12p40, IL-12p70 or IL-23 from JAWS II DCs with only a low level of significant 
IL-27 secretion (p≤ 0.001) whereas BMDCs in response to TLR3 stimulation 
secreted significant levels IL-12p40 and IL-27p28 (p≤ 0.05, p≤ 0.001) and high 
levels of IL-12p70 and IL-23 [Figure 3.6]. Poly (I:C) stimulation induced significant 
levels of IL-6 and TNF-α  (p≤ 0.01, p≤ 0.05, p≤ 0.001)  high levels of IL-10 
compared to control from both JAWSII DCs and BMDCs, IL-1β was secreted at low 
levels in response to PGN in BMDCs and was not induced in JAWSII DCs  [Figure 
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3.7].  MIP-1α and MIP-2 were significantly secreted from JAWSII DCs in response 
to PGN (p≤ 0.05). There was significant secretion of MIP-1α (p≤ 0.05) and a higher 
amount of MIP-2 (not statistically significant) in BMDCs in response to PGN 
however levels were much lower than JAWSII DCs [Figure 3.8].  
 
3.2.5 COMPARISON OF CYTOKINE AND CHEMOKINE 
SECRETION FROM JAWSII DCS AND BMDCS FOLLOWING 
ACTIVATION WITH THE TLR4 LIGAND, LIPOPOLYSACCHARIDE 
(LPS)  
 
BMDCs harvested from C57BL/6 mice and JAWS II DCs were cultured for seven 
days in the presence of r-GM-CSF (Sigma ®) and plated at 1 x 10
6
 cell/ml. Cells 
were then stimulated with 100 ng/ml LPS (E. coli serotype R515) for 24h. 
Supernatants were removed and analysed for the levels of, IL-12p40, IL-12p70, IL-
23, IL-27p28 [Figure 3.9], IL-1β, IL-6, IL-10, TNF-α [Figure 3.10], MIP-1α and 
MIP-2 [Figure 3.11] using specific immunoassays. 
 
BMDCs secreted significant levels of IL-12p40, IL-23 and IL-27p28 (p≤ 0.001, p≤ 
0.01) and high levels of IL-12p70 in response to LPS stimulation compared to 
undetectable secretion levels of IL-12p40, IL-12p70 or IL-23 and only low levels of 
IL-27p28 (p≤ 0.001) from JAWS II DCs [Figure 3.9].  
 
IL-1β was significantly secreted by JAWS II DCs and BMDCs following LPS 
stimulation (p≤ 0.05, p≤ 0.01) however at higher levels from JAWSII DCs. IL-6, IL-
10 and TNF-α were all significantly secreted by JAWS II DCs and BMDCs 
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following LPS stimulation at comparable levels (p≤ 0.001, p≤ 0.05, p≤ 0.01) [Figure 
3.10]. TLR4 activation promoted significant secretion of MIP-1α and MIP-2 from 
JAWS II DCs and BMDCs however at higher levels from JAWSII DCs (p≤ 0.001) 
[Figure 3.11].  
 
3.2.6 COMPARISON OF CYTOKINE AND CHEMOKINE 
SECRETION FROM JAWSII DCS AND BMDCS FOLLOWING 
ACTIVATION WITH THE TLR5 LIGAND, FLAGELLIN 
 
BMDCs harvested from C57BL/6 mice and JAWS II DCs were cultured for seven 
days in the presence of r-GM-CSF (Sigma ®) and plated at 1 x 10
6
 cell/ml. Cells 
were then stimulated with 5 µg/ml of Flagellin for 24h. Supernatants were removed 
and analysed for the levels of, IL-12p40, IL-12p70, IL-23, IL-27p28 [Figure 3.12], 
IL-1β, IL-6, TNF-α, IL-27p28 [Figure 3.13], MIP-1α and MIP-2 [Figure 3.14] 
using specific immunoassays. 
 
Stimulation with the TLR5 agonist resulted in a low level of significant secretion of 
IL-27p28 by JAWS II DCs but no secretion of IL-12p40, IL-12p70 or IL-23 (p≤ 
0.01). BMDCs secreted significant levels IL-12p40 (p≤ 0.01) and high levels of IL-
12p70 (not statistically significant) and not IL-23 and IL-27p28 in response to 
Flagellin [Figure 3.12].  BMDCs produced low levels of IL-1β, IL-6, IL-10 and 
TNF-α, however secretion was not up-regulated in response to Flagellin. JAWSII 
DCs however did significantly secrete IL-10 and TNF-α (p≤ 0.05) and high levels of 
IL-6 (not statistically significant) in response to TLR5 activation [Figure 3.13]. 
MIP-1α secretion was only detected in TLR5 stimulated JAWS II DCs. Although 
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MIP-2 secretion was higher in JAWS II DCs than BMDCs it was not induced by 
Flagellin stimulation whereas it was significantly secreted from BMDCs (p≤ 0.01) 
[Figure 3.14]. 
 
3.2.7 COMPARISON OF CYTOKINE AND CHEMOKINE 
SECRETION FROM JAWSII DCS AND BMDCS FOLLOWING 
ACTIVATION WITH THE TLR7 LIGAND, LOXORIBINE 
 
BMDCs harvested from C57BL/6 mice and JAWS II DCs were cultured for seven 
days in the presence of r-GM-CSF (Sigma ®) and plated at 1 x 10
6
 cell/ml. Cells 
were then stimulated with 1 mM Loxoribine for 24 h. Supernatants were removed 
and analysed for the levels of, IL-12p40, IL-12p70, IL-23, IL-27p28 [Figure 3.15], 
IL-1β, IL-6, IL-10, TNF-α [Figure 3.16], MIP-1α and MIP-2 [Figure 3.17] using 
specific immunoassays. 
 
Stimulation using the TLR7 ligand resulted in no secretion of IL-12p70 and IL-23 
and low significant levels of IL-12p40 and IL-27 in JAWS II DCs (p≤ 0.001). 
BMDCs secreted significant levels of IL-12p40 and IL-27 but not IL-23 (p≤ 0.05, p≤ 
0.01) in response to Loxoribine. IL-12p70 was secreted by BMDCs but not induced 
following TLR activation [Figure 3.15]. IL-1β, IL-6, IL-10 and TNF-α secretion 
was significantly secreted from both JAWS II DCs and BMDCs following 
Loxoribine stimulation (p≤ 0.05, p≤ 0.01, p≤ 0.001), however at higher levels in the 
JAWS II DCs [Figure 3.16]. There was significant secretion of MIP-1α and MIP-2 
in response to Loxoribine from JAWSII DCs and BMDCs with higher levels from 
JAWS II DCs compared to BMDCs (p≤ 0.001, p≤ 0.01) [Figure 3.17]. 
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3.2.8 COMPARISON OF CYTOKINE AND CHEMOKINE 
SECRETION FROM JAWSII DCS AND BMDCS FOLLOWING 
ACTIVATION WITH THE TLR9 LIGAND, CPG 
OLIGODEOXYNUCLEOIDES (CPG ODN) 
 
BMDCs harvested from C57BL/6 mice and JAWS II DCs were cultured for seven 
days in the presence of r-GM-CSF (Sigma ®) and plated at 1 x 10
6
 cell/ml. Cells 
were then stimulated with 2 µM CpG oligodeoxynucleotides (CpG ODN) for 24h. 
Supernatants were removed and analysed for the levels of, IL-12p40, IL-12p70, IL-
23, IL-27p28 [Figure 3.18], IL-1β, IL-6, IL-10, TNF-α [Figure 3.19] MIP-1α and 
MIP-2 [Figure 3.20] using specific immunoassays. 
 
BMDCs secreted significant levels of IL-12p40, IL-23 and IL-27 (p≤ 0.01, p≤ 0.001) 
with high levels if IL-12p70 (not statistically significant) in response to CpG 
stimulation. JAWSII DCs also secreted significant levels of IL-12p40 and IL-27p28 
(p≤ 0.01) in response to CpG but at much lower amounts compared to BMDCS and 
did not secrete any IL-12p70 or IL-23 [Figure 3.18]. IL-6, IL-10 and TNF-α were all 
significantly secreted from BMDCs in response to CpG stimulation (p≤ 0.05, p≤ 
0.001, p≤ 0.01) however at smaller levels from JAWSII DCs. IL-1β was secreted 
from JAWSII DCs and BMDCs however its expression was not induced upon CpG 
stimulation [Figure 3.19]. Secretion of MIP-1α and MIP-2 was significantly secreted 
from BMDCs following CpG stimulation (p≤ 0.001, p≤ 0.01). MIP-1α was not 
secreted from JAWSII DC and MIP-2 was secreted however was not induced by 
CpG stimulation [Figure 3.20].  
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3.2.9 COMPARISON OF CELL SURFACE MARKER EXPRESSION 
ON JAWSII DCS AND BMDCS FOLLOWING ACTIVATION WITH 
THE TLR2 LIGAND, PEPTIDOGLYCAN (PGN) 
 
BMDCs harvested from C57BL/6 mice and JAWS II DCs were cultured for seven 
days in the presence of r-GMSCF (Sigma ®) and plated at 1 x 10
6
 cell/ml. Cells 
were then stimulated with 5µg/ml PGN for 24h. Cells were subsequently washed and 
stained with fluorochrome-labelled monoclonal antibodies to the cell surface 
markers, TLR-4-MD-2, TLR-2, CD14 [Figure 3.21], CD40, CD80, CD86, and 
MHC II [Figure 3.22] in preparation for cytometric analysis by flow cytometry. MFI 
values are shown stimulated versus control cells.  
 
Activation of TLR2 resulted in small increases of expression of TLR4-MD-2 (MFI 
JAWS 238 v 196, MFI BMDCs 3430 v 3416), TLR2 (MFI JAWS 586 v 534, MFI 
BMDCs 3340 v 2596) and CD14 (MFI JAWS 808 v 582, MFI BMDCs 17100 v 
3970), in both JAWS II DCs and BMDCs [Figure 3.21]. Expression of CD80 (MFI 
JAWS 662 v 612, MFI BMDCs 16900 v 10900) and MHC II (MFI JAWS 424 v 
365, MFI BMDCs 48500 v 37600), were up-regulated in both JAWS II DCs and 
BMDCs but at smaller levels in JAWSII DCs [Figure 3.22]. CD40 (MFI BMDCs 
7311 v 2121) and CD86 (MFI BMDCs 16900 v 10900), were up-regulated in 
BMDCs in response to TLR2 stimulation but not present in JAWSII DCs [Figure 
3.22]. Summarised in Table 3.1 and Table 3.2.  
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3.2.10 COMPARISON OF CELL SURFACE MARKER EXPRESSION 
ON JAWSII DCS AND BMDCS FOLLOWING ACTIVATION WITH 
THE TLR3 LIGAND, POLYINOSINIC-POLYCYTIDYLIC (POLY 
(I:C)) 
 
BMDCs harvested from C57BL/6 mice and JAWS II DCs were cultured for seven 
days in the presence of r-GMSCF (Sigma ®) and plated at 1 x 10
6
 cell/ml. Cells 
were then stimulated with 10 µg/ml Poly (I:C)  for 24hours. Cells were subsequently 
washed and stained with fluorochrome-labelled monoclonal antibodies to the cell 
surface markers, TLR-4-MD-2 , TLR-2, CD14, [Figure 3.23] CD40, CD80, CD86, 
and MHC II [Figure 3.24] in preparation for cytometric analysis by flow cytometry. 
Expression of TLR-2 (MFI JAWS 768 v 534, MFI BMDCs 2980 v 2596) was 
slightly up-regulated in JAWS II DCs and BMDCs in response to the TLR3 ligand. 
TLR-4-MD-2 (MFI JAWS 269 v 196, MFI BMDCs 3338 v 3416) and CD14 (MFI 
JAWS 693 v 582, MFI BMDCs 3928 v 3970) were up-regulated in JAWS II DCs 
and down-regulated in BMDCs in response to PGN [Figure 3.23]. There was 
increased expression of MHC II in JAWS II DCs and BMDCs. CD40 (MFI BMDCs 
5103 v 2121), CD80 (MFI BMDCs 15500 v 10900) and CD86 (MFI BMDCs 4452 v 
3504), remained unchanged in JAWS II DCs however was up-regulated in BMDCs 
following PGN stimulation. [Figure 3.24]. Summarised in Table 3.1 and Table 3.2.  
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3.2.11 COMPARISON OF CELL SURFACE MARKER EXPRESSION 
ON JAWSII DCS AND BMDCS FOLLOWING ACTIVATION WITH 
THE TLR4 LIGAND, LIPOPOLYSACCARIDE (LPS) 
 
BMDCs harvested from C57BL/6 mice and JAWS II DCs were cultured for seven 
days in the presence of r-GMSCF (Sigma ®) and plated at 1 x 10
6
 cell/ml. Cells 
were then stimulated with 100 ng/ml LPS (E.coli serotype R515) for 24h. Cells were 
subsequently washed and stained with fluorochrome-labelled monoclonal antibodies 
to the cell surface markers, TLR-4-MD-2, TLR-2, CD14 [Figure 3.25], CD40, 
CD80, CD86, and MHC II [Figure 3.26] in preparation for cytometric analysis by 
flow cytometry.  
Ligation of the TLR4 agonist LPS resulted in up-regulation of TLR2 (MFI JAWS 
1016 v 511, MFI BMDCs 3313 v 3040) and CD14 (MFI JAWS 1511 v 724, MFI 
BMDCs 12000 v 4930) expression in JAWS II DCs and BMDCs. TLR-4-MD-2 
(MFI JAWS 254 v 509, MFI BMDCs 1603 v 1285) was down-regulated in JAWS II 
DCs and an up-regulation in BMDCs following LPS stimulation [Figure 3.25]. 
CD40 (MFI BMDCs 10400 v 1276), CD80 (MFI JAWS 766 v 655, MFI BMDCs 
18900 v 8270), CD86 (MFI JAWS 187 v 121, MFI BMDCs 4282 v 1891) and MHC 
II (MFI JAWS 727 v 343, MFI BMDCs 23800 v 15500) expression were all highly 
up-regulated in BMDCs however this was seen to a lesser extent in JAWS II DCs, 
with again no expression of CD40 in response to LPS [Figure 3.26]. Summarised in 
Table 3.1 and Table 3.2. 
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3.2.12 COMPARISON OF CELL SURFACE MARKER EXPRESSION 
ON JAWSII DCS AND BMDCS FOLLOWING ACTIVATION WITH 
THE TLR5 LIGAND, FLAGELLIN 
 
BMDCs harvested from C57BL/6 mice and JAWS II DCs were cultured for seven 
days in the presence of r-GMSCF (Sigma ®) and plated at 1 x 10
6
 cell/ml. Cells 
were then stimulated with 5 µg/ml of Flagellin for 24 h. Cells were subsequently 
washed and stained with fluorochrome-labelled monoclonal antibodies to the cell 
surface markers, TLR-4-MD-2 , TLR-2, CD14, [Figure 3.27] CD40, CD80, CD86, 
and MHC II [Figure 3.28] in preparation for cytometric analysis by flow cytometry.  
Activation of TLR5 in JAWS II DCs resulted in no change of expression of TLR2, 
CD14 and a small up-regulation in TLR4 (MFI JAWS 263 v 196) however in 
BMDCs there was an up-regulation of TLR2 (MFI BMDC 4472 v 3040), CD14 
(MFI BMDC 10700 v 4930) and TLR4 (MFI BMDC 1481 v 1285) following 
Flagellin stimulation [Figure 3.27]. There was no change in expression of CD80, 
CD86 and MHC II following activation of TLR5 in JAWS II DCs and once again 
there was no expression of CD40. Expression of CD80 (MFI BMDC 13500 v 8270), 
CD86 (MFI BMDC 2665 v 1891), MHC II (MFI BMDC 20200 v 15500) and CD40 
(MFI BMDC 3042 v 1276) were all up-regulated in BMDCs. [Figure 3.28]. 
Summarised in Table 3.1 and Table 3.2.  
 
3.2.13 COMPARISON OF CELL SURFACE MARKER EXPRESSION 
ON JAWSII DCS AND BMDCS FOLLOWING ACTIVATION WITH 
THE TLR7 LIGAND, LOXORIBINE  
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BMDCs harvested from C57BL/6 mice and JAWS II DCs were cultured for seven 
days in the presence of r-GMSCF (Sigma ®) and plated at 1 x 10
6
 cell/ml. Cells 
were then stimulated with 1 mM Loxoribine for 24 h. Cells were subsequently 
washed and stained with fluorochrome-labelled monoclonal antibodies to the cell 
surface markers, TLR-4-MD-2, TLR-2, CD14 [Figure 3.29], CD40, CD80, CD86, 
and MHC II [Figure 3.30] in preparation for cytometric analysis by flow cytometry. 
 
Activation of TLR7 resulted in a similar response in JAWS II DCs and BMDCs with 
the up-regulation TLR-4-MD-2 (MFI JAWS 265 v 196, MFI BMDCs 3069 v 1174), 
TLR-2  (MFI JAWS 708 v 534, MFI BMDCs 6185 v 3040) and CD14 (MFI JAWS 
2286 v 582, MFI BMDCs 28500 v 4930) [Figure 3.29]. Expression of CD80 (MFI 
JAWS 985 v 612, MFI BMDCs 16900 v 8270) and MHC II (MFI JAWS 814 v 365, 
MFI BMDCs 27400 v 3040) were also up-regulated JAWSII DCs and BMDCs 
following Loxoribine stimulation. There was an upregulation of the markers CD40 
(MFI BMDCs 11200 v 1276) and CD86 (MFI BMDCs 3625 v 1891) in BMDCs but 
not in JAWSII DCs. [Figure 3.30]. Summarised in Table 3.1 and Table 3.2. 
 
3.2.14 COMPARISON OF CELL SURFACE MARKER EXPRESSION 
ON JAWSII DCS AND BMDCS FOLLOWING ACTIVATION WITH 
THE TLR9 LIGAND, CPG OLOGODEOXYNUCLEOTIDES (CPG 
ODN) 
 
BMDCs harvested from C57BL/6 mice and JAWS II DCs were cultured for seven 
days in the presence of r-GMSCF (Sigma ®) and plated at 1 x 10
6
 cell/ml. Cells 
were then stimulated with 2 µM of CpG oligodeoxynucleotides for 24 h. Cells were 
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subsequently washed and stained with fluorochrome-labelled monoclonal antibodies 
to the cell surface markers, TLR-4-MD-2, TLR-2, CD14 [Figure 3.31], CD40, 
CD80, CD86, and MHC II [Figure 3.32] in preparation for cytometric analysis by 
flow cytometry.  
 
Stimulation with CpG in BMDCs resulted in the up-regulation of the surface marker 
expression of TLR-4-MD-2 (MFI BMDCs 3720 v 3416), TLR2 (MFI BMDCs 2709 
v 2596)  and CD14 (MFI BMDCs 6620 v 3971) however there was no up-regulation 
of these markers in JAWSII DCs [Figure 3.31]. Expression in BMDCs of CD40 
(MFI BMDCs 7544 v 2121), CD80 (MFI BMDCs 7544 v 2121), CD86 (MFI 
BMDCs 4294 v 3504) and MHC II (MFI BMDCs 34300 v 16800) were all 
upregualted in response to CpG stimualtion. JAWS II DCs did not upregulate CD80 
and MHC II following CpG stimulation and there was no expression of CD40 or 
CD86 in control or CpG stimulated JAWSII DCs. [Figure 3.32]. Summarised in 
Table 3.1 and Table 3.2. 
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FIGURE 3.1: The concentrations of TLR ligands do not significantly affect the 
viability JAWS II DCs. JAWS II DCs were plated at 1x10
5
 cells/well overnight and 
then treated 5µg/ml peptidoglycan (PGN), 10µg/ml Polyinosinic-polycytidylic 
acid (Poly (I:C)), 100ng/ml Lipopolysaccharide (LPS) (E. coli serotype R515), 
5µg/ml Flagellin, 1mM Loxoribine or 2µM CpG oligodeoxynucleotides (CpG 
ODN). Following 24 hr treatment cellular viability was assessed using an [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium inner salt (MTS) assay (Cell Titer 96 Aqueous One Solution – Promega, 
WI, USA). Results are expressed as a percentage of untreated cells. Results are mean 
± SEM of quadruplicate assays and represent three independent experiments. 
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FIGURE 3.2: The secretion of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α 
and IL-27p28) from JAWS II DCs in response to a time course of LPS. DCs 
were cultured in r-GM-CSF for seven days. Cells were plated at (1x10
6
 cells/ml) and 
left to rest overnight. Cells were then stimulated in vitro with LPS (100 ng/ml) and 
supernatants recovered after 24h. Levels of pro- inflammatory cytokines were 
measured using specific immunoassays. Results are mean ± SEM of quadruplicate 
assays and represent three independent experiments. ***p≤0.001, **p≤0.01, *p≤0.05 
comparing CTL vs 1 h, 2 h, 4 h, 6 h, 12 h and 24 h  groups as determined by one-
way ANOVA test.   
A 
A 
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TLR 2 
 
 
 
 
FIGURE 3.3: Comparison of cytokine secretion from JAWS II DCs and 
BMDCs following TLR2 activation. DCs were cultured in r-GM-CSF for seven 
days and subsequently were plated (1x10
6
 cells/ml) and left to rest overnight. Cells 
were then stimulated with 5 µg/ml PGN and supernatants were recovered after 24 h 
and assessed for levels of cytokines using specific immunoassays. Results are ± 
SEM of quadruplicate assays and represent three independent experiments. **p≤ 
0.01 comparing  control versus 5μg/ml PGN stimulated JAWSII DCs or BMDCs as 
determined by a two-tailed t-test.  
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FIGURE 3.4: Comparison of cytokine secretion from JAWS II DCs and 
BMDCs following TLR2 activation. DCs were cultured in r-GM-CSF for seven 
days and subsequently were plated (1x10
6
 cells/ml) and left to rest overnight. Cells 
were then stimulated with 5 µg/ml PGN and supernatants were recovered after 24 h 
and assessed for levels of cytokines using specific immunoassays. Results are ± 
SEM of quadruplicate assays and represent three independent experiments. *p≤ 0.05, 
**p≤ 0.01 and ***p≤0.001 comparing control versus 5 μg/ml PGN stimulated 
JAWSII DCs or BMDCs as determined by a two-tailed t-test.  
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FIGURE 3.5: Comparison of chemokine secretion from JAWS II DCs and 
BMDCs following TLR2 activation. DCs were cultured in r-GM-CSF for seven 
days and subsequently were plated (1x10
6
 cells/ml) and left to rest overnight. Cells 
were then stimulated with 5 µg/ml PGN and supernatants were recovered after 24 h 
and assessed for levels of chemokines using specific immunoassays. Results are ± 
SEM of quadruplicate assays and represent three independent experiments. **p≤ 
0.01 comparing control versus 5 μg/ml PGN stimulated JAWSII DCs or BMDCs as 
determined by a two-tailed t-test.     
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FIGURE 3.6: Comparison of cytokine secretion from JAWS II DCs and 
BMDCs following TLR3 activation. DCs were cultured in r-GM-CSF for seven 
days and subsequently were plated (1x10
6
 cells/ml) and left to rest overnight. Cells 
were then stimulated with 10 µg/ml Poly (I:C) and supernatants were recovered after 
24 h and assessed for levels of cytokines using specific immunoassays. Results are ± 
SEM of quadruplicate assays and represent three independent experiments. *p≤ 0.05, 
and ***p≤0.001 comparing control versus 10 μg/ml Poly IC stimulated JAWSII DCs 
or BMDCs as determined by a two-tailed t-test.   
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FIGURE 3.7: Comparison of cytokine secretion from JAWS II DCs and 
BMDCs following TLR3 activation. DCs were cultured in r-GM-CSF for seven 
days and subsequently were plated (1x10
6
 cells/ml) and left to rest overnight. Cells 
were then stimulated with 10 µg/ml Poly (I:C) and supernatants were recovered after 
24 h and assessed for levels of cytokines using specific immunoassays. Results are ± 
SEM of quadruplicate assays and represent three independent experiments. *p≤ 0.05, 
**p≤ 0.01 and ***p≤0.001 comparing control versus 10 μg/ml Poly IC stimulated 
JAWSII DCs or BMDCs as determined by a two-tailed t-test.    
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FIGURE 3.8: Comparison of chemokine secretion from JAWS II DCs and 
BMDCs following TLR3 activation. DCs were cultured in r-GM-CSF for seven 
days and subsequently were plated (1x10
6
 cells/ml) and left to rest overnight. Cells 
were then stimulated with 10 µg/ml Poly (I:C) and supernatants were recovered after 
24 h and assessed for levels of chemokines using specific immunoassays. Results are 
± SEM of quadruplicate assays and represent three independent experiments. *p≤ 
0.05 comparing control versus 10μg/ml PGN stimulated JAWSII DCs or BMDCs as 
determined by a two-tailed t-test.    
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FIGURE 3.9: Comparison of cytokine secretion from JAWS II DCs and 
BMDCs following TLR4 activation. DCs were cultured in r-GM-CSF for seven 
days and subsequently were plated (1x10
6
 cells/ml) and left to rest overnight. Cells 
were then stimulated with 100 ng/ml LPS and supernatants were recovered after 24 h 
and assessed for levels of cytokines using specific immunoassays. Results are ± 
SEM of quadruplicate assays and represent three independent experiments. **p≤ 
0.01 and ***p≤0.001 comparing control versus 100ng/ml LPS stimulated JAWSII 
DCs or BMDCs as determined by a two-tailed t-test.    
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FIGURE 3.10: Comparison of cytokine secretion from JAWS II DCs and 
BMDCs following TLR4 activation. DCs were cultured in r-GM-CSF for seven 
days and subsequently were plated (1x10
6
 cells/ml) and left to rest overnight. Cells 
were then stimulated with 100 ng/ml LPS and supernatants were recovered after 24 h 
and assessed for levels of cytokines using specific immunoassays. Results are ± 
SEM of quadruplicate assays and represent three independent experiments. *p≤ 0.05, 
**p≤ 0.01 and ***p≤0.001 comparing control versus 100ng/ml LPS stimulated 
JAWSII DCs or BMDCs as determined by a two-tailed t-test.   
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FIGURE 3.11: Comparison of chemokine secretion from JAWS II DCs and 
BMDCs following TLR4 activation. DCs were cultured in r-GM-CSF for seven 
days and subsequently were plated (1x10
6
 cells/ml) and left to rest overnight. Cells 
were then stimulated with 100 ng/ml LPS and supernatants were recovered after 24 h 
and assessed for levels of chemokines using specific immunoassays. Results are ± 
SEM of quadruplicate assays and represent three independent experiments. 
***p≤0.001 comparing control versus 100 ng/ml LPS stimulated JAWSII DCs or 
BMDCs as determined by a two-tailed t-test. 
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FIGURE 3.12: Comparison of cytokine secretion from JAWS II DCs and 
BMDCs following TLR5 activation. DCs were cultured in r-GM-CSF for seven 
days and subsequently were plated (1x10
6
 cells/ml) and left to rest overnight. Cells 
were then stimulated with 5 µg/ml Flagellin and supernatants were recovered after 
24 h and assessed for levels of cytokines using specific immunoassays. Results are ± 
SEM of quadruplicate assays and represent three independent experiments. **p≤ 
0.01 comparing control versus 5 μg/ml Flagellin stimulated JAWSII DCs or BMDCs 
as determined by a two-tailed t-test. 
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FIGURE 3.13: Comparison of cytokine secretion from JAWS II DCs and 
BMDCs following TLR5 activation. DCs were cultured in r-GM-CSF for seven 
days and subsequently were plated (1x10
6
 cells/ml) and left to rest overnight. Cells 
were then stimulated with 5 µg/ml Flagellin and supernatants were recovered after 
24 h and assessed for levels of cytokines using specific immunoassays. Results are ± 
SEM of quadruplicate assays and represent three independent experiments. *p≤ 0.05, 
comparing control versus 5 μg/ml Flagellin stimulated JAWSII DCs or BMDCs as 
determined by a two-tailed t-test. 
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FIGURE 3.14: Comparison of chemokine secretion from JAWS II DCs and 
BMDCs following TLR5 activation. DCs were cultured in r-GM-CSF for seven 
days and subsequently were plated (1x10
6
 cells/ml) and left to rest overnight. Cells 
were then stimulated 5 µg/ml Flagellin and supernatants were recovered after 24 h 
and assessed for levels of chemokines using specific immunoassays. Results are ± 
SEM of quadruplicate assays and represent three independent experiments. **p≤ 
0.01  comparing control versus 5 μg/ml Flagellin stimulated JAWSII DCs or 
BMDCs as determined by a two-tailed t-test.    
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FIGURE 3.15: Comparison of cytokine secretion from JAWS II DCs and 
BMDCs following TLR7 activation. DCs were cultured in r-GM-CSF for seven 
days and subsequently were plated (1x10
6
 cells/ml) and left to rest overnight. Cells 
were then stimulated with 1 mM Loxoribine and supernatants were recovered after 
24 h and assessed for levels of cytokines using specific immunoassays. Results are ± 
SEM of quadruplicate assays and represent three independent experiments. *p≤ 0.05, 
**p≤ 0.01 and ***p≤0.001 comparing control versus 1 mM Loxoribine stimulated 
JAWSII DCs or BMDCs as determined by a two-tailed t-test. 
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FIGURE 3.16: Comparison of cytokine secretion from JAWS II DCs and 
BMDCs following TLR7 activation. DCs were cultured in r-GM-CSF for seven 
days and subsequently were plated (1x10
6
 cells/ml) and left to rest overnight. Cells 
were then stimulated with 1 mM Loxoribine and supernatants were recovered after 
24 h and assessed for levels of cytokines using specific immunoassays. Results are ± 
SEM of quadruplicate assays and represent three independent experiments. *p≤ 0.05, 
**p≤ 0.01 and ***p≤0.001 comparing control versus 1 mM Loxoribine stimulated 
JAWSII DCs or BMDCs as determined by a two-tailed t-test.    
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FIGURE 3.17: Comparison of chemokine secretion from JAWS II DCs and 
BMDCs following TLR7 activation. DCs were cultured in r-GM-CSF for seven 
days and subsequently were plated (1x10
6
 cells/ml) and left to rest overnight. Cells 
were then stimulated with 1 mM Loxoribine and supernatants were recovered after 
24 h and assessed for levels of chemokines using specific immunoassays. Results are 
± SEM of quadruplicate assays and represent three independent experiments. **p≤ 
0.01 and ***p≤0.001 comparing control versus 1 mM Loxoribine stimulated 
JAWSII DCs or BMDCs as determined by a two-tailed t-test.   
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FIGURE 3.18: Comparison of cytokine secretion from JAWS II DCs and 
BMDCs following TLR9 activation. DCs were cultured in r-GM-CSF for seven 
days and subsequently were plated (1x10
6
 cells/ml) and left to rest overnight. Cells 
were then stimulated with 2 µM CpG and supernatants were recovered after 24 h and 
assessed for levels of cytokines using specific immunoassays. Results are ± SEM of 
quadruplicate assays and represent three independent experiments.**p≤ 0.01 and 
***p≤0.001 comparing control versus 2 μM CpG stimulated JAWSII DCs or 
BMDCs as determined by a two-tailed t-test. 
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FIGURE 3.19: Comparison of cytokine secretion from JAWS II DCs and 
BMDCs following TLR9 activation. DCs were cultured in r-GM-CSF for seven 
days and subsequently were plated (1x10
6
 cells/ml) and left to rest overnight. Cells 
were then stimulated with 2 µM CpG and supernatants were recovered after 24 h and 
assessed for levels of cytokines using specific immunoassays. Results are ± SEM of 
quadruplicate assays and represent three independent experiments. *p≤ 0.05, **p≤ 
0.01 and ***p≤0.001 comparing control versus 2 μM CpG stimulated JAWSII DCs 
or BMDCs as determined by a two-tailed t-test. 
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FIGURE 3.20: Comparison of chemokine secretion from JAWS II DCs and 
BMDCs following TLR9 activation. DCs were cultured in r-GM-CSF for seven 
days and subsequently were plated (1x10
6
 cells/ml) and left to rest overnight. Cells 
were then stimulated with 2 µM CpG and supernatants were recovered after 24 h and 
assessed for levels of chemokines using specific immunoassays. Results are ± SEM 
of quadruplicate assays and represent three independent experiments. **p≤ 0.01 and 
***p≤0.001 comparing control versus 2 μM CpG stimulated JAWSII DCs or 
BMDCs as determined by a two-tailed t-test.     
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FIGURE 3.21: Comparison of surface marker expression on JAWS II and 
BMDCs following TLR2 activation. JAWS II and BMDC were differentiated in 
the presence of r-GMCSF for seven days and then stimulated with PGN (5 µg/ml) 
for 24 h. Subsequently, cells were washed and stained with specific antibodies or 
with an isotype matched control. Results of flow cytometric analysis and 
corresponding Mean Fluorescence Intensity (MFI) values are shown. Control DCs 
(grey filled histogram) vs PGN stimulated DCs (pink line) and isotype control (blue 
line). Profiles are shown for a single experiment and are representative of three 
experiments. 
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FIGURE 3.22: Comparison of surface marker expression on JAWS II and 
BMDCs following TLR2 activation. JAWS II and BMDC were differentiated in 
the presence of r-GMCSF for seven days and then stimulated with PGN (5 µg/ml) 
for 24 h. Subsequently, cells were washed and stained with specific antibodies or 
with an isotype matched control. Results of flow cytometric analysis and 
corresponding MFI values are shown. Control DCs (grey filled histogram) vs PGN 
stimulated DCs (pink line) and isotype control (blue line). Profiles are shown for a 
single experiment and are representative of three experiments.  
CHAPTER 3                                             CHARACTERISATION OF JAWSII DCS 
 
103 
 
 
 
 
FIGURE 3.23: Comparison of surface marker expression on JAWS II and 
BMDCs following TLR3 activation. JAWS II and BMDC were differentiated in 
the presence of r-GMCSF for seven days and then stimulated with Poly (I:C) (10 
µg/ml) for 24 h. Subsequently, cells were washed and stained with specific 
antibodies or with an isotype matched control. Results of flow cytometric analysis 
and corresponding MFI values are shown. Control DCs (grey filled histogram) vs 
Poly (I:C) stimulated DCs (pink line) and isotype control (blue line). Profiles are 
shown for a single experiment and are representative of three experiments. 
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FIGURE 3.24: Comparison of surface marker expression on JAWS II and 
BMDCs following TLR3 activation. JAWS II and BMDC were differentiated in 
the presence of r-GMCSF for seven days and then stimulated with Poly (I:C) (10 
µg/ml) for 24 h. Subsequently, cells were washed and stained with specific 
antibodies or with an isotype matched control. Results of flow cytometric analysis 
and corresponding MFI values are shown. Control DCs (grey filled histogram) vs 
Poly (I:C) stimulated DCs (pink line) and isotype control (blue line). Profiles are 
shown for a single experiment and are representative of three experiments.  
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FIGURE 3.25: Comparison of surface marker expression on JAWS II and 
BMDCs following TLR4 activation. JAWS II and BMDC were differentiated in 
the presence of r-GMCSF for seven days and then stimulated with (LPS 100 ng/ml) 
for 24 h. Subsequently, cells were washed and stained with specific antibodies or 
with an isotype matched control. Results of flow cytometric analysis and 
corresponding MFI values are shown. Control DCs (grey filled histogram) vs LPS 
stimulated DCs (pink line) and isotype control (blue line). Profiles are shown for a 
single experiment and are representative of three experiments. 
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FIGURE 3.26: Comparison of surface marker expression on JAWS II and 
BMDCs following TLR4 activation. JAWS II and BMDC were differentiated in 
the presence of r-GMCSF for seven days and then stimulated with (LPS 100 ng/ml) 
for 24 h. Subsequently, cells were washed and stained with specific antibodies or 
with an isotype matched control. Results of flow cytometric analysis and 
corresponding MFI values are shown. Control DCs (grey filled histogram) vs LPS 
stimulated DCs (pink line) and isotype control (blue line). Profiles are shown for a 
single experiment and are representative of three experiments.  
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FIGURE 3.27: Comparison of surface marker expression on JAWS II and 
BMDCs following TLR5 activation. JAWS II and BMDC were differentiated in 
the presence of r-GMCSF for seven days and then stimulated with Flagellin (5 
µg/ml) for 24 h. Subsequently, cells were washed and stained with specific 
antibodies or with an isotype matched control. Results of flow cytometric analysis 
and corresponding MFI values are shown. Control DCs (grey filled histogram) vs 
flagellin stimulated DCs (pink line) and isotype control (blue line). Profiles are 
shown for a single experiment and are representative of three experiments. 
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FIGURE 3.28: Comparison of surface marker expression on JAWS II and 
BMDCs following TLR5 activation. JAWS II and BMDC were differentiated in 
the presence of r-GMCSF for seven days and then stimulated with Flagellin (5 
µg/ml) for 24 h. Subsequently, cells were washed and stained with specific 
antibodies or with an isotype matched control. Results of flow cytometric analysis 
and corresponding MFI values are shown. Control DCs (grey filled histogram) vs 
flagellin stimulated DCs (pink line) and isotype control (blue line). Profiles are 
shown for a single experiment and are representative of three experiments. 
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FIGURE 3.29: Comparison of surface marker expression on JAWS II and 
BMDCs following TLR7 activation. JAWS II and BMDC were differentiated in 
the presence of r-GMCSF for seven days and then stimulated with Loxoribine (1 
mM) for 24 h. Subsequently, cells were washed and stained with specific antibodies 
or with an isotype matched control. Results of flow cytometric analysis and 
corresponding MFI values are shown. Control DCs (grey filled histogram) vs 
Loxoribine stimulated DCs (pink line) and isotype control (blue line). Profiles are 
shown for a single experiment and are representative of three experiments. 
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FIGURE 3.30: Comparison of surface marker expression on JAWS II and 
BMDCs following TLR7 activation. JAWS II and BMDC were differentiated in 
the presence of r-GMCSF for seven days and then stimulated with Loxoribine (1 
mM) for 24 h. Subsequently, cells were washed and stained with specific antibodies 
or with an isotype matched control. Results of flow cytometric analysis and 
corresponding MFI values are shown. Control DCs (grey filled histogram) vs 
Loxoribine stimulated DCs (pink line) and isotype control (blue line). Profiles are 
shown for a single experiment and are representative of three experiments.  
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FIGURE 3.31: Comparison of surface marker expression on JAWS II and 
BMDCs following TLR9 activation. JAWS II and BMDC were differentiated in 
the presence of r-GMCSF for seven days and then stimulated with CpG (2 µM) for 
24 h. Subsequently, cells were washed and stained with specific antibodies or with 
an isotype matched control. Results of flow cytometric analysis and corresponding 
MFI values are shown. Control DCs (grey filled histogram) vs CpG stimulated DCs 
(pink line) and isotype control (blue line). Profiles are shown for a single experiment 
and are representative of three experiments. 
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FIGURE 3.32: Comparison of surface marker expression on JAWS II and 
BMDCs following TLR9 activation. JAWS II and BMDC were differentiated in 
the presence of r-GMCSF for seven days and then stimulated with CpG (2 µM) for 
24 h. Subsequently, cells were washed and stained with specific antibodies or with 
an isotype matched control. Results of flow cytometric analysis and corresponding 
MFI values are shown. Control DCs (grey filled histogram) vs CpG stimulated DCs 
(pink line) and isotype control (blue line). Profiles are shown for a single experiment 
and are representative of three experiments. 
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TABLE 3.1 and 3.2: Summary of Surface Marker Expression on JAWS II DCs 
and BMDCs following stimulation with a panel of TLR ligands. JAWS II and 
BMDC were differentiated in the presence of r-GMCSF for seven days and then 
stimulated with 5 µg/ml peptidoglycan (PGN), 10 µg/ml Polyinosinic-polycytidylic 
acid (Poly (I:C)), 100 ng/ml Lipopolysaccharide (LPS) (E. coli serotype R515), 5 
µg/ml Flagellin, 1 mM Loxoribine or 2 µM CpG oligodeoxynucleotides (CpG ODN) 
for 24h. NE = Not Expressed.   Subsequently, cells were washed and stained with the 
specific antibodies or with an isotype matched control.   
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3.3 DISCUSSION 
 
The characterisation of DCs began less than thirty years ago yet in that time have 
proven to be essential for the generation of a functional immune response. They do 
so by the capture and processing of antigens, expression of surface co-stimulatory 
molecules, migration to lymphoid organs and secretion of cytokines and chemokine 
(Steinman 1998). Understanding these actions, such as their ability to drive T helper 
cell responses makes the DC a powerful tool for manipulating the immune system. 
In this study our key objective was to compare the JAWS II DCs cell line to the 
BMDCs in order to determine whether they would be a suitable model for 
characterising SNARE function in DCs. In order to do this we assessed their 
response to a panel of TLR ligands. The parameters assessed included cytokine and 
chemokine secretion and expression of co-stimulatory molecules.  
 
To date 13 murine TLR ligands have been described and can be divided into two 
groups, those expressed on the surface of the cell or those which reside 
intracellularly. In this study we examined the effect of stimulation of BMDCs and 
JAWS II DCs with six TLR ligands. TLR 2, 4 and 5 are surface TLRs which 
recognise markers from the exterior of a pathogen and intracellular TLRs, TLR3, 7 
and 9 which recognise nucleic acids (McGettrick and O'Neill 2010). TLR4, the best 
characterised cell surface TLR, is responsible for the recognition of LPS, a 
glycolipid component of the outer wall of gram-negative bacteria. Activation of 
BMDCs and their cytokine, chemokine and surface marker expression has been well 
characterised in the literature and our findings on the effects of LPS on BMDCs 
concur with this. 
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Dowling et al, showed similar levels of secretion of the cytokines, IL-6, IL-10, IL-
12p40, IL-12p70 and TNF-α from BMDCs following LPS stimulation. Surface 
marker expression of CD40, CD80 and CD86 were also up-regulated similar to the 
profile we observed in BMDCs (Dowling, Hamilton and O'Neill 2008). Secretion of 
IL-1β and MIP-1α and up-regulation of MHC II in response to LPS has also been 
reported by Dearman et al., 2008 consistent with our data (Dearman et al. 2009). 
 
Flagellin, a structural protein subunit of the flagellum from gram-negative bacteria, 
mediates DC activation through TLR5 activation. It has been shown to evoke the 
production of low levels of pro-inflammatory cytokines, minimal levels of 
chemokines, such as MIP-1α and up-regulation of the surface markers CD40, CD80, 
CD86 and MHC II (Dearman et al. 2009, Didierlaurent et al. 2004) . BMDCs in this 
study responded in a similar manner consistent with this published data. This low 
level of response compared to other ligands may also be caused genetically. Indeed it 
has been reported there is a lack of expression of TLR5 mRNA in BMDCs isolated 
from C57BL6 mice (Means et al. 2003). PGN from gram-positive bacteria is 
reported to be a potent activator of NFκB and TNF-α through another surface TLR, 
TLR2. PGN also has several other recognition molecules including CD14, a family 
of peptidoglycan recognition proteins (PGRPs), Nod1 and Nod2, and PGN-lytic 
enzymes (lysozyme and amidases) (Dziarski 2003). PGN is a component of a 
bacterial cell wall covalently attached to other polymers such as lipoproteins and 
lipoteichoic acid. It has been reported that PGN induces the up-regulation of CD86 
and MHC II during DC maturation and stimulates the secretion of IL-6, TNFα, IL-12 
and MIP-2, which correlates well with our findings (Michelsen et al. 2001). 
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Intracellular TLRs play an important role in detecting and combating both bacterial 
and viral infections. TLR3, TLR7 and TLR9 recognise double-stranded (ds)RNA, 
single-stranded(ss)RNA and un-methylated CpG motifs respectively (Akira and 
Hemmi 2003). The presence of dsRNA in a cell is due to viral replication which can 
stimulate immune cells via TLR3. This dsRNA binds and activates the dsRNA 
activated protein kinase, PKR, initiating down-stream signalling that inhibits viral 
replication and secretion of pro-inflammatory cytokines (Akira and Hemmi 2003). 
Dowling et al., reported secretion of moderate levels of IL-6 and IL-12p40 with 
negligible levels of TNF-α from BMDCs stimulated with Poly (I:C) which correlates 
well with our data presented in this chapter. Surface marker levels of CD40, CD80 
and CD86 were all up-regulated which were comparable with our results. A plethora 
of natural and synthetic agonists for TLR7 have been identified. Guanosine 
analogue, Loxoribine (7-Allyl-8-oxo-G), activates NF-κB through TLR7. Activation 
induces production of pro-inflammatory cytokines and chemokines such as TNF-α, 
IL-12 and MIP-1α (Gorden et al. 2005, Lee et al. 2003). We noted similar responses 
although information on specific BMDCs response to Loxoribine as an agonist to 
TLR7 is not well reported. Unmethylated CpG-dinucleotide-containing sequences 
(CpG ODNs) act as a TLR9 agonist in immune cells. These sequences are found 
much more frequently in bacterial genomes than in vertebrate genomes which are 
also usually methylated  (Akira and Hemmi 2003). Treatment of BMDCs with CpG 
has been reported to be associated with a preferential type 1 cytokine and chemokine 
profile, similar to response of LPS stimulation. In agreement with this, CpG 
stimulation evoked secretion of high levels of IL-12. High levels of chemokine 
secretion in response to CpG has also been reported which we demonstrated with 
MIP-1α and MIP-2 (Dearman et al. 2009). Furthermore CD40, CD80 and CD86 
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expression were all up-regulated, in agreement with previously published work 
(Dowling, Hamilton and O'Neill 2008).  
 
In summary, we have demonstrated that the BMDCs in this study display a distinct 
pattern of TLR responsiveness consistent with the published literature. Different 
TLR ligation provoked selective cytokine and chemokine secretion along with 
surface marker expression. In order to determine if we could use JAWS II DCs as a 
model to examine the role of SNAREs in DCs we wanted to compare their response 
to TLR ligands to the response we observed with BMDCs. When we compared 
between primary BMDCs and the JAWS II DC cell line there were some differences 
in these parameters.  
 
The IL-12 cytokine family is composed of IL-12, IL-23, IL-27 and the recently 
identified IL-35. The ability of DCs to release IL-12 in response to microbial stimuli 
is considered pivotal for the induction of a TH1 response (Collison et al. 2007). We 
demonstrated BMDCs secreted IL-12 in response to most TLR ligation. In 
comparison JAWS DCs secreted negligible levels of IL-12p40 and IL-27p28, IL-
12p70 and IL-23. IL-12 is composed of p35 and p40 subunits, which when the come 
together form the bioactive IL-12p70. IL-23 is also composed of the IL-12p40 
subunit and IL-23p19 (Gee et al. 2009) . The lack of IL-12p70 and IL-23 expression 
seen in this study may accounted for by the low levels of IL-12p40 secreted from the 
JAWS II DCs. IL-27p28 subunit which makes up IL-27 when combined with 
Epstein-Barr virus induced gene 3 (EBI3) subunit is also expressed at low levels 
possibly indicating a redundancy in the IL-12 family in JAWS II DCs. There are 
conflicting reports in the literature regarding the secretion of IL-12 from JAWS II 
DCs. Jiang et al., reported similar levels of IL-12 secretion from JAWS II and 
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BMDCs when stimulated with LPS and Chlamydia (Jiang et al. 2008) however 
Jørgensen et al., also reported lack of IL-12 production along with Zapala et al 
(Jorgensen, Haase and Michelsen 2002, Zapala et al. 2011) Indeed Pajtasz-Piasecka 
et al., had to transduce JAWS II DCs with IL-12 genes to generate an anti tumor 
response in immunotherapy of C57BL/6 mice bearing transplantable murine colon 
carcinoma (MC38) which strongly supports our findings (Pajtasz-Piasecka et al. 
2007). 
 
Other cytokines have been reported to be secreted in large amounts, such as, IL-1, 
IL-6 and TNF-α from JAWS II DCs in response to LPS (Jorgensen, Haase and 
Michelsen 2002), and  Poly (I:C)  (Zapala et al. 2011). This correlated with our 
results but to a lesser degree with Poly (I.C.). These discrepancies can be somewhat 
explained by the time-points used in our study, which was 24 hours and the 
published studies which used 48 hours. We also reported novel data regarding the 
secretion of these cytokines which were only slightly up-regulated in response to 
TLR2 and TLR5 stimulation and not with TLR9 agonist. Loxoribine stimulation 
resulted in a similar pattern of secretion to TLR4 stimulation.  
 
Basal expression of IL-10, can be seen in JAWSII DCs. This could be indicative of 
picogram levels of endotoxin. FCS used in the fully supplemented media has been 
reported to contain this contaminating endotoxin (Rinehart et al., 1997). However the 
IL-10 levels are at such low amount and co-stimulatory markers are not up-regulated 
it would suggest that the JAWS DCs have not been matured due to the presence of 
an endotoxin.  
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Chemokine production has been reported on to a much lesser extent however Zapala 
et al., report that monocyte chemotactic protein-1 (MCP-1) is secreted in response to 
LPS and Poly (I:C) stimulation and MIP-2 expression was seen at high levels when 
stimulated with TLR4 and TLR7 but not induced in response to TLR2, TLR3, TLR5 
and TLR9 from JAWS II DCs (Zapala et al. 2011). This MIP-2 expression correlated 
well with our data. BMDCs secrete a wide range of chemokines upon stimulation so 
would need to be assessed further in JAWS II DCs. We show novel chemokine data 
of high-levels of MIP-1α when stimulated with TLR4 and TLR7 and smaller 
amounts with TLR2, TLR3 and TLR5. There was no secretion following stimulation 
with TLR9. Previously reported data on the lack of TLR9 expression on DCs may be 
responsible for the lack of responsiveness to CpG stimulation (Zapala et al. 2011).  
 
High levels of expression of MHC II have previously been reported in JAWS II DCs 
in response to LPS (Jorgensen, Haase and Michelsen 2002) which is in agreement 
with our results. We also noted expression of MHC II in response to TLR2, TLR3, 
TLR7 simulation but not with TLR5 or TLR9. Co-stimulatory molecules such as 
CD80 and CD86 were up-regulated in response to a TLR4 agonist, as was CD14 
expression post TLR4 activation, which is in agreement with previously published 
work (Jorgensen, Haase and Michelsen 2002). CD14 expression was also up-
regulated in response to TLR2, TLR3 and TLR7, which to our knowledge is novel 
data as was Loxoribine being the only other TLR ligand to stimulate any expression 
of CD80 or CD86.  
 
Zapala et al., showed LPS, Poly (I:C) and CpG induced the expression of TLR2 
JAWS II DCs (Zapala et al. 2011). This is in agreement with our data and we also 
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showed that TLR2 expression was up-regulated in response to PGN and Loxoribine 
stimulation. TLR4 expression has been reported to be “moderately” expressed on 
control JAWSII DCs and show little to no change following activation with TLR3, 
TLR4 or TLR9 ligands (Zapala et al. 2011), however we report that TLR4 
expression was induced by TLR2, TLR3, and TLR7 activation but not TLR9 and 
TLR4.  
 
Another important finding was that, JAWS II DCs appear not to have expression of 
the cell surface marker CD40 even after stimulation of with the TLR ligands. 
Jørgensen et al. also noted this with LPS stimulation (Jorgensen, Haase and 
Michelsen 2002). CD40 is a co-stimulatory molecule reported necessary for 
activation of naïve T cells. Interestingly Haase et al, used the fact that JAWS II DCs 
do not express this marker to investigate its function and concluded that CD40 is 
necessary for activation of naïve T cells in vivo but not in vitro (Haase, Michelsen 
and Jorgensen 2004) . 
 
Overall JAWS II DCs expressed markers of maturation and secreted immune 
mediators similar to BMDCs in response to a panel of TLR ligands. However two 
key differences included lack of CD40 expression and significantly reduced IL-12 
secretion. Given that the purpose of the model will be to examine the role of 
SNAREs in DCs, the fact they do not secrete certain cytokines or chemokines in 
response to particular TLR ligands may provide us with a useful model to study its 
secretion by comparing SNARE expression in BMDCs versus JAWS II DCs.  
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4.1  INTRODUCTION 
 
Since the 1980s when SNARE proteins were first discovered there has been much 
work to characterise their function. In the 1990s Sudof et al., was one of the first to 
look at SNARE proteins in membrane fusion. They did this with in vivo experiments 
which showed that membrane fusion could not occur when SNARE proteins were 
destroyed with neurotoxins. This study indicated an essential role for SNAREs in the 
trafficking of molecules and membranes within cells (Sudhof 1995). To date there 
are 38 members of the SNARE family, the subcellular locations and differential 
combinations of SNARE proteins differ between cell types. The pairing of SNARE 
proteins is selective, this limits trafficking and membrane fusion between 
intracellular organelles or membrane fusion (Stow, Manderson and Murray 2006a). 
Studies into expression of individual SNAREs and their subcellular locations has led 
to the mapping intracellular pathways. More advanced work has begun to assign 
functions to SNAREs in specific cellular immune responses such as the role of STX6 
and Vti1b in the secretion of TNF from activated macrophage (Murray et al. 2005b).  
In the previous chapter we confirmed the value of using the JAWS II DC cell line to 
examine the role of SNAREs in DCs. Given the important role of cytokine secretion 
from DCs in inflammatory disease we were particularly interested in exploring the 
SNAREs necessary for secretion of these key cytokines and chemokines. 
In order to examine the role of SNAREs in DCs we used reverse transcriptase-
polymerase chain reaction (RT-PCR) and reverse transcriptase quantitative 
polymerase chain reaction (RT-qPCR). Since 2009 and the publication of the 
Minimum Information for Publication of Quantitative Real Time PCR Experiments 
(MIQE) guidelines the procedures for PCR have become more stringent. These 
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guidelines are helping to create credible, consistent and reliable data which allow 
results be reproducible from lab to lab and allow for more reliable publications 
(Bustin et al. 2009). These guidelines and requirements have formed the basis of the 
protocols used in this chapter and are shown in the preliminary experiments at the 
start of this chapter. For example RNA integrity was investigated for each individual 
experiment; all details on qPCR target information such as gene symbol, sequence 
accession number and amplicon length are provided. Identification of a robust 
endogenous control was undertaken and primers have been validated by means of 
calibration curves. 
 
The differential cytokine and chemokine secretion between BMDCs and JAWS II 
DCs and within the JAWS II DCs itself to TLR ligands, provides the opportunity to 
identify SNARE candidates which play key roles in specific cytokine or chemokine 
secretion. The objective of this chapter was to characterise the expression of SNARE 
proteins in JAWS II DCs following activation with TLR ligands. An up-regulation of 
SNARE expression in DCs following activation may indicate a role for them in 
cytokine or chemokine secretion. Furthermore identifying the expression and 
localization of SNARE proteins could provide us with potential therapeutic targets to 
modulate cytokine or chemokine secretion by DCs. Therefore we investigated the 
expression of SNARE mRNA in JAWS II DCs following activation with a number 
of TLR ligands.  
We also wanted to determine the relevance of any up-regulated SNAREs in 
inflammatory disease. Therefore we examined their expression in two models of 
experimental IBD, the dextran sodium sulphate (DSS)-induced colitis mouse model 
and the Citrobacter rodentium infection model.   
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4.2 RESULTS 
 
4.2.1 INSURANCE REMOVAL OF GENOMIC DNA  
 
JAWS II DCs were cultured for seven days in the presence of murine recombinant 
GM-CSF (Sigma ®) and plated at 1 x 10
6
 cell/ml. Cells were then stimulated with 
100ng/ml LPS (E. coli serotype R515) for 24 hours. Total RNA was extracted from 
the cells using the Nucleospin ™ RNA II extraction kit (Machinery Nagel, Dueren, 
Germany). RNA purity was checked by Nanodrop ™ Spectrometer and RNA quality 
by electrophoresis on a denaturing agarose gel. Only intact RNA, which appeared as 
two sharp bands at 28S and 18S, was used for any experiment hereon [Figure 4.1A]. 
cDNA was synthesised using High Capacity Reverse Transcription Kit (Applied 
Biosystems™).  
 
As can be seen from Table 4.1 most of the primers target the non-coding mRNA. To 
prevent any amplification of this region, a DNase step was carried out to remove the 
genomic DNA in the RNA extraction. To ensure the removal of genomic DNA the 
use of an intron flanking primer was employed. PCR was performed using GoTaq® 
DNA polymerase (Promega, Southampton, UK) and the PCR products run out on an 
agarose gel [Figure 4.1B]. Presence of genomic DNA would result in two 
amplicons, one large amplicion containing the genomic DNA and one smaller 
containing the desired PCR product. All mRNA was checked by this means for 
genomic contamination, however none was detected.  
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4.2.2 EXPRESSION OF SNARE MRNA DURING LPS ACTIVATION 
 
JAWS II DCs were cultured for seven days in the presence of murine recombinant 
GM-CSF (Sigma®) and plated at 1 x 10
6
 cell/ml. Cells were then stimulated with 
100ng/ml LPS (E. coli serotype R515) for 24 hours. Total RNA was extracted from 
the cells using the NuceloSpin RNA II extraction kit (Machinery Nagel, Dueren, 
Germany). cDNA was synthesised using High Capacity Reverse Transcription Kit 
(Applied Biosystems), PCR was performed using GoTaq® DNA polymerase 
(Promega, Southampton, UK) and the PCR products run out on an agarose gel 
[Figure 4.2].  
Of the 38 known mammalian SNAREs, we screened 18 SNAREs for their presence 
in the JAWS II DCs. All eighteen SNAREs were expressed in the mRNA of the 
JAWS II DCs in response to LPS (100ng/ml) for 24 hours [Figure 4.2].  
 
4.2.3 IDENTIFICATION OF ROBUST ENDOGENOUS CONTROL 
FOR RT-QPCR 
 
JAWS II DCs were cultured for seven days in the presence of murine recombinant 
GM-CSF (Sigma ®) and plated at 1 x 10
6
 cell/ml. Cells were then stimulated with 
100ng/ml LPS (E. coli serotype R515) and 1mM Loxoribine for 24 hours. Total 
RNA was extracted and converted to cDNA and RT-qPCR was performed using 18S 
Ribosomal RNA (S18), β-actin and Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) primers. Raw Cq’s were plotted and S18 showed the smallest standard 
deviation between the technical replicates and the samples and thus was used for all 
subsequent experiments [Figure 4.3].  
CHAPTER 4                 SNARE EXPRESSION DURING IMMUNE ACTIVATION 
126 
 
 
4.2.4 PRIMER OPTIMISATION 
As PCR efficiency is highly dependant on the primers, PCR amplification efficiency 
was established by means of a calibration curve. JAWS II DCs were cultured for 
seven days in the presence of murine recombinant GM-CSF (Sigma ®) and plated at 
1 x 10
6
 cell/ml. Cells were then stimulated with 100 ng/ml LPS (E. coli serotype 
R515) for 24 hours. Total RNA was extracted and converted to cDNA. Using a 
series of ten-fold dilutions of this neat cDNA, absolute quantification RT-PCR was 
run. A calibration curve was prepared with the logarithm of the initial cDNA 
concentration plotted on the x axis and Cq on the y axis. From this the regression co-
efficient was calculated and the slope. PCR efficiency was calculated using the 
following formula:  
𝑃𝐶𝑅 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =   10
 −1 𝑠𝑙𝑜𝑝𝑒  − 1 ∗ 100% 
 
A good primer set should have an efficiency between 90% and 110% which 
corresponds to a slope of between -3.58 and -3.10. SNAP-23 achieved 99% [Figure 
4.4] and the other 17 SNAREs and subsequent primers used in this thesis were also 
deemed to achieve efficiencies within the acceptable range [Table 4.1].  
 
4.2.7 MRNA EXPRESSION OF SNARES IN JAWS DCS 
FOLLOWING TIME DEPENDENT ACTIVATION WITH A TLR 
LIGAND; TLR-2 PEPTIDOGLYCAN (PGN), TLR 4 
LIPOPOLYSACCARIDE (LPS) AND TLR7  LOXORIBINE 
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JAWS II DCs were cultured for seven days in the presence of murine recombinant 
GM-CSF (Sigma ®) and plated at 1 x 10
6
 cell/ml. Cells were then stimulated with 
5μg/ml PGN, 100ng/ml LPS (E. coli serotype R515) or 1mM Loxoribine over a 
time-course. Total RNA was extracted, converted to cDNA, which was then 
subjected to quantitative real-time PCR. 2
−ΔΔCq
 formula of the delta-delta Cq method 
was used and a fold change in expression of SNARE genes was normalized against 
that of endogenous control S18. SNARE mRNA levels were determined relative to 
expression in the absence of TLR stimulation, which is given an arbitrary value of 1.  
 
 4.2.7.1 mRNA EXPRESSION OF Qa-SNAREs, STX2, STX3, STX4, 
STX5, STX7, STX11, STX12 AND STX16  
Activation of JAWSII DCs with LPS and Loxoribine resulted in a significant 
decrease in STX2 mRNA expression at 4 hours (h) post stimulation compared to 
control cells (p≤0.001) [Figure 4.5]. However STX2 levels in response to PGN 
remained unchanged compared to control cells [Figure 4.5]. Expression of STX3 
mRNA in JAWSII DCs significantly increased following activation with LPS and 
Loxoribine post 1h and 4h stimulation (p≤0.01 and p≤0.05) [Figure 4.6]. In contrast 
STX3 levels in response to PGN were decreased significantly at 1h, 4h and 12h 
(p≤0.01, p≤0.05 and p≤0.05) compared to control cells [Figure 4.6]. STX4 mRNA 
expression generally remained unchanged with LPS and PGN stimulation at 1h, 4h 
and 12h [Figure 4.7]. There was a significant decrease one hour post Loxoribine 
stimulation (p≤0.05) in STX4 mRNA expression compared to control cells [Figure 
4.7]. No significant changes in STX5 mRNA were observed with LPS or Loxoribine 
stimulation at 1h, 4h or 12h [Figure 4.8], however PGN stimulation at 4h and 12h 
significantly increased STX5 mRNA expression compared to control cells (p≤0.05, 
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p≤0.001) [Figure 4.8]. Loxoribine stimulation for 12h significantly decreased STX7 
mRNA expression in JAWS II DCs compared to control cells (p>0.05) [Figure 4.9]. 
One hour stimulation of PGN significantly decreased mRNA expression of STX7 
(p≤0.05) [Figure 4.9]. STX7 mRNA remained unchanged with LPS stimulation at 
1h, 4h or 12h compared to control cells [Figure 4.9]. STX11 mRNA expression in 
JAWSII DCs increased significantly with LPS , Loxoribine and PGN at 1h and 4h 
compared to control cells (p≤0.001) [Figure 4.10]. 12h stimulation with LPS and 
Loxoribine also resulted in significantly up-regulated STX11 compared to control 
cells (p≤0.001) [Figure 4.10]. LPS stimulation of JAWSII DCs resulted in 
significant up-regulation of STX12 mRNA at 1h and 4 h compared to control cells 
(p≤0.01, p≤0.001) [Figure 4.11]. Loxoribine stimulation also significantly increased 
STX12 mRNA at 4h compared to control cells (p≤0.001) and PGN stimulation had 
no effect on STX12 mRNA levels compared to control cells [Figure 4.11]. There 
was significant up-regulation of STX16 mRNA in JAWSII DCs 4h and 12h post 
LPS stimulation in comparison to control cells (p≤0.05, p≤0.001) [Figure 4.12]. 
Loxoribine stimulation also resulted in significant up-regulation of STX16 compared 
to control cells at 12h (p≤0.001) and STX16 mRNA expression was significantly 
down-regulated at 1h (p≤0.05) and subsequently significantly up-regulated at 12h 
(p≤0.05) post PGN stimulation [Figure 4.12]. 
 
4.2.7.2 mRNA EXPRESSION OF Qbc SNARE SNAP23 
 
SNAP-23 mRNA expression increased significantly post 12h stimulation with 
Loxoribine (p≤0.001) and PGN (p≤0.05) compared to control cells. SNAP-23 levels 
in response to LPS remained unchanged compared to control cells [Figure 4.13]. 
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 4.2.7.3 mRNA EXPRESSION OF Qb-SNAREs, VTI1a and VTI1b 
 
There was a significant up-regulation of Vti1a mRNA at 4h and 12h post LPS and 
Loxoribine stimulation (p≤0.01, p≤0.001, p≤0.01) in comparison to control cells 
[Figure 4.14] Vti1a mRNA expression was significantly up-regulated following 
PGN at 1h and 4h (p≤0.05, p≤0.01) in comparison to control [Figure 4.14]. Vti1b 
mRNA expression was significantly down-regulated following stimulation with LPS 
and Loxoribine at 1h (p≤0.05) in comparison to control cells and in response to PGN 
stimulation was not significantly changed in response to PGN stimulation [Figure 
4.15]. 
 
 4.2.7.4  mRNA EXPRESSION OF Qc SNARE, STX6 
 
STX6 mRNA remained unchanged with LPS stimulation at 1, 4 or 12 hour [Figure 
4.16]. However Loxoribine and PGN stimulation at 12 hour resulted in significant 
increase of STX6 mRNA expression compared to control cells (p≤0.001, p≤0.01) 
[Figure 4.16]. 
 
 4.2.7.5  mRNA EXPRESSION OF VAMP2, VAMP3, VAMP4, 
VAMP7 AND VAMP8   
 
Following LPS, Loxoribine and PGN stimulation, VAMP1 expression was 
significantly down-regulated in JAWSII DCs at 1 h and 4 h (p≤0.001) in comparison 
to control cells and was also significantly down-regulated in response to Loxoribine 
and PGN at 12 h (p≤0.001, p≤0.01). [Figure 4.17]. There was significant up-
regulation of VAMP2 mRNA expression at 12 h when stimulated with LPS, 
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Loxoribine and PGN (p≤0.01) compared to control cells [Figure 4.18]. Following 
LPS stimulation VAMP3 expression was significantly up-regulated after 1h 
compared to control cells (p≤0.05) however this expression was significantly down-
regulated following 12 h of LPS stimulation (p≤0.05) [Figure 4.19]. Loxoribine 
significantly up-regulated VAMP3 expression after 4h (p≤0.05) compared to control 
cells and stimulation of PGN significantly down-regulated VAMP3 expression after 
1 hour (p≤0.05) in comparison to control [Figure 4.19]. Loxoribine stimulation 
significantly down-regulated VAMP4 expression at 1 and 4 hour (p≤0.05, p≤0.01) in 
JAWS II DCs compared to control cells, however PGN stimulation resulted in an up-
regulation at 12 hour (p≤0.05) compared to control cells. [Figure 4.20]. LPS 
stimulation did not have any significant effect on VAMP4 expression [Figure 4.20]. 
VAMP7 expression remained unchanged following stimulation with LPS and 
Loxoribine compared to control. However PGN stimulation resulted in significant 
down-regulation of VAMP7 after 1 hour (p≤0.05) compared to control cells [Figure 
4.21]. Following Loxoribine stimulation VAMP8 expression was significantly 
down-regulated at 12 hour (p≤0.05) and up-regulated following PGN stimulation 
after 4h. LPS stimulation did not have any significant effect on VAMP8 expression 
[Figure 4.22].  
 
The SNARE mRNA up-regulation from JAWSII DCs following TLR ligand 
stimulation data was tablulated along with JAWSII cytokine and chemokine to aid in 
identification of candidate SNAREs, see Table 4.2. 
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4.2.8 mRNA EXPRESSION OF PRO-INFLAMMATORY 
CYTOKINES AND CHEMOKINES IN THE COLON IN A OF DSS 
INDUCED COLITIS MODEL 
 
Given that there were some significant changes in expression of SNAREs following 
activation of DCs with TLR ligands, in particular there were significant changes in 
STX3, STX11 and Vti1a (candidate SNAREs) with little changes  in STX4, 
SNAP23 and VAMP4, we therefore wanted to assess whether they were regulated in 
vivo during inflammatory disease. For this we used the DSS model experimentally 
induced colitis. DSS is a negatively charged glucose polymer with engrafted sulphate 
groups, which, when delivered in drinking water of mice induces intestinal 
inflammation mimicking the clinical and histological features of IBDs that have 
characteristics of UC (Laroui et al. 2012).  
This DSS colitis model was carried out in collaboration with Silvia Melgar in the 
Alimentary Pharmabiotic Centre, University College Cork. C57BL mice were split 
randomly into 5 groups. The control group contained 6 mice and the 4 test groups 
had 6-8 mice. DSS (Sigma) was prepared fresh daily and added to the drinking water 
of the mice at a final concentration of 3% for 5 days. Early acute, late acute and 
chronic mice were culled at 7, 12 and 26 days respectively. Mice were weighed and 
scored for daily disease activity (DDAI) every 3-4 days. DDAI was based on stool 
composition, fur texture and posture indicators of gut inflammation. The control 
group maintained a healthy weight and gained weight over the course of the study as 
expected. DSS treated groups lost weight immediately with the biggest loss in 
weight observed when the early acute mice were culled (day 7). Late acute and 
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chronic mice then began to recover and gain weight. Late acute mice (day 12) 
demonstrated a minor recovery in weight and when chronic mice (day 26) had 
recovered to their original weight with a slight gain [Figure 4.23(a)]. The DDAI 
clinical scoring showed a comparable pattern of disease with no disease observed in 
the control mice and a rapid increase in disease activity in all DSS-treated groups 
with some recovery in the chronic group at day 26 [Figure 4.23(b)]. The washed 
colons of each animal were removed, measured and weighed individually. Colon 
length and weight are indicators of gut inflammation as cell infiltration and 
inflammation increases the weight and shrinks the length of the colon. Colon length 
and weight from all DSS treated groups showed signs of gut  inflammation with a 
significant increase in weight and significant decrease in colon length (p≤0.01, 
p≤0.05) [Figure 4.23(d),(e)]. Once the colons had been measured and weighted a 
small section of distal colon was removed for histology and homogenisation for total 
RNA isolation. The colon tissue was cast in optimal cutting temperature (OCT) 
compound and snap frozen in liquid nitrogen and stored at -80
o
C.  Sections were 
then cut on a cryostat mounted onto slides and subjected to Hematoxylin and Eosin 
(H&E) staining for histological analysis. H&E staining demonstrated a healthy colon 
in the control group with good crypt formation and no infiltrating cells in the lower 
muscle layer of the gut. The early and late acute H&E staining shows a breakdown 
of crypt structures and infiltration of cells (purple spots) in the muscular layer with 
the worst infiltration evident in the late acute group. The chronic group shows some 
mild recovery with crypt structure evident and less infiltrating cells in the muscular 
layer consistent with the rest of the data [Figure 4.23(e)]. 
 
Total RNA was extracted from homogenised colonic tissue of mice at various stages 
of DSS colitis; early acute, late acute and chronic including controls, converted to 
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cDNA, which was then subjected to quantitative real-time PCR. 2
−ΔΔCq
 formula of 
the delta-delta Cq method was used and a fold change in expression of cytokine or 
chemokine genes was normalized against that of endogenous control S18. SNARE 
mRNA levels are relative to its expression in the absence of colitis, which is given an 
arbitrary value of 1.  
 
This model is well characterised with increased cytokine and chemokine secretion 
during disease. Therefore we first confirmed disease in the colon by examining the 
level of pro-inflammatory cytokines and chemokines present. IL-6 mRNA 
expression was significantly up-regulated in early and late acute stages of DSS 
colitis (p≤0.001, p≤0.05) [Figure 4.24]. mRNA expression of TNF-α was 
significantly up-regulated in all stages of DSS colitis in comparison to healthy 
controls (p≤0.001, p≤0.01 and p≤0.05) [Figure 4.24]. Early acute stage of DSS 
colitis resulted in significant levels of IFN-γ mRNA expression compared to healthy 
controls (p≤0.001) [Figure 4.24]. MIP-1α mRNA expression was significantly 
increased in the early acute, late acute and chronic stages of DSS colitis in 
comparison to healthy controls (p≤0.001 and p≤0.01) [Figure 4.24]. Early and late 
acute stages of disease resulted in significant increased levels of chemokine MIP-2 
mRNA levels (p≤0.001 and p≤0.05) [Figure 4.24]. MCP mRNA expression was also 
up-regulated during early and late acute stages of disease along with chronic stage of 
DSS colitis in comparison to healthy controls (p≤0.001 and p≤0.05) [Figure 4.24].  
 
4.2.9 mRNA EXPRESSION OF SNARES IN THE COLON 
FOLLOWING INDUCTION OF DSS INDUCED COLITIS MODEL 
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After confirming inflammation in the colon, we next examined expression of 
candidate SNAREs STX3, STX11 and Vti1a and unchanged SNARE, STX4, 
SNAP23 and VAMP4 post DC activation in DSS induced colitis.  
 
Total RNA was extracted from colonic tissue of mice at various stages of DSS 
colitis; early acute, late acute and chronic including controls, converted to cDNA, 
which was then subjected to quantitative real-time PCR. 2
−ΔΔCq
 formula of the delta-
delta Cq method was used and a fold change in expression of SNARE genes was 
normalized against that of endogenous control S18. SNARE mRNA levels are 
expressed relative to its expression in the absence of colitis, which is given an 
arbitrary value of 1.  
 
STX11 and STX3 were the two SNAREs to be most significantly up-regulated in the 
DSS model. STX11 was significantly up-regulated in DSS induced colitis model 
with a ~30 fold change in early stages and a ~10 fold change in the late stages 
(p≤0.001, p≤0.01) [Figure 4.25]. STX3 mRNA expression was significantly 
increased with a ~3 fold change in the late acute stages of DSS colitis (p≤0.01). 
SNAP23 was also up-regulated significantly in late acute phase of stages of DSS 
colitis (p≤0.01) and STX4 mRNA expression was significantly increased in both the 
early and late acute stages of disease (p≤0.05) [Figure 4.25]. Early and late acute 
stages of DSS induced colitis have significantly up-regulated expression of Vti1a 
mRNA expression in comparison to healthy controls (p≤0.01, p≤0.05) [Figure 4.25]. 
Vamp4 was the only SNARE to be significantly decreased in expression during DSS 
colitis, which was during the early acute phase of disease (p≤0.05) [Figure 4.25].  
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4.2.10  mRNA EXPRESSION OF PRO-INFLAMMATORY 
CYTOKINES AND CHEMOKINES IN THE COLON FOLLOWING 
INFECTION WITH CITROBACTER RODENTIUM   
 
We next wanted to examine the expression of the candidate SNAREs in another 
model of colitis, which is induced by Citrobacter rodentium infection. However we 
first had to assess the cytokine and chemokine production in the colons of the mice 
to confirm inflammation. C. rodentium is a gram negative murine specific bacterium 
that causes a similar pathology in mice to that caused by enteropathogenic 
Escherichia coli in humans. This rare model offers the opportunity for understanding 
chronic inflammatory responses seen in genetically susceptible IBD patients 
following abnormal exposure to enteric bacteria of the intestinal muscosal immune 
system (Bhinder et al. 2013). 
The C. rodentium colitis model was also performed in collaboration with Silvia 
Melgar in the Alimentary Pharmabiotic Centre, University College Cork. C57BL 
mice in groups of 6-8 were inoculated orally by a 200 μl gavage of approximately 
200x10
9
 CFU C. rodentium. Mice were sacrificed at 9, 14, 21 and 28 days for tissue 
processing. Colons were removed, washed, measured and weighed to assess gut 
inflammation. There was a significant increase in colon weight at day 9 (p≤0.001) of 
infection which recovered at days 14, 21 and 28 [Figure 4.26].  The average colon 
length in the infected mice was also significantly decreased at day 9 (p≤0.05), with 
mild recovery at days 14, 21 and 28 [Figure 4.26]. These parameters indicate colitis 
like symptoms of inflammation in the C. rodentium infected mice.  
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In order to confirm disease total RNA was extracted from homogenised sections of 
the distal colon of mice infected with Citrobacter rodentium over a 21 day period, 
converted to cDNA, which was then subjected to quantitative real-time PCR. 
2
−ΔΔCq
 formula of the delta-delta Cq method was used and a fold change in 
expression of cytokine or chemokine genes was normalized against that of 
endogenous control S18. Cytokine or chemokine mRNA levels are expressed 
relative to its expression in the absence of colitis, which is given an arbitrary value of 
1.  
IL-6, TNF-α and IFN-γ mRNA expression was significantly increased on day 9 of C. 
rodentium infection in comparison to healthy controls (p≤0.05, p≤0.01 and p≤0.001) 
[Figure 4.27]. There were no significant changes in MIP-1α in comparison to 
healthy controls [Figure 4.27]. MIP-2 mRNA expression was significantly increased 
at day 3 and day 9 post infection with C. rodentium in comparison to healthy 
controls (p≤0.05 and p≤0.01) and MCP mRNA expression was significantly up-
regulated at 9 and 21 days in comparison to healthy controls (p≤0.001 and p≤0.01)  
[Figure 4.27].  
 
4.2.11 MRNA EXPRESSION OF SNARES IN THE COLON 
FOLLOWING INFECTION WITH CITROBACTER RODENTIUM   
 
Total RNA was extracted from colonic tissue of mice infected with C. rodentium 
over a 21 day period, converted to cDNA, which was then subjected to quantitative 
real-time PCR. 2
−ΔΔCq
 formula of the delta-delta Cq method was used and a fold 
change in expression of SNARE genes was normalized against that of endogenous 
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control S18. SNARE mRNA levels are relative to its expression in the absence of 
infection, which is given an arbitrary value of 1.  
There were little to no changes in SNAP23 or STX4 in C. rodentium infection with a 
small increase of expression at day 9 and day 3 respectively (p≤0.01, p≤0.05) 
[Figure 4.28]. Vamp4 mRNA expression was up-regulated at day 9 post infection 
with C. rodentium in comparison to healthy controls (p≤0.01) [Figure 4.28]. 
Interestingly STX3 was the only SNARE to be down-regulated during C. rodentium 
infection. It was significantly down-regulated at day 3 and day 21 post infection in 
comparison to healthy controls (p≤0.001 and p≤0.01) [Figure 4.28]. STX-11 was 
up-regulated but at day 9 and day 14 of C. rodentium infection in comparison to 
healthy controls (p≤0.05) [Figure 4.28]. Vti1a was up-regulated at day3, day 9 and 
day 14 post infection in comparison to healthy controls (p≤0.01, p≤0.001 and 
p≤0.05) [Figure 4.28].  
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FIGURE 4.1: mRNA quality and integrity. A: To assess the integrity of the 
mRNA post extraction an RNA gel electrophoresis was performed. The clear 
appearance of the 28S, the 18S and the 5S rRNA with no smearing indicates high 
quality of RNA. B: To ensure the removal of all genomic DNA during the mRNA 
extraction a PCR using of intron flanking primers, STX7, was conducted for every 
mRNA extraction. Presence of this contamination would have result in 1 large and 1 
small amplicon when the PCR product was run out on a 1% agarose gel. 
 
mRNA amplicon 
236bp 
 
 
dDNA amplicon 
25629 bp 
 
 
28S 
18S 
5S 
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Table 4.1: Gene, Ref Seq ID, Primer sequences, amplicon length and location of amplicon within the genome. 
 
 
Gene Ref Seq ID Forward [5’ to 3’] Reverse [5’ to 3’] Location of amplicon Amplicon 
Length 
SNAP-23  NM_009222  GTTCTTGCTCAGGCTTCC CCAACCAACCAATACCAATAATG 3’ UTR of transcripts 1, 2, and 3 184bp 
STX2  NM_007941  GGTGGCAAAGGTGATGTT CAGGTATGGTCGGAGTCA 3’ UTR of transcripts 1 134bp 
STX3 NM_001025307  CCACAACCACTAGCATCATAA CTCAAGAGATATTCCGCCTTAA 3’ UTR of transcripts 1 and 2 157bp 
STX4  NM_009294  GGTGTCAAGTGTGAGAGAG AACCTCATCTTCATCGTCTG 5’ UTR of transcripts 1 148bp 
STX5 NM_001167799.1 GCAAGTCCCTCTTTGATGAT TTCAGATTCTCAGTCCTCACT  Intron Flanking Primer of transcript 1and 2 244bp 
STX6 NM_021433  CAAGGATTGTTTCAGAGATGGA CCTGACAATTTGCCGAGTA  Intron Flanking Primer 237bp 
STX7  NM_016797   CACAACGCATCTCCTCTAAC TAATCGGTCTTTCTGTATCTTTCTC  Intron Flanking Primer of transcript 1 236bp 
STX11 NM_001163591.1 ATCACGGCAAAATGAAGGA GGTCGGTCTCGAACACTA  3’ UTR of transcripts 1 126bp 
STX12 NM_133887 CGCAAGAAGATGTGTATCCT CTCTGAGGCAAGCACTTC 3’UTR 100bp 
STX-16 NM_001102432.1   GAGCAGTACCAGAAGAAGAAC CAAGTCCTATCACCAATAATCCA  Exon location 3 155bp 
Vti1a  NM_016862   GAATGTATAGCAACAGGATGAGA CCGTGTTATCCAGCAGATG Exon Location 3 and 6 of transcript 201, 203, 201 165bp 
Vti1b  NM_016862   TACCTTGGAGAACGAGCAT TGGACATTGAGCGAAGAATC  Intron Flanking of transcript 1 254bp 
VAMP1  NM_001080557   CCCTCTGTTTGCTTTCTCA CGTTGTCTTCGGGTAGTG 3’ UTR of transcripts 1 and 2 162bp 
VAMP2  NM_009497   CTCCTTCCCTTGGATTTAACC TGAAACAGACAGCGTATGC 3’ UTR of transcripts 1 246bp 
VAMP3  NM_009498  TTGTTCTTGTTGTATATCACTCCTAA GGCTCGCTCTCACAGTAT 3’ UTR of transcripts 1 202bp 
VAMP4  NM_016796  GTATGCCTCCCAAGTTCAAG TGTAGTTCATCCAGCCTCTC 5’ UTR of all transcripts 256bp 
VAMP7  NM_011515 GATGGAGACTCAAGCACAAG GACACAATGATATAGATGAACACAAT Intron Flanking 242bp 
VAMP8  NM_016794  GGCGAAGTTCTGCTTTGA CTTGACTCCCTCCACCTC 5' UTR of transcript 1 111bp 
Mip-1α/CCL3 NM_011337 CCTTGCTGTTCTTCTCTGTACC- CGATGAATTGGCGTGGAATC Exon Location: 1 - 2 122bp 
MIP-2/CXCL2 NM_009140 CAGAAGTCATAGCCACTCTCAAG CTTTCCAGGTCAGTTAGCCTT - Exon Location: 2 - 4 1191bp 
MCP/CCL2 NM_011333 CATCCACGTGTTGGCTCA AACTACAGCTTCTTTGGGACA- Exon Location: 1 - 3 142bp 
TNF-α NM_013693 AGA CCCTCA CACTCA GAT CA TCT TTG AGATCC ATG CCGTTG Exon Location: 2 - 4 145bp 
IL-6 NM_031168 AGC CAG AGT CCT TCA GAG A TCC TTA GCC ACT CCT TCT GT Exon Location: 4 - 5 146bp 
IFN-γ NM_008337.3  ATGAACGCACACACTGCATC CCATCCTTTTGCCAGTTCCTC Intron Flanking 137bp 
S18 NM_011296 CTGAGAAGTTCCAGCACATT GCTTTCCTCAACACCACAT Intron Flanking Primer of transcript 1 and 2 126bp 
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FIGURE 4.2: mRNA expression of SNAREs in JAWS II DCs.  JAWSII DCs were plated at 1x10
6
/ml and stimulated with 100 ng/ml LPS for 
24 hours. mRNA was extracted and RT-PCR was to detect all 18 SNAREs; STX2, STX3, STX4, STX5, STX6, STX7, STX11, STX12, STX16, 
SNAP23, Vti1a, Vti1b, VAMP1, VAMP2, VAMP3, VAMP4, VAMP7, VAMP8 and endogenous control S18. Expression of all targets was 
detected at their respective bp product size.   
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FIGURE 4.3: Identification of an endogenous control for JAWS II DCs. Cells 
were plated at 1x10
6
/ml and left to rest overnight. Cells were then stimulated with 
LPS 100 ng/ml and Loxoribine 1mM for 24hours. mRNA was then extracted and 
RT-qPCR was performed.  
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FIGURE 4.4: Assay Validation: Primer Efficiency Curve for SNAP23. RT-
qPCR was performed using SNAP-23 primers. Six-fold dilution of neat cDNA of 
LPS 100 ng/ml JAWS II DCs was prepared. Every dilution was run in triplicate. A: 
Amplification plot of SNAP23. B: Standard Curve obtained from SNAP23. The 
efficiency was 99.37% and the regression squared value was 0.996.  
  
A 
B 
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Table 4.2: Assay Validation: Primer Efficiency Curves. RT-qPCR was 
performed. Six-fold dilution of neat cDNA of LPS 100 ng/ml JAWS II DCs was 
prepared. Every dilution was run in triplicate. From the standard curves obtained 
efficiency and the regression squared value were obtained.  
Primer R
2
 Efficiency 
SNAP23 0.996 99% 
STX2 0.971 102% 
STX3 0.991 108% 
STX4 0.992 91% 
STX5 0.970 90% 
STX6 0.999 90% 
STX7 0.955 100% 
STX11 0.996 96% 
STX12 0.995 102% 
STX16 0.991 98% 
Vti1a 0.985 92% 
Vti1b 0.995 90% 
VAMP1 0.988 90% 
VAMP2 0.989 120% 
VAMP3 0.995 94% 
VAMP4 0.999 86% 
VAMP7 0.984 91% 
VAMP8 0.999 98% 
S18 0.988 93% 
 
 
Table 4.3: Assay Validation: Primer Efficiency Curves. RT-qPCR was 
performed. Six-fold dilution of neat cDNA of colonic tissue was prepared. Every 
dilution was run in triplicate. From the standard curves obtained efficiency and the 
regression squared value were obtained.  
Primer R
2
 Efficiency 
SNAP23 0.955 92% 
STX3 0.997 110% 
STX4 0.998 99% 
STX11 0.955 109% 
VAMP4 0.997 103% 
S18 0.997 98% 
TNF-α 0.997 100% 
IFN-γ 0.998 110% 
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Figure 4.5: Effect of TLR ligand stimulation on STX2 mRNA expression in 
JAWS II DCs.  JAWS II DCs was plated 1x10
6/
ml and stimulated with 100 ng/ml 
LPS, 1 mM Loxoribine or 5 μg/ml PGN at 1 h, 4 h, and 12 h. The amount of STX2 
was quantified by reverse transcription followed by RT-qPCR using an ABI 7900 
HT detection system. STX2 levels were assayed in triplicate (using SYBR green 
technology) and normalised with S18 levels. Fold differences were calculated 
relative to STX2 levels at time zero (assigned value of 1). Results are mean ± SEM 
of quadruplicate assays. A two sample, two tailed student’s t-test comparing ∆Cts of 
control and 1h, 4h, or 12h stimulated sample ***p≤0.001. 
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Figure 4.6: Effect of TLR ligand stimulation on STX3 mRNA expression in 
JAWS II DCs.  JAWS II DCs was plated 1x10
6/
ml and stimulated with 100 ng/ml 
LPS, 1 mM Loxoribine or 5 μg/ml PGN at 1 h, 4 h, and 12 h. The amount of STX3 
was quantified by reverse transcription followed by RT-qPCR using an ABI 7900 
HT detection system. STX3 levels were assayed in triplicate (using SYBR green 
technology) and normalised with S18 levels. Fold differences were calculated 
relative to STX3 levels at time zero (assigned value of 1). Results are mean ± SEM 
of quadruplicate assays. A two sample, two tailed student’s t-test comparing ∆Cts of 
control and 1h, 4h, or 12h stimulated sample *p≤0.05, **p≤0.01 ***p≤0.001.  
TLR4 
TLR7 
TLR2 
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Figure 4.7: Effect of TLR ligand stimulation on STX4 mRNA expression in 
JAWS II DCs. JAWS II DCs was plated 1x10
6/
ml and stimulated with 100 ng/ml 
LPS, 1mM Loxoribine or 5μg/ml PGN at 1 h, 4 h, and 12 h. The amount of STX4 
was quantified by reverse transcription followed by RT-qPCR using an ABI 7900 
HT detection system. STX4 levels were assayed in triplicate (using SYBR green 
technology) and normalised with S18 levels. Fold differences were calculated 
relative to STX4 levels at time zero (assigned value of 1). Results are mean ± SEM 
of quadruplicate assays. A two sample, two tailed student’s t-test comparing ∆Cts of 
control and 1h, 4h, or 12h stimulated sample *p≤0.05. 
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Figure 4.8: Effect of TLR ligand stimulation on STX5 mRNA expression in 
JAWS II DCs. JAWS II DCs was plated 1x10
6/
ml and stimulated with 100 ng/ml 
LPS, 1 mM Loxoribine or 5 μg/ml PGN at 1 h, 4 h, and 12 h. The amount of STX5 
was quantified by reverse transcription followed by RT-qPCR using an ABI 7900 
HT detection system. STX5 levels were assayed in triplicate (using SYBR green 
technology) and normalised with S18 levels. Fold differences were calculated 
relative to STX5 levels at time zero (assigned value of 1). Results are mean ± SEM 
of quadruplicate assays. A two sample, two tailed student’s t-test comparing ∆Cts of 
control and 1h, 4h, or 12h stimulated sample *p≤0.05, ***p≤0.001. 
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Figure 4.9: Effect of TLR ligand stimulation on STX7 mRNA expression in 
JAWS II DCs. JAWS II DCs was plated 1x10
6/
ml and stimulated with 100 ng/ml 
LPS, 1 mM Loxoribine or 5 μg/ml PGN at 1 h, 4 h, and 12 h. The amount of STX7 
was quantified by reverse transcription followed by RT-qPCR using an ABI 7900 
HT detection system. STX7 levels were assayed in triplicate (using SYBR green 
technology) and normalised with S18 levels. Fold differences were calculated 
relative to STX7 levels at time zero (assigned value of 1). Results are mean ± SEM 
of quadruplicate assays. A two sample, two tailed student’s t-test comparing ∆Cts of 
control and 1h, 4h, or 12h stimulated sample *p≤0.05. 
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Figure 4.10: Effect of TLR ligand stimulation on STX11 mRNA expression in 
JAWS II DCs. JAWS II DCs was plated 1x10
6/
ml and stimulated with 100 ng/ml 
LPS, 1 mM Loxoribine or 5 μg/ml PGN at 1 h, 4 h, and 12 h. The amount of STX11 
was quantified by reverse transcription followed by RT-qPCR using an ABI 7900 
HT detection system. STX11 levels were assayed in triplicate (using SYBR green 
technology) and normalised with S18 levels. Fold differences were calculated 
relative to STX11 levels at time zero (assigned value of 1). Results are mean ± SEM 
of quadruplicate assays. A two sample, two tailed student’s t-test comparing ∆Cts of 
control and 1h, 4h, or 12h stimulated sample *p≤0.05, ***p≤0.001. 
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Figure 4.11: Effect of TLR ligand stimulation on STX12 mRNA expression in 
JAWS II DCs. JAWS II DCs was plated 1x10
6/
ml and stimulated with 100 ng/ml 
LPS, 1 mM Loxoribine or 5 μg/ml PGN at 1 h, 4 h, and 12 h. The amount of STX12 
was quantified by reverse transcription followed by RT-qPCR using an ABI 7900 
HT detection system. STX12 levels were assayed in triplicate (using SYBR green 
technology) and normalised with S18 levels. Fold differences were calculated 
relative to STX12 levels at time zero (assigned value of 1). Results are mean ± SEM 
of quadruplicate assays. A two sample, two tailed student’s t-test comparing ∆Cts of 
control and 1h, 4h, or 12h stimulated sample *p≤0.05, ***p≤0.001. 
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Figure 4.12: Effect of TLR ligand stimulation on STX16 mRNA expression in 
JAWS II DCs. JAWS II DCs was plated 1x10
6/
ml and stimulated with 100 ng/ml 
LPS, 1 mM Loxoribine or 5 μg/ml PGN at 1 h, 4 h, and 12 h. The amount of STX16 
was quantified by reverse transcription followed by RT-qPCR using an ABI 7900 
HT detection system. STX16 levels were assayed in triplicate (using SYBR green 
technology) and normalised with S18 levels. Fold differences were calculated 
relative to STX16 levels at time zero (assigned value of 1). Results are mean ± SEM 
of quadruplicate assays. A two sample, two tailed student’s t-test comparing ∆Cts of 
control and 1h, 4h, or 12h stimulated sample *p≤0.05, ***p≤0.001. 
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Figure 4.13: Effect of TLR ligand stimulation on SNAP23 mRNA expression in 
JAWS II DCs.  JAWS II DCs was plated 1x10
6/
ml and stimulated with 100 ng/ml 
LPS, 1 mM Loxoribine or 5 μg/ml PGN at 1 h, 4 h, and 12 h. The amount of 
SNAP23 was quantified by reverse transcription followed by RT-qPCR using an 
ABI 7900 HT detection system. SNAP23 levels were assayed in triplicate (using 
SYBR green technology) and normalised with S18 levels. Fold differences were 
calculated relative to SNAP23 levels at time zero (assigned value of 1). Results are 
mean ± SEM of quadruplicate assays. A two sample, two tailed student’s t-test 
comparing ∆Cts of control and 1h, 4h, or 12h stimulated sample *p≤0.05 and 
***p≤0.001. 
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Figure 4.14: Effect of TLR ligand stimulation on Vti1a mRNA expression in 
JAWS II DCs. JAWS II DCs was plated 1x10
6/
ml and stimulated with 100 ng/ml 
LPS, 1 mM Loxoribine or 5 μg/ml PGN at 1 h, 4 h, and 12 h.. The amount of Vti1a 
was quantified by reverse transcription followed by RT-qPCR using an ABI 7900 
HT detection system Vti1a levels were assayed in triplicate (using SYBR green 
technology) and normalised with S18 levels. Fold differences were calculated 
relative to Vti1a levels at time zero (assigned value of 1). Results are mean ± SEM 
of quadruplicate assays. A two sample, two tailed student’s t-test comparing ∆Cts of 
control and 1h, 4h, or 12h stimulated sample *p≤0.05, **p≤0.01, ***p≤0.001. 
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Figure 4.15: Effect of TLR ligand stimulation on Vti1b mRNA expression in 
JAWS II DCs. JAWS II DCs was plated 1x10
6/
ml and stimulated with 100 ng/ml 
LPS, 1 mM Loxoribine or 5 μg/ml PGN at 1 h, 4 h, and 12 h. The amount of Vti1b 
was quantified by reverse transcription followed by RT-qPCR using an ABI 7900 
HT detection system Vti1b levels were assayed in triplicate (using SYBR green 
technology) and normalised with S18 levels. Fold differences were calculated 
relative to Vti1b levels at time zero (assigned value of 1). Results are mean ± SEM 
of quadruplicate assays. A two sample, two tailed student’s t-test comparing ∆Cts of 
control and 1h, 4h, or 12h stimulated sample *p≤0.05. 
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Figure 4.16: Effect of TLR ligand stimulation on STX6 mRNA expression in 
JAWS II DCs. JAWS II DCs was plated 1x10
6/
ml and stimulated with 100 ng/ml 
LPS, 1 mM Loxoribine or 5 μg/ml PGN at 1 h, 4 h, and 12 h. The amount of STX-6 
was quantified by reverse transcription followed by RT-qPCR using an ABI 7900 
HT detection system. STX6 levels were assayed in triplicate (using SYBR green 
technology) and normalised with S18 levels. Fold differences were calculated 
relative to STX6 levels at time zero (assigned value of 1). Results are mean ± SEM 
of quadruplicate assays. A two sample, two tailed student’s t-test comparing ∆Cts of 
control and 1h, 4h, or 12h stimulated sample *p≤0.05, ***p≤0.001 
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Figure 4.17: Effect of TLR ligand stimulation on VAMP1 mRNA expression in 
JAWS II DCs. JAWS II DCs was plated 1x10
6/
ml and stimulated with 100 ng/ml 
LPS, 1 mM Loxoribine or 5 μg/ml PGN at 1 h, 4 h, and 12 h. The amount of 
VAMP1 was quantified by reverse transcription followed by RT-qPCR using an ABI 
7900 HT detection system. VAMP1 levels were assayed in triplicate (using SYBR 
green technology) and normalised with S18 levels. Fold differences were calculated 
relative to VAMP1 levels at time zero (assigned value of 1). Results are mean ± 
SEM of quadruplicate assays. A two sample, two tailed student’s t-test comparing 
∆Cts of control and 1h, 4h, or 12h stimulated sample **p≤0.01, ***p≤0.001. 
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Figure 4.18: Effect of TLR ligand stimulation on VAMP2 mRNA expression in 
JAWS II DCs. JAWS II DCs was plated 1x10
6/
ml and stimulated with 100 ng/ml 
LPS, 1 mM Loxoribine or 5 μg/ml PGN at 1 h, 4 h, and 12 h. The amount of 
VAMP2 was quantified by reverse transcription followed by RT-qPCR using an ABI 
7900 HT detection system. VAMP2 levels were assayed in triplicate (using SYBR 
green technology) and normalised with S18 levels. Fold differences were calculated 
relative to VAMP2 levels at time zero (assigned value of 1). Results are mean ± 
SEM of quadruplicate assays. A two sample, two tailed student’s t-test comparing 
∆Cts of control and 1h, 4h, or 12h stimulated sample **p≤0.01. 
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Figure 4.19: Effect of TLR ligand stimulation on VAMP3 mRNA expression in 
JAWS II DCs. JAWS II DCs was plated 1x10
6/
ml and stimulated with 100 ng/ml 
LPS, 1 mM Loxoribine or 5 μg/ml PGN at 1 h, 4 h, and 12 h. The amount of 
VAMP3 was quantified by reverse transcription followed by RT-qPCR using an ABI 
7900 HT detection system. VAMP3 levels were assayed in triplicate (using SYBR 
green technology) and normalised with S18 levels. Fold differences were calculated 
relative to VAMP3 levels at time zero (assigned value of 1). Results are mean ± 
SEM of quadruplicate assays. A two sample, two tailed student’s t-test comparing 
∆Cts of control and 1h, 4h, or 12h stimulated sample *p≤0.05. 
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Figure 4.20: Effect of TLR ligand stimulation on VAMP4 mRNA expression in 
JAWS II DCs. JAWS II DCs was plated 1x10
6/
ml and stimulated with 100 ng/ml 
LPS, 1 mM Loxoribine or 5 μg/ml PGN at 1 h, 4 h, and 12 h. The amount of 
VAMP4 was quantified by reverse transcription followed by RT-qPCR using an ABI 
7900 HT detection system. VAMP4 levels were assayed in triplicate (using SYBR 
green technology) and normalised with S18 levels. Fold differences were calculated 
relative to VAMP4 levels at time zero (assigned value of 1). Results are mean ± 
SEM of quadruplicate assays. A two sample, two tailed student’s t-test comparing 
∆Cts of control and 1h, 4h, or 12h stimulated sample *p≤0.05. 
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Figure 4.21: Effect of TLR ligand stimulation on VAMP7 mRNA expression in 
JAWS II DCs. JAWS II DCs was plated 1x10
6/
ml and stimulated with 100 ng/ml 
LPS, 1 mM Loxoribine or 5 μg/ml PGN at 1 h, 4 h, and 12 h. The amount of 
VAMP7 was quantified by reverse transcription followed by RT-qPCR using an ABI 
7900 HT detection system. VAMP7 levels were assayed in triplicate (using SYBR 
green technology) and normalised with S18 levels. Fold differences were calculated 
relative to VAMP7 levels at time zero (assigned value of 1). Results are mean ± 
SEM of quadruplicate assays. A two sample, two tailed student’s t-test comparing 
∆Cts of control and 1h, 4h, or 12h stimulated sample *p≤0.05. 
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Figure 4.22: Effect of TLR ligand stimulation on VAMP8 mRNA expression in 
JAWS II DCs. JAWS II DCs was plated 1x10
6/
ml and stimulated with 100 ng/ml 
LPS, 1 mM Loxoribine or 5 μg/ml PGN at 1 h, 4 h, and 12 h. The amount of 
VAMP8 was quantified by reverse transcription followed by RT-qPCR using an ABI 
7900 HT detection system. VAMP8 levels were assayed in triplicate (using SYBR 
green technology) and normalised with S18 levels. Fold differences were calculated 
relative to VAMP8 levels at time zero (assigned value of 1). Results are mean ± 
SEM of quadruplicate assays. A two sample, two tailed student’s t-test comparing 
∆Cts of control and 1h, 4h, or 12h stimulated sample *p≤0.05. 
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Table 4.2 – Cytokine up-regulation correlated with mRNA up-regulation  
 
  
CHAPTER 4                 SNARE EXPRESSION DURING IMMUNE ACTIVATION 
163 
 
 
 
 
Figure 4.23 - Disease associated symptoms in the DSS colitis model – C57BL 
mice were grouped into a control group of 6 mice and 4 test groups.  DSS was 
administered to mice in the drinking water for 5 days at a final concentration of 3%.  
Mice were weighed and disease scored based on fur texture/posture for a daily 
disease activity index (DDAI) every 3-4 days (A).  The average % weight change of 
the 4 groups is plotted to the end point for each group.  The starting weight on Day 0 
is plotted as 100% of the weight with the rest of the weight relative to this value.  
Two control mice were culled at the end point for each test group.  There is a drop in 
body weight for all test groups after day 0 and a healthy gain in weight for control 
mice (B).  At the end point of each group the length (C) and weight (D) of each 
removed and washed colon was measured and used as an indication of inflammation 
in the colon.  Sections of the distal colon were removed for histology and H&E 
staining in order to confirm inflammation.  The control shows a healthy colon while 
infiltration and loss of crypt structure is evident in the acute slides with recovery in 
the chronic slides as expected (E). Results are means ±SEM of at least 5 mice, a two 
sample, two tailed student’s t-test was used to determine if differences between 
control and disease states were significant (*p≤0.05, **p≤0.01). 
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Figure 4.24: Cytokine and chemokine mRNA expression in DSS colitis mouse 
model.. The amount of target mRNA at various stages of colitis post induction of 
colitis (early acute, late acute and chronic disease) were quantified by reverse 
transcription followed by RT-qPCR using an ABI 7900 HT detection system mRNA 
levels were assayed in triplicate (using SYBR green technology) and normalised 
with S18 levels. Fold differences were calculated relative to target mRNA levels at 
control (assigned value of 1). ). Results are means ±SEM of at least 5 mice. A two 
sample, two tailed student’s t-test comparing ∆Cts of control and disease groups. 
*p≤0.05, **p≤0.01, ***p≤0.001.  
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Figure 4.25: SNARE mRNA expression in DSS colitis mouse model.. The amount 
of target mRNA at various stages of colitis post induction of colitis (early acute, late 
acute and chronic disease) were quantified by reverse transcription followed by RT-
qPCR using an ABI 7900 HT detection system mRNA levels were assayed in 
triplicate (using SYBR green technology) and normalised with S18 levels. Fold 
differences were calculated relative to target mRNA levels at control (assigned value 
of 1). ). Results are means ±SEM of at least 5 mice. A two sample, two tailed 
student’s t-test comparing ∆Cts of control and disease groups. *p≤0.05, **p≤0.01, 
***p≤0.001.  
CHAPTER 4                 SNARE EXPRESSION DURING IMMUNE ACTIVATION 
166 
 
Colon Weight in C. rodentium infected mice 
 
 
 
Colon Length in C. rodentium infected mice 
 
 
Figure 4.26 - Colon weight of mice infected with Citrobacter rodentium - C57BL 
mice were housed in groups of 6-8 mice and test mice were  inoculated with 
C.rodentium orally by a 200μl gavage of approximately 200x109 CFU C.rodentium. 
Mice were sacrificed at 9, 14, 21 and 28 days.  Colons were collected from mice and 
the contents carefully removed before washing and patting dry.  At the end point of 
each group the length and weight of each colon was measured individually and used 
as an indication of colitis in the mouse model.  There is a significant increase in 
colon weight at day 9 with a recovery in the later days. There is a significant 
decrease in colon length at day 9 with moderate recovery in the following days. 
Results are means ±SEM of at least 5 mice, two tailed student’s t-test was used to 
determine if differences between control and disease states were significant 
(*p≤0.05, ***p≤0.001). 
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Figure 4.27: Cytokines and chemokine mRNA expression in Citrobacter 
rodentium infection. The amount of target mRNA in the colonic tissue of healthy 
and a time course of 21days of Citrobacter rodentium infected mice was quantified 
by reverse transcription followed by RT-qPCR using an ABI 7900 HT detection 
system mRNA levels were assayed in triplicate (using SYBR green technology) and 
normalised with S18 levels. Fold differences were calculated relative to target 
mRNA levels at control (assigned value of 1). Results are means ±SEM of at least 5 
mice. A two sample, two tailed student’s t-test comparing ∆Cts of control and 
disease groups. *p≤0.05, **p≤0.01, ***p≤0.001. 
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Figure 4.28: SNARE mRNA expression in Citrobacter rodentium infection. The 
amount of target mRNA in the colonic tissue of healthy and a time course of 21days 
of Citrobacter rodentium infected mice was quantified by reverse transcription 
followed by RT-qPCR using an ABI 7900 HT detection system mRNA levels were 
assayed in triplicate (using SYBR green technology) and normalised with S18 levels. 
Fold differences were calculated relative to target mRNA levels at control (assigned 
value of 1). ). Results are means ±SEM of at least 5 mice. A two sample, two tailed 
student’s t-test comparing ∆Cts of control and disease groups. *p≤0.05, **p≤0.01, 
***p≤0.001.  
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4.3 DISCUSSION  
 
Eukaryotic cells have the remarkable feature of transporting bio-chemically distinct 
intracellular vesicles to and from the cell surface. The specific mechanism for the 
secretion of immune mediators such as cytokines and chemokines has not been well 
studied however it is now known that SNARE proteins play a central role in this 
process (Stow, Manderson and Murray 2006a). Expression of SNAREs in immune 
cells, especially at mRNA level has not been well characterised. Investigating their 
expression in immune cells may provide valuable insight into their involvement in 
cytokine and/or chemokine secretion and provide potential targets for inhibition of 
cytokines and chemokines in inflammatory disease.  
 
Real time-qPCR is often referred to as the gold standard and believed to be easy, 
however the emergence of new guideline has confirmed that this is not the case. RT-
qPCR has a high level of variability and involves many steps involved in optimising 
the assay. To streamline this complex assay, MIQE was published to offer easy to 
follow guidelines (Bustin et al. 2009). The key issues highlighted by the guidelines 
include sample quality, reverse transcription, assay validation, PCR efficiency and 
normalisation. To follow these guidelines, at the start of all experiments purity and 
integrity of mRNA were checked and only used if at high enough standard.  
Secondly, primers had to be optimised. PCR amplification efficiency is highly 
dependant on the primers used and this was assessed using calibration curves. A 
serial dilution of the cDNA was used for each sample and the log was plotted on the 
x axis (independent variable).and corresponding Cq (dependant variable) on the y 
axis.  Using the slope and the equation 10
-1/slope
-1, a theorical max of 1 or (100%) 
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would be expected as the Cq should double with each cycle. However efficiencies 
between 90%-110% are acceptable. All primer sets fell within this range. This 
successful validation means the assays are efficient, robust and sensitive. Only after 
these guidelines were followed could examination of the expression of SNAREs 
mRNA in JAWS II DCs begin. 
 
We initially used RT-PCR to assess the expression of mRNA of eighteen SNARE 
proteins in JAWS II DCs following TLR4 stimulation. This proved evidence that all 
eighteen SNAREs were present in the JAWSII DCs. Subsequently we then examined 
the expression of these SNAREs using RT-qPCR following TLR2, TLR4 and TLR7 
activation over a time course. Our data demonstrated that the expression of SNAREs 
following TLR ligation, differed dependently on the TLR ligand used. Furthermore 
there was huge variation in the level of expression of individual SNAREs in the 
DCs. 
 
VAMP8 has been previously indicated to also be involved in dendritic cell function, 
phagocytosis. Ho et al., reported that an over-expression of VAMP8 significantly 
inhibited phagocytosis suggesting that VAMP8 negatively regulates phagocytosis 
(Ho et al. 2008). Although we did not report any change in mRNA expression of 
VAMP8 in JAWS II DCs the same group in another study note that although they 
have indicated a role for VAMP8  in DCs, VAMP8 mRNA was not significantly 
elevated during DC maturation and accredited this to regulation at the mRNA level 
of VAMP8 by caspases (Ho et al. 2009). However VAMP8 mRNA has been shown 
to be up-regulated in over-reactive human platelets. There was a higher fold 
expression of 4.8 in hyper-reactive platelets compared to hypo-reactive platelets 
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(Kondkar et al. 2010). This highlights the role for caspases and other molecules 
involved in post transcriptional regulation of SNARE mRNA.  
 
Several other SNAREs in this study also remained unchanged. This was of interest 
as some SNAREs have been well reported to play a role in other immune cells for 
example STX6 mRNA was up-regulated 2 hours post stimulation of LPS was 
reported in RAW 264.7 macrophage cells (Murray et al. 2005b) and SNAP23 
mRNA from the skeletal muscle of patients with type II diabetes was up-regulated 
(Bostrom et al. 2010). As SNAREs are used up during the fusion reactions and are 
recycled for numerous rounds of transport (Malsam, Kreye and Soellner 2008), we 
propose that along with caspases, other post-transcriptional regulation and recycling 
of SNAREs may be another reason for the lack of changes of mRNA expression.  
 
In a study by Stow et al., there was up-regulation of STX4 protein levels at the same 
time-point as TNF secretion from macrophage following LPS stimulation prompted 
the investigation of the role of STX-4 (Murray et al. 2005b) (Stow, Manderson and 
Murray 2006a, Murray et al. 2005b). This study using the correlation of SNARE 
expression and cytokine expression concept may help us in the following chapter to 
elucidate the SNAREs involved in cytokines or chemokines secretion within our 
own data.  
We demonstrated that there was a significant up-regulation of Vti1a mRNA at 4 and 
12 hours post LPS and Loxoribine stimulation. It has previously been reported that 
up-regulation of Vti1a and Vti1b inhibits phagocytosis in DCs (Cai et al. 2011). As 
mature DCs are known to have reduced phagocytic ability (Ruedl and Hubele 1997) 
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it may suggest that Vti1a was up-regulated to inhibit phagocytosis as the DC 
matured.  
 
One of most significant increases in mRNA expression over time was that of STX-3. 
Expression of STX3 mRNA in JAWSII DCs significantly increased following 
activation with LPS and Loxoribine 1 and 4 hour post stimulation and conversely 
was significantly down-regulated following PGN activation. A role for STX3 has 
been documented in mast cells and epithelial cells but not yet in DCs. STX3 and 
VAMP7 have been shown to be important for apical transport of trans-membrane 
and secretory proteins in epithelial cells (Carmosino et al. 2010). Interestingly a role 
for STX3 has been recently documented in the secretion of chemokines from mast 
cells. This study demonstrated that blocking STX3 activity with neutralising 
antibodies inhibited the secretion of chemokines following IgE stimulation. The 
chemokines inhibited included IL-8, MCP, MIP-1α and MIP-1β (Frank et al. 2011). 
As the JAWS II DCs secreted large amounts of MIP-1α it may suggest that STX3 
also has a role in chemokine secretion in DCs.  
 
Another interesting finding was the significant up-regulation of STX11 mRNA 
expression in response to LPS Loxoribine and PGN compared to control cells. 
STX11 is highly expressed in cells of the immune system and interestingly has an 
already established role in an immune disease. Loss or mutation of the STX11 gene 
results in an autosomal recessive disorder known as, familial hemophagocytic 
lymphohistiocytosis type-4 (FHL-4), which causes immune dysregulation This 
disorder is characterised by high levels of inflammatory cytokines and defective 
function of T cells and natural killer cell (Offenhaeuser et al. 2011). STX11 has been 
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reported to be up-regulated in dendritic cells following LPS activation but Stx11 
deficiency did not appear to affect DC function (D'Orlando et al. 2013) STX11 has 
been indicated to regulate other cells of the immune system such as NK, CD8
+
 T 
cells, macrophage, platelets and in human blood neutrophils where up-regulation of 
STX11 mRNA expression during differentiation of has been reported (Offenhaeuser 
et al. 2011, Xie et al. 2009, D'Orlando et al. 2013).  
It was clear from our findings that SNAREs are regulated in JAWS II DCs in 
response to TLR ligation and that their expression changed depending on the type of 
TLR ligand used to activate the cell. To further the work it would be advantageous to 
screen the SNARE expression in BMDCs. This would led to a more comprehensive 
model of SNARE expression in DC following activation with TLR ligands that 
could be correlated with cytokine or chemokine expression.  
Given the role SNAREs have during immune activation in vitro, we identified 
candidate which were significantly changes in DCs, STX3, STX11 and Vti1a and 
candidate SNAREs with little changes, STX4, SNAP23 and VAMP4. We therefore 
wanted to assess whether they were regulated in vivo during inflammatory disease, – 
in this case - two models of experimental IBD, the dextran sodium sulphate (DSS)-
induced colitis mouse model and Citrobacter rodentium infection. Expression of a 
large number of cytokines and other soluble immune mediators have been previously 
reported to up-regulated or down-regulated during mouse models of colitis. The 
reason mice colitis models are an attractive way to study inflammatory disease owes 
to the fact a similar expression of cytokines in colitis mouse models has been 
described for the human homologues when measured in intestinal tissue obtained 
from IBD patients (Boismenu and Chen 2000).  
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We employed RT-qPCR to study specific pro-inflammatory cytokines and 
chemokines as that have been reported to play a role in chemically induced model of 
intestinal inflammation, the DSS model (Yan et al. 2009). DSS is a negatively 
charged glucose polymer with engrafted sulphate groups, when delivered in drinking 
water of mice induces intestinal inflammation mimicking the clinical and 
histological features of IBDs that have characteristics of UC (Laroui et al. 2012). 
During early acute inflammation there was significant increase in expression of all 
cytokines and chemokines; IL-6, TNF-α, IFN-γ, MIP-1α, MIP-2 and MCP and 
associated decrease of these cytokines and chemokines in the chronic states. This 
trend of IL-6 and TNF-α expression was also observed by Alex et al., up-regulation 
of IFN-γ mRNA in DSS colitis correlates with previously published data and Yan et 
al., reported similar profile of cytokines IL-6 and TNF-α and the chemokine MIP-2 
(Yan et al. 2009, Alex et al. 2009, Egger et al. 2000). In fact, MIP-2, which acts in a 
similar manner to IL-8 in humans, was reported to be expressed during DSS colitis 
in another study but also to enhance effects of DSS due to its presence (Ohtsuka and 
Sanderson 2003). Although colonic tissue consists of many cells which can secrete 
these cytokines and chemokines, DCs have been previously indicated in the 
development of acute DSS due to their production of TNF-α, MIP-1α, MIP-2 and 
MCP-1 (Berndt et al. 2007). In parallel with the increases of IL-6, TNF-α, IFN-γ, 
MIP-1α, MIP-2 and MCP during acute early inflammation there was a significant 
increase in expression of STX11 and Vti1a which persisted in the late acute phase of 
disease. Expression of STX11 and Vti1a were most significantly up-regulated with 
some of the highest fold changes during DSS colitis model. There was also a 
significant up-regulation in SNAP23 and STX3 in the late acute phase which 
correlates with increased levels of IL-6, TNF-α, MIP-1α, MIP-2 and MCP. The 
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correlation between inflammatory cytokines and chemokines and the increase in 
expression of SNAREs such as STX3, STX11 and Vti1a points to a potential role for 
these SNAREs in the secretion of these cytokines during inflammation. Furthermore 
our data showing that these SNAREs are increased in DCs following activation 
further supports a role for them in cytokine and chemokine secretion. 
 
As IBD is a multifactorial disease of unknown aetiology (Perse and Cerar 2012) we 
employed the use of a second colitis model – C.rodentium infection. C.rodentium 
can colonise the gut of mice with over 10
9
 organisms within 7 to 14 days but is 
virtually cleared by day 21. C.rodentium is part of a group of enteric pathogens 
which is related to E.coli but as E.coli is poorly pathogenic in mice and C.rodentium 
is a natural mouse pathogen it provides us with an excellent in vivo model of 
infections of the lumen of the intestine (Mundy et al. 2005). Day 9 post C.rodentium 
infection cytokines and chemokine data was significantly up-regulated. Smith et al, 
also reported an increase in the mRNA of pro-inflammatory cytokines, IL-6, TNF-α, 
IFN-γ and the chemokine MCP-1 (Smith et al. 2011) Another study examining IFN-
γ and TNF-α expression also correlated with our data (Higgins et al. 1999). 
Expression of SNAREs, SNAP-23, STX11, VAMP4 and Vi1a were also 
significantly up-regulated nine days post C.rodentium infection. Interestingly STX3 
mRNA expression was significantly down-regulated 3 days post infection and 
remained down-regulated over the 21 days of the model. 
 
The results in this chapter indicate that specific SNAREs are up-regulated in vitro 
and in vivo in two models of inflammatory disease. To the best of our knowledge 
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this is the first time the expression of SNAREs have been characterised in colitis 
models and hence implicated in inflammatory disease of the gastrointestinal tract. 
This data highlights the possibility of targeting SNAREs in inflammatory disease as 
a therapeutic measure. In the final chapter we will aim to elucidate the roles of the 
SNAREs, STX3 and STX11, as they have indicated in vivo and in vitro they might 
have a role in dendritic cells during immune activation.  
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5.1  INTRODUCTION 
 
In the previous chapter, a number of SNAREs were identified, that may have a role 
in dendritic cell secretion. Following on from this, it was of interest to further 
elucidate the roles of the SNARE proteins, STX3 and STX11 as these SNAREs 
showed the most change in vitro and in vivo. This was achieved by means of RNAi 
and use of Stx11
-/- 
BMDCs. 
In the last chapter, it was shown that STX3 was highly up-regulated following 
activation with TLR4 and TLR7 but not TLR2. This was correlated with the 
secretion of IL-6 from JAWSII DCs since IL-6 was secreted at high levels from 
JAWSII DCs when stimulated with TLR4 and TLR7 but not TLR2. STX3 was first 
identified in the plasma membrane by Bennett et al., and subsequently, it was 
reported to be involved in trafficking exocytic vesicles from the TGN to the apical 
plasma membrane of polarized epithelial cells (Bennett et al. 1993, Low et al. 1996). 
STX3 has also been implicated in human cytomegalovirus (Cepeda et al., 2010). It 
has been suggested that STX3 is involved in late endosomes/lysosomes since RNAi 
inhibition of STX3 results in the reduced expression of lysosomal membrane 
glycoproteins (Cepeda et al., 2010). Recently, STX3 has been indicated as an 
essential requirement, partnered with SNAP23 for chemokine release of IL-8, MCP 
and MIP-1α from mature human mast cells (Frank et al. 2011). However, missing 
from the literature is a role for STX3 in dendritic cells secretion.  
Since it was shown that STX11 was significantly up-regulated in response to all 3 
TLR ligands, highly expressed in experimental models of inflammatory disease and 
has been defined in familial hemophagocytic lymphohistiocytosis type-4 (FHL-4 
hyper-inflammatory disease known it was of interest to investigate the possible role 
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of STX11 in dendritic cell secretion. STX11 is an atypical SNARE which was first 
identified in 1998. It was shown that patients with the hyper-inflammatory disease 
FHL-4 have a deletion or a mutation in STX11. As a result of this these patients 
possess high levels of pro-inflammatory cytokines (IFN-γ, IL-6, TNF-α and IL-18) 
and a higher number of activated macrophages. As a consequence, patients with 
FHL-4 have defective cytotoxic T lymphocytes (CTL) and natural killer (NK) cell 
activity. Furthermore, the high numbers of activated macrophages results in incorrect 
phagocytosis of cell from the hematopoietic lineage (D'Orlando et al. 2013, Marsh et 
al. 2010).  
Recently, STX11 was examined in BMDCs and it was reported that although mRNA 
levels were up-regulated in BMDCs, STX11 deficiency did not affect BMDC 
activities or TLR-induced secretion of IL-12, IL-6 or TNF-α. This study went on to 
identify a role for STX11 in NK and CD8
+
 T-cell cytoxicity and neutrophil 
degranulation and also noted that CTLs and NK cells produced abnormal levels of 
IFN-γ (D'Orlando et al. 2013). In order to further investigate the possible role of 
STX11 we assessed additional parameters of BMDC activation by examining 
secretion of more cytokines, including chemokines and investigate cell surface 
markers compared to the study by D’Orlando et al. (D'Orlando et al. 2013).  
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5.2 RESULTS 
5.2.1 RE-CAP OF STX3 MRNA EXPRESSION AND JAWS II AND BMDC 
CYTOKINE AND CHEMOKINE SECRETION DATA 
 
As previously reported in Chapter 4, STX3 expression was highly up-regulated in 
response to LPS and Loxoribine stimulation at 1 hour and 4 hour [Figure 5.1.A]. To 
identify patterns in cytokine and chemokine secretion that may correlate with the 
mRNA data we analysed the secretion of IL-6, TNF-α and MIP-1α over the same 
time-course of 1, 4 and 12 hours [Figure 5.1.B]. 
JAWS II DCs were cultured for seven days in the presence of r-GM-CSF (Sigma ®) 
and plated at 1 x 10
6
 cell/ml. Cells were then stimulated with 5 μg/ml PGN, 100 
ng/ml LPS and 1nM Loxoribine for 1, 4 and 12 h. Supernatants were removed and 
analysed for the levels of IL-6, TNF-α and MIP-1α [Figure 5.1.B] using specific 
immunoassays. IL-6 secretion was significantly up-regulated from JAWSII DCs 
following LPS stimulation at 4 and 12 hours and Loxoribine at 12 hours (p≤ 0.01, p≤ 
0.001) but remained unchanged following PGN stimulation. TNF secretion was 
significantly up-regulated at 4 and 12 hours following LPS, Loxorbine and PGN 
stimulation (p≤ 0.001, p≤ 0.05 and p≤ 0.01) and MIP-1α secretion was significantly 
up-regulated following LPS stimulation at 4 and 12 hours (p≤ 0.01 and p≤ 0.001) 
and Loxoribine stimulation at 12 hours (p≤0.001) but not with PGN stimulation 
[Figure 5.1.B]. The trend of expression of IL-6 and TNF-α in response to LPS and 
Loxoribine stimulation at 4 and 12 hour and MIP-1 α at 4 hours post correlated with 
up-regulation of STX3 mRNA expression at 1 hour following LPS and Loxoribine 
stimulation but not PGN stimulation [Figure 5.1.A and Figure 5.1.B].  
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The data in chapter 3 was re-examined and it was identified that IL-6 was secreted 
by BMDCs when activated with all three TLR ligands (LPS, Loxoribine and PGN). 
However it was shown that IL-6 was only secreted significantly following 
stimulation with LPS and Loxoribine [Figure 5.1.C]. This was later drawn upon for 
subsequent experiments.  
 
5.2.2 KNOCKDOWN OF STX3 SIGNIFICANTLY DECREASES THE 
SECRETION OF IL-6 AND MIP-1 ALPHA FROM JAWSII DCS 
 
STX3 was knocked down by use of STX3 specific siRNAs (Invitrogen™). JAWS II 
DCs were cultured for seven days in the presence of r-GM-CSF (Sigma ®) and 
plated at 0.5 x 10
6
 cell/ml overnight. The following day, cells were transfected with 
1nM STX3 specific siRNA (Invitrogen™), 1nM scrambled non-silencing siRNA and 
1nM of fluorescently labelled Cy™3 labelled GAPDH (Invitrogen™) [See 
Appendix], using GeneSilencer ® (Genelantis) according to manufacturer’s 
instructions. Supernatants were removed after 24 hours and replaced with fresh 
media. Supernatants were subsequently removed 4 hours later and analysed for the 
levels of IL-1β, IL-6, TNF-α and MIP-1α [Figure 5.2]. In the absence of STX3, IL-6 
and MIP-1α are significantly decreased (p≤ 0.05 and p≤ 0.01) whereas IL-1β is 
significantly increased (p≤ 0.05), with no significant changes in TNF-α secretion 
[Figure 5.2]. 
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5.2.2 NEUTRALISATION OF STX3 WITH A STX3 SPECIFIC ANTIBODY 
SIGNIFICANTLY DECREASES THE SECRETION OF IL-6 FROM JAWS II 
DCS 
 
To further elucidate and confirm the role of STX3 in secretion of cytokines and 
chemokines from JAWSII DCs, STX3 was neutralised using specific STX3 
monoclonal antibody, which binds to the cytoplasmic NH2-terminal region required 
for SNARE binding. JAWS II DCs were cultured for seven days in the presence of r-
GM-CSF (Sigma ®) and plated at 1 x 10
6
 cell/ml overnight. The cells were then 
temporarily permeabilised with bacterial derived toxin SLO (20 μg/ml) for 15 
minutes to deliver the STX3 neutralising antibody (20 μg/ml). Fresh media was then 
added to the cells and either left for 4 hours [Figure 5.3] or stimulated with 100 
ng/ml LPS for 4h [Figure 5.4]. Supernatants were subsequently removed and 
analysed for the levels of, IL-1β, IL-6, TNF and MIP-1α with or without LPS 
stimulation. When STX3 was neutralised IL-6 secretion was significantly decreased 
both in unstimulated cells (*p≤ 0.05) [Figure 5.3] and 4 hours post LPS (*p≤ 0.05) 
[Figure 5.4]. Neutralisation of STX3 did not result in a significant change in IL-1β 
or TNF-α in unstimulated or stimulated cells. There was a decrease in MIP-1α but it 
was not statistically significant.  
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5.2.3 IMMUNOFLUORESCENT ANALYSIS OF THE SNARE STX3 
TRANSLOCATES TO THE PLASMA MEMBRANE ONLY IN IL-6 
SECRETING JAWSII DCS AND BMDCS  
 
It has been established that the activation of JAWSII DCs with LPS and Loxoribine 
resulted in up-regulation of STX3 mRNA and IL-6 secretion and that knockdown of 
STX3 in these cells suppressed secretion of IL-6. Furthermore, it was demonstrated 
that PGN did not result in up-regulation of STX3 mRNA or IL-6 secretion in 
JAWSII DCs but in BMDCs PGN stimulation resulted in IL-6 secretion. It was 
decided to visualise the location of STX3 in JAWSII DCs and BMDCs and 
therefore, immunofluorescent staining was performed. BMDCs were harvested from 
C57BL/6 mice and JAWS II DCs were cultured for seven days in the presence of r-
GM-CSF (Sigma ®). Cells were then seeded at 0.5 x 10
6
 cell/ml onto 0.13-0.16mm 
(RA 1.5) cover-slips and left to adhere overnight. Cells were then stimulated with 
LPS (100 ng/ml), Loxoribine (1 mM) and PGN (5 μg/ml) for 1h. Cover-slips were 
incubated with STX3 specific monoclonal antibody followed by appropriate 
fluorescently labelled secondary antibody. In JAWSII DCs the nucleus was stained 
with PI for 5 minutes, however no nuclear stain was applied to the BMDCs. Slides 
were then imaged using a Zeiss LSM 710 inverted confocal microscope.  
 
STX3 was detected in the cytoplasm of control JAWSII and following stimulation 
with LPS and Loxoribine STX3 translocated to the plasma membrane after 1 hour. 
PGN stimulation in JAWS DCs did not result in translocation of STX3 to the plasma 
membrane. In BMDCs which do respond to to PGN and secrete IL-6, activation with 
PGN resulted in STX3 translocation [Figure 5.5]. 
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Overview of STX3 findings are summarised in Figure 5.6.  
 
5.2.4 MEMBERS OF THE IL-12 FAMILY ARE SIGNIFICANTLY UP-
REGULATED IN STX11
-/-
 BMDCS COMPARED TO WILD TYPE 
 
It was decided to investigate the role of STX11 in dendritic cell secretion as it was 
up-regulated in DCs and in disease. This was performed by the use of knockout 
SNARE mouse model. Stx11
-/- 
mice were acquired from Silvia Bulfone-Paus’ group 
in the Borstel Research Institute, Hamburg, Germany.  
BMDCs harvested from Stx11
-/-
 and Wild type (WT) matched C57BL/6 mice were 
cultured for seven days in the presence of r-GM-CSF (Sigma ®) and plated at 1 x 
10
6
 cell/ml. Cells were then stimulated with 100 ng/ml LPS/100 μg/ml rIL-12, 2μM 
CpG, 5 μg/ml PGN and 1 μg/ml PAM over a time-course of 2, 6 and 24 hours. 
Supernatants were removed and analysed for the levels of IL-12p40, IL-23 and IL-
27p28 [Figure 5.7, Figure 5.8 and Figure 5.9]. 
IL-12p40 was significantly up-regulated in unstimulated Stx11
-/-
 BMDCs compared 
to control WT (p≤ 0.05) [Figure 5.7]. Following 2 h, 6 h and 24 h LPS/IL-12 
stimulation Stx11
-/-
 BMDCs have significantly higher secretion of IL-12p40 
compared to WT BMDCs (p≤ 0.05, p≤ 0.001and p≤ 0.01) [Figure 5.7]. 2 and 6 
hours post CpG stimulation Stx11
-/-
 BMDCs secrete significantly higher amounts of 
IL-12p40 compared to WT BMDCs (p≤ 0.05) [Figure 5.7]. 2 and 24 hour 
stimulation with PGN resulted in significantly higher secretion of IL-12p40 from 
Stx11
-/-
 BMDCs compared to control WT (p≤ 0.05) and 2 and 6 hour stimulation 
with PAM also had significantly higher secretion of IL-12p40 from Stx11
-/-
 BMDCs 
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compared to control WT (p≤ 0.01 and p≤ 0.05) [Figure 5.7]. Interestingly, secretion 
of IL-12p40 was down-regulated in Stx11
-/-
 BMDCs compared to control WT post 
24 hour PAM stimulation (p≤ 0.01) [Figure 5.7]. 
Secretion of IL-23 from Stx11
-/-
 BMDCs compared to control WT at basal level was 
significantly up-regulated (p≤ 0.05) [Figure 5.8]. Following stimulation with 
LPS/IL-12 for 2, 6 and 24 hours, Stx11
-/-
 BMDCs had significantly increased 
secretion of IL-23 compared to WT BMDCs (p≤ 0.01 and p≤ 0.05) [Figure 5.8]. 
Similarly following 2, 6 and 24 hours stimulation with CpG Stx11
-/-
 BMDCs have 
significantly higher secretion compared to WT BMDCs (p≤ 0.01 and p≤ 0.05). 
Following TLR2 stimulation with PGN Stx11
-/-
 BMDCs have significantly higher 
secretion of IL-23 compared to WT BMDCs at 2, 6 and 24 (p≤ 0.05) [Figure 5.8]. 
Stimulation for 6 hours was the only time point post stimulation with PAM (1μg/ml) 
to show any significant up-regulation of IL-23 from  Stx11
-/-
 BMDCs compared to 
control WT (p≤ 0.01) [Figure 5.8]. 
 
IL-27p28 basal level of secretion was significantly higher in Stx11
-/-
 BMDCs 
compared to control WT (p≤ 0.01) [Figure 5.9]. Following stimulation with LPS/IL-
12 for 2 and 24 hours, Stx11
-/-
 BMDCs had significantly higher secretion of IL-
27p28 compared to WT BMDCs (p≤ 0.05) [Figure 5.9]. Following 2 hours 
stimulation with CpG Stx11
-/-
 BMDCs had significantly higher secretion compared 
to WT BMDCs (p≤ 0.01). 2, 6 and 24 hour stimulation with PGN, Stx11-/- BMDCs 
had significantly increased levels of IL-27 compared to WT BMDCs (p≤ 0.05) and 
IL-27p28 was also up-regulated in Stx11
-/-
 BMDCs compared to control WT post 6 
and 24 hour PAM stimulation (p≤ 0.01) [Figure 5.9]. 
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5.2.5 IFN- GAMMA IS SIGNIFICANTLY UP-REGULATED IN STX11-/- 
BMDCS COMPARED TO WILD TYPE 
 
IFN-γ secretion had not been measured from DCs during our previous chapters, as 
IFN-γ has only recently been indicated to be secreted from DCs and does so in small 
amounts. However IFN-γ has been previously reported to be over expressed from 
CD8+ CLT in Stx11
-/-
 mice (D’Orlando et al., 2013). BMDCs harvested from Stx11-/- 
and WT mice were stimulated and IFN-γ was quantified as previously described 
[Section 5.2.4].  
Secretion of IFN-γ from unstimulated Stx11-/- BMDCs compared to control WT was 
significantly up-regulated (p≤ 0.01) [Figure 5.10]. Following stimulation with 
LPS/IL-12 at 2 and 6 hours, Stx11
-/-
 BMDCs had significantly higher secretion of 
IFN-γ compared to WT BMDCs (p≤ 0.01). CpG stimulation also resulted in 
significantly higher levels of IFN-γ after 2, 4 and 24 hours from Stx11-/- BMDCs 
compared to WT BMDCs (p≤ 0.001 and p≤ 0.05). Secretion of IFN-γ from Stx11-/- 
BMDCs was significantly increased compared to WT BMDCs following simulation 
with PGN (p≤ 0.01 and p≤ 0.05). PAM stimulation for 2, 6 and 24 hours section of 
IFN-γ did result in a small increase in IFN-γ from Stx11-/- BMDCs compared to WT, 
however, this was not statistically significant [Figure 5.10]. 
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5.2.6 CHEMOKINES ARE SIGNIFICANTLY UP-REGULATED IN STX11
-/-
 
BMDCS COMPARED TO WT  
 
BMDCs harvested from Stx11
-/-
 and WT mice were stimulated and chemokines, 
MIP-1α [Figure 5.11] and MIP-2 [Figure 5.12] and quantified as previously 
described [Section 5.2.4].   
MIP-1α secretion was significantly up-regulated from unstimulated Stx11-/- BMDCs 
when compared to control WT BMDCs at basal level (p≤ 0.05) [Figure 5.11]. 
Following LPS/IL-12 stimulation, Stx11
-/-
 BMDCs had significantly up-regulated 
MIP-1α secretion at 2, 6 and 24 hours compared to WT BMDC (p≤ 0.001 and p≤ 
0.05). MIP-1α secretion following activation with CpG was significantly up-
regulated at 2 and 6 hours from Stx11
-/-
 BMDCs compared to WT BMDCs (p≤ 0.01 
and p≤ 0.05). MIP-1α secretion was also significantly increased from Stx11-/- 
BMDCs compared to WT BMDCs following 6 and 12 hours PGN and PAM 
stimulation (p≤ 0.01 and p≤ 0.001) [Figure 5.11].  
At basal level MIP-2 secretion was significantly up-regulated from control Stx11
-/-
 
BMDCs compared to control WT BMDCs (p≤ 0.01) [Figure 5.12]. MIP-2 secretion 
following activation with LPS/IL-12 was significantly up-regulated at 2 and 6 hours 
from Stx11
-/-
 BMDCs compared to WT BMDCs (p≤ 0.05). Following CpG 
stimulation of Stx11
-/-
 BMDCs had significantly up-regulated MIP-2 secretion at 2, 6 
and 24 hours compared to WT BMDC (p≤ 0.05 and p≤ 0.01). A significant increase 
in MIP-2 was also observed at 2, 4 and 24 hours post stimulation with PGN and 2 
hours with PAM stimulation from Stx11
-/-
 BMDCs compared to WT BMDCs (p≤ 
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0.01 and p≤ 0.05). There was also a significant down-regulation of MIP-2 following 
24 hours PAM stimulation from Stx11
-/-
 BMDCs compared to WT BMDCs (p≤ 
0.001) [Figure 5.12]. 
 
5.2.7 CYTOKINES IL-6, IL-10 AND TNF-ALPHA FROM STX11
-/-
 BMDCS 
COMPARED TO WT  
 
BMDCs harvested from Stx11
-/-
 and WT mice were stimulated and cytokines 
quantified as previously described [Section 5.2.4].  
There were no significant differences in basal level of IL-6 secretion from Stx11
-/-
 
BMDCs when compared to WT BMDCs [Figure 5.13]. There was only significant 
up-regulation of IL-6 production following 2 hours stimulation of CpG, 24 hours 
PGN stimulation and 6 hours PAM  stimulation  from Stx11
-/-
 BMDCs when 
compared to WT BMDCs (p≤ 0.05 and p≤ 0.001). Otherwise IL-6 secretion was not 
significantly changed or was down-regulated in the cases of 24 h LPS/IL12 
stimulation, 2 h PGN stimulation and 24 hour PAM stimulation from Stx11
-/-
 
BMDCs when compared to WT BMDCs (p≤ 0.05, p≤ 0.001 and p≤ 0.01) [Figure 
5.13]. 
There was a significant up-regulation of basal IL-10 from Stx11
-/-
 BMDCs when 
compared to WT BMDCs (p≤ 0.01) [Figure 5.14]. Significant up-regulation of IL-
10 was also observed 2 hours post LPS/IL-12 stimulation, 24 hours post CpG 
stimulation, 6 hours post PGN and PAM  stimulation from Stx11
-/-
 BMDCs when 
compared to WT BMDCs (p≤ 0.01, p≤ 0.05 and p≤ 0.001) [Figure 5.14]. Otherwise 
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IL-10 secretion was not significantly different between Stx11
-/-
 BMDCs and WT 
BMDCs [Figure 5.14]. 
 
TNF-α secretion at basal level was not significantly different between Stx11-/- 
BMDCs and WT BMDCs [Figure 5.15]. Significant up-regulation of TNF-α was 
observed 2 hours post CpG and PAM stimulation and 6 hour post PGN stimulation 
from Stx11
-/-
 BMDCs when compared to WT BMDCs (p≤ 0.001 and p≤ 0.05). TNF-
α was significantly down-regulated in response to 24 hours LPS/IL-12, 6 hours CpG, 
2 hours PAM and PGN stimulation from Stx11
-/-
 BMDCs when compared to WT 
BMDCs (p≤ 0.01, p≤ 0.05 and p≤ 0.001 ). [Figure 5.15].  
 
5.2.8 HIGHER BASAL LEVEL SURFACE MARKER EXPRESSION ON 
STX11
-/-
 BMDCS COMPARED TO WT AND MODULATION OF THE 
DENDRITIC CELL MARKER CD11C 
 
BMDCs harvested from Stx11
-/-
 BMDCs and WT matched C57BL/6 mice were 
cultured for seven days in the presence of r-GM-CSF (Sigma ®) and plated at 1 x 
10
6
 cell/ml. Cells were then stimulated with 100 ng/ml LPS/100 μg/ml rIL-12, 2 μM 
CpG, 5 μg/ml PGN and 1 μg/ml PAM over a time-course of 2, 6 and 24 hours. Cells 
were subsequently washed and stained with fluorochrome-labelled monoclonal 
antibodies to the cell surface markers, TLR-4-MD-2 [Figure 5.16], CD14, [Figure 
5.17] CD40 [Figure 5.18], CD80 [Figure 5.19], CD86 [Figure 5.20], MHC II 
[Figure 5.21] and CD11c [Figure 5.22].  
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There was a higher expression of TLR-4-MD-2 on unstimulated Stx11
-/-
 BMDCs 
when compared to WT BMDCs at basal levels. [Figure 5.16]. Post stimulation with 
CpG TLR-4-MD-2 expression was increased at 2, 6 and 24 hour time points in WT 
BMDCs which was comparable to Stx11
-/-
 BMDCs, However, Stx11
-/-
 BMDCs 
expression was not as high. TLR-4-MD-2 was down-regulated on both WT BMDCs 
and Stx11
-/-
 BMDCs after LPS stimulation at 2 and 6 hours. However TLR-4-MD2 
expression after 24 hours LPS stimulation was up-regulated on both WT BMDCs 
and Stx11
-/-
 BMDCs compared to control cells. Expression of TLR-4-MD2 was 
higher on WT BMDCs after 24 hours when compared to Stx11
-/-
 BMDCs. Post PAM 
stimulation TLR-4-MD2 expression remained relatively un-changed on WT 
BMDCs. Stx11
-/-
 BMDCs showed down-regulated expression of TLR-4-MD-2 
following 2, 6 and 24 hours of PAM stimulation. 24 hours post PGN stimulation WT 
BMDCs up-regulated TLR-4-MD-2 compared to control cells, in contrast Stx11
-/-
 
BMDCs down-regulated expression of TLR-4-MD-2 at 24 hours. Expression of 
TLR-4-MD2 in Stx11
-/-
 BMDCs was also down-regulated at 2 and 6 hours post PGN 
this was comparable in WT cells. [Figure 5.16]. 
 
Expression of CD14 at basal level was up-regulated in Stx11
-/-
 BMDCs when 
compared to WT. [Figure 5.17]. Following CpG stimulation at 2 hours WT and 
Stx11
-/- 
BMDCs up- regulated CD14 expression compared to control cells. However, 
at 6 and 24 hours post CpG stimulation CD14 expression was up-regulated in both 
Stx11
-/-
 BMDCs and WT BMDCs, and was higher in the STX11
-/- 
BMDCs. 24 hours 
post LPS/IL12 stimulation CD14 was up-regulated compared to control and was 
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higher in the Stx11
-/-
 BMDCs. CD14 was incrementally increased over time in the 
WT BMDCs, at 2, 6 and 24 hours. However, in Stx11
-/-
 BMDCs CD14 expression 
was down-regulated at 2 and 6 hours compared to control before being up-regulated 
at 24 hours. Following PAM stimulation CD14 expression increased over the time 
course of 2, 6 and 24 hours in WT BMDCs and Stx11
-/-
 BMDCs was comparable. 
Following PGN stimulation over the time-course, WT BMDC expression of CD14 
increased over time. This expression was similar in Stx11
-/-
 BMDCs with the 
exception of a down-regulation at 2 hours compared to control. 24 hours stimulation 
with PGN had a higher expression in WT BMDCs when compared to in Stx11
-/-
 
BMDCs [Figure 5.17].  
 
CD40 expression on Stx11
-/-
 BMDCs was much higher than WT BMDCs on 
unstimulated cells [Figure 5.18]. Following a time-course of stimulation with CpG, 
CD40 expression increased over time in both in Stx11
-/-
 BMDCs and WT. However 
expression was higher overall in Stx11
-/-
 BMDCs. The CD40 expression following 
LPS/IL-12 stimulation over 2, 6 and 24 hours also increased over time in both in 
Stx11
-/-
 BMDCs and WT. However, expression was higher overall in Stx11
-/-
 
BMDCs with the exception of a slight down-regulation of the 2 hour LPS/IL-12 
stimulation in Stx11
-/-
 BMDCs. Post PAM stimulation over the time-course WT 
BMDCs had increased the expression of CD40 whereas in Stx11
-/-
 BMDCs CD40 
expression was down-regulated compared to controls. PGN stimulation resulted in 
up-regulation of expression of CD40 in a time dependant manner in WT BMDCs. 
However, Stx11
-/-
 BMDCs expression of CD40 was down-regulated in response to 2 
hour stimulation of CpG compared to control and its expression at 6 and 24 hours 
was then up-regulated compared to control [Figure 5.18]. 
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CD80 was up-regulated on unstimulated Stx11
-/-
 BMDCs compared to WT BMDCs 
[Figure 5.19]. Activation with CpG, LPS, PAM and PGN resulted in a time-
dependant up-regulation of CD80 at 2, 6 and 24 hours in WT BMDCs. In Stx11
-/-
 
BMDCs expression of CD80 was highly up-regulated in basal levels. There was an 
initial down-regulation of CD80 expression in response to CpG, LPS and PGN at 2 
hours and 2 and 6 hours following PAM stimulation but subsequently up-regulated 
its expression was increased compared to control Stx11
-/-
 BMDCs [Figure 5.19]. 
Expression of CD86 was up-regulated in Stx11
-/-
 BMDCs when compared to WT 
BMDCs [Figure 5.20]. Activation with CpG, LPS, PAM and PGN resulted in a 
time-dependant up-regulation of CD86 at 2, 6 and 24 hours in WT BMDCs. There 
was also an up-regulation of Stx11
-/-
 BMDCs CD86 expression over the time-course 
of TLR stimulation when compared to controls with the exception of a down-
regulation at 12 hours in response to CpG, PAM and PGN stimulation [Figure 5.20]. 
MHCII expression in Stx11
-/-
 BMDCs compared to WT BMDCs was up-regulated at 
basal levels [Figure 5.21]. Following activation with CpG, LPS, PAM and PGN,  
Stx11
-/-
 BMDCs and WT BMDCs at 2 and 6 hours had up-regulated MHCII 
expression in a time dependant manner with a slight fall off in expression at 24 
hours. MHCII in Stx11
-/-
 BMDCs was higher than WT BMDCs at every time point 
[Figure 5.21]. 
To assess the DC phenotype we assessed the dendritic cell marker, CD11c. CD11c 
expression was significantly decreased in Stx11
-/-
 BMDCs compared to WT BMDCs 
(p≤0.01) [Figure 5.22].  
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5.2.8 STX11 EXPRESSION IS SIGNIFICANTLY UP-REGULATED AT 
THE SAME TIMEPOINT IFN-GAMMA IS UP-REGULATED 
 
In an attempt to correlate STX11 requirement and cytokine or chemokine secretion 
data, the mRNA profile of STX11 was examined in WT BMDCs in response to TLR 
ligands. Since IFN-γ was significantly up-regulated from Stx11-/- BMDCs when 
compared to WT BMDCs and has reported to be overexpressed from CD8+ CLT in 
Stx11
-/-
 mice, it was decided to investigate IFN-γ expression, which we confirmed 
with the previous IFN-γ data at protein level.  
Stx11
-/-
 BMDCs and WT BMDCs were cultured for seven days in the presence of 
murine rGM-CSF (Sigma ®) and plated at 1 x 10
6
 cell/ml. Cells were then 
stimulated with 100 ng/ml LPS/100 μg/ml rIL-12, 2 μM CpG, 5 μg/ml PGN and 1 
μg/ml PAM for 6 hours. Total RNA was extracted, converted to cDNA, which was 
then subjected to quantitative real-time PCR. 2
−ΔΔCq
 formula of the delta-delta Cq 
method was used and a fold change in expression of STX11 and IFN-γ genes was 
normalized against that of endogenous control S18. SNARE mRNA levels were 
determined as expression in the absence of stimulation, which is given an arbitrary 
value of 1.  
STX11 expression in WT BMDCs was seen to be significantly up-regulated 6 hours 
after LPS/IL-12 stimulation (p≤0.05) [Figure 5.23(A)]. This correlated with 
increased mRNA expression of IFN-γ in Stx11-/- BMDCs and WT BMDCs, with an 
increase in IFN-γ expression following stimulation with PGN (p≤0.05) and LPS/IL-
12 (not statistically significant) from Stx11
-/-
 BMDCs when compared to WT 
BMDCs [Figure 5.23(B)]. This correlated well with the increased production of 
CHAPTER 5                                     FUNCTIONAL ROLES OF STX3 AND STX11 
194 
 
IFN-γ that was shown from Stx11-/- BMDCs when compared to WT BMDCs at 6 
hours in a previous experiment [Figure 5.23]. 
5.2.9 WT BMDCS UP-REGULATE THEIR EXPRESSION OF SURFACE 
MARKERS WHEN DIFFERENTIATED IN THE PRESENCE OF IFN-
GAMMA 
 
The previous data suggested that STX11 has a possibly having a regulatory role in 
IFN-γ secretion from BMDCs. The next step was to access the effect IFN-γ would 
have BMDC surface marker expression in order to see if it produced a DC with 
similar phenotypes to the Stx11
-/-
 BMDCs.  
 
BMDCs were harvested from WT mice, cultured for three days in the presence of r-
GM-CSF (Sigma ®) and in high or low levels of r-IFN-γ (200pg/ml or 10ng/ml). 
Cells were subsequently washed and stained with fluorochrome-labelled monoclonal 
antibodies to the cell surface markers, TLR-4-MD-2, CD14, CD40 [Figure 5.24], 
CD80, CD86, MHC II [Figure 5.25] and CD11c [Figure 5.26].  
 
Expression of TLR-4-MD-2, CD14, CD4, CD80, CD86 and MHC II were all up-
regulated at basal level when differentiated in the presence of low or high levels of 
IFN-γ [Figure 5.24, Figure 5.25]. Expression of these markers were also up-
regulated in a dose-dependant manner which was dependant on the concentration of 
IFN-γ the BMDCs were grown in. BMDCs cultured in high levels of IFN-γ had 
higher expression of surface markers when compared to BMDCs grown in lower 
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levels of IFN-γ [Figure 5.24, Figure 5.25]. CD11c expression was significantly 
down-regulated in BMDCs grown in low and high levels of IFN-γ (p≤0.001) [Figure 
5.26].  
 
5.2.10 WT BMDCS UP-REGULATE THEIR EXPRESSION OF IL-12 WHEN 
DIFFERENTIATED IN THE PRESENCE OF IFN-GAMMA 
 
It was of interest to access the effect of BMDCs grown in IFN-γ would have on 
cytokine secretion of the IL-12 family in order to see if it resulted in a phenotype 
similar to Stx11
-/-
 BMDCs. The IL-12 family were one of the groups of cytokines to 
be most significantly up-regulated in Stx11
-/-
 BMDCs when compared to WT 
BMDCs. BMDCs harvested from and WT mice, cultured for seven days in the 
presence of r-GM-CSF (Sigma ®) and in high or low levels of r-IFN-γ (200 pg/ml or 
10 ng/ml). Cells were then plated at 1 x 10
6
 cell/ml and left to rest overnight. Cells 
were then stimulated with LPS (100ng/ml) for 24 hours. Supernatants were removed 
and analysed for the levels of IL-12p40 and IL-23 [Figure 5.27].  
IL-12p40 and IL-23 were significantly up-regulated following LPS stimulation in 
BMDCs grown in low levels of IFN-γ (p≤0.001) [Figure 5.27]. Conversely IL-
12p40 and IL-23 were significantly down-regulated following LPS stimulation in 
BMDCs cultured in high levels of IFN-γ (p≤0.001) [Figure 5.27].  
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5.2.11 THE ADDITION OF AN ANTI-IFN-GAMMA NEUTRALIZING 
ANTIBODY TO STX11
-/-
 BMDCS RESULTED IN A PHENOTYPE SIMILAR 
TO WT BMDCS 
 
Since WT BMDCs cultured in IFN-γ had similar characteristics to that of Stx11-/- 
BMDCs, it was decided to investigate whether or not an α-IFN-γ antibody would 
restore the phenotype of Stx11
-/-
 BMDCs to WT BMDCs.  
BMDCs were harvested from Stx11
-/-
 BMDCs and WT matched C57BL/6 mice were 
cultured for seven days in the presence of r-GM-CSF (Sigma ®) and plated at 1 x 
10
6
 cell/ml. Cells were then stimulated with 100 ng/ml LPS/100 μg/ml rIL-12 for 24 
hours. Cells were subsequently washed and stained with fluorochrome-labelled 
monoclonal antibodies to the cell surface markers, CD40, CD80, CD86 and MHC II 
[Figure 5.28].  
 
CD40 expression was higher in Stx11
-/-
 BMDCs when compared to WT BMDCs 
following LPS stimulation. In the presence of an α-IFN-γ antibody Stx11-/- BMDCs 
surface expression was down-regulated to similar levels observed in WT BMDCs 
[Figure 5.28]. This pattern was also observed for CD80, CD86 and MHCII 
expression [Figure 5.28].  
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5.2.11 EXPRESSION OF THE MATURATION MARKER CCR5 IS DOWN-
REGULTED IN STX11
-/-
 BMDCS AND REVERSED IN THE PRESENCE OF 
AN ANTI-IFN-GAMMA ANTIBODY 
 
The CCR5 surface marker is known to be lost from the surface of a maturing DC. To 
examine where or not the Stx11
-/-
 BMDCs have a more mature phenotype when 
compared to WT BMDCs the  CCR5 expression was assessed in Stx11
-/-
 BMDCs 
and compared to WT BMDCs. In addition, it was of intereste whether the Stx11
-/-
 
BMDCs CCR5 expression could be reversed with an α-IFN-γ antibody.  
 
BMDCs harvested from Stx11
-/-
 BMDCs and WT matched C57BL/6 mice were 
cultured for seven days in the presence of r-GM-CSF (Sigma ®) and plated at 1 x 
10
6
 cell/ml. Cells were then stimulated with 100 ng/ml LPS/100 μg/ml rIL-12, CpG 
(2 μM) and PGN (5 μg/ml) for 24 hours. Cells were subsequently washed and 
stained with fluorochrome-labelled monoclonal antibodies to the cell surface marker, 
CCR5 [Figure 5.29].  
 
CCR5 expression was down-regulated on the surface of unstimulated Stx11
-/-
 
BMDCs compared to WT BMDCs [Figure 5.29]. Following LPS/IL-12 stimulation 
CCR5 was down-regulated on Stx11
-/-
 BMDCs and WT BMDCs. CCR5 expression 
on LPS/IL-12 stimulated Stx11
-/-
 BMDCs was lower than LPS/IL-12 stimulated WT 
BMDCs. In the presence of an α-IFN-γ antibody, CCR5 expression on Stx11-/- 
BMDCs was comparable to WT BMDC level [Figure 5.29]. This pattern of LPS 
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stimulation and reversal of CCR5 expression with α-IFN-γ antibody was also 
observed with CpG and PAM stimulation.  
5.2.12 EXPRESSION OF PD-L1 IS UP-REGULATED IN STX11
-/-
 BMDCS 
AND REVERSED IN THE PRESENCE OF AN ANTI-IFN-GAMMA 
ANTIBODY 
 
Expression of PD-L1 has previously been reported to be up-regulated in response to 
IFN-γ in BMDCs. PD-L1 is an inhibitory receptor expressed on APCs , such as DCs 
which regulates tolerance and autoimmunity. 
 
PD-L1 expression was up-regulated on the surface of LPS/IL-12 stimulated WT 
BMDCs when compared to unstimulated WT BMDCs (MFI 1009 v 682) and 
LPS/IL12 stimulated Stx11
-/-
 BMDCs compared to unstimluated Stx11
-/-
 BMDCs 
(MFI 1204 v 428) [Figure 5.30]. PD-L1 expression on LPS/IL-12 stimulated Stx11
-/-
 
BMDCs was higher than LPS/IL-12 stimulated WT BMDCs (MFI 1204 v 1009). In 
the presence of an α-IFN-γ antibody, PD-L1 expression was reduced on Stx11-/- 
BMDCs (MFI 854 v 1204) [Figure 5.30].   
 
5.2.12 STX11
-/-
 BMDCS HAVE IMPAIRED ABILTY TO PRIME T CELLS 
BY INHIBITION OF CYTOKINE SECRETION  
 
It is known that PD-L1 is up-regulated on the Stx11
-/-
 BMDCs, which is associated 
with impaired DC-T cell activation (Shen et al. 2010) and bone marrow pre-cursors 
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which are differentiated in the presence of GM-CSF and IFN-γ induce T cells 
hyporesponsiveness (Rongcun et al. 1998). To this end it was of interest to examine 
the ability of Stx11
-/-
 BMDCs to prime T cells by analysing T cell proliferation in a T 
cell:Stx11
-/-
 BMDC co-culture and cytokine production of the T-cells.  
WT and STX11
-/-
BMDCs were cultured in r-GM-CSF for seven days and 
subsequently were plated (1x10
6
 cells/ml) and left to rest overnight. Cells were then 
stimulated with LPS (100 ng/ml) for 4 hours.  
CD4
+
 T cells were isolated using a Stemcell Easysep™ system. This system removes 
unwanted cells by negative selection of non-CD4
+
 T-cells using biotinylated 
antibody cocktails. The cells suspension was then placed into a magnetic field which 
holds the non-CD4
+
 T-cells and the un-labelled CD4
+ 
T cells are decanted.   
 
CD4
+
 T cells were then stained with CFSE and co-cultured with control and LPS 
stimulated Stx11
-/-
 BMDCs and WT BMDCs for 72 hours. Cells were removed from 
plate, washed and stained with a CD4 antibody and PI and analysed on FACS Aria. 
The data was then analysed using FlowJo analysis software (Treestar).  Cells were 
gated on PI negative, CD4
+
 positive cells. CFSE data was plotted and analysed using 
the proliferation algorithm on FlowJo in order to calculate the percentage of divided 
cells, and number of cells in each generation after 72 hours of co-culture. 
 
DC differentiated in the presence of IFN-γ have been reported to inhibit the 
proliferation of T cells (Rojas and Krishnan 2010). Interestingly, proliferation of the 
T cells showed no differences between Stx11
-/-
 BMDCs and WT BMDCs [Figure 
5.31]. Secretion of IL-2 from T cells co-cultured with control and LPS-stimulated 
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Stx11
-/-
 BMDCs was however significantly down regulated (p≤0.05) [Figure 5.32], 
TNF-α secretion significantly down-regulated from T cells co-cultured with control 
Stx11
-/-
 BMDCs (p≤0.05) and there was significant down-regulation of IL-4 
secretion from T cells co-cultured with LPS stimulated Stx11
-/-
 BMDCs (p≤0.05) 
[Figure 5.32].   
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Figure 5.1: Indication for STX3 involvement in cytokine or chemokine secretion 
overview. (A) Recap of STX3 mRNA data (B). Time-course of cytokine and 
chemokine secretion from JAWSII DCs in response to TLR2, TLR4 and TLR7 data 
and (C) cytokine secretion from BMDC v JAWSII DC in response to TLR2, TLR4 
and TLR7. Results are mean ± SEM of triplicate assays. *p≤ 0.05, **p≤ 0.01 and 
***p≤ 0.01 comparing control to TLR stimulated treated JAWSII DCs as determined 
by a two- tailed t-test for (A) and (C) whereas  in (B) ***p≤0.001, **p≤0.01, 
*p≤0.05 comparing CTL vs 1h, 4h, 12h TLR stimulated groups as determined by 
one-way ANOVA test.  
A 
A 
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Figure 5.2: Knockdown of STX3 by siRNA. JAWSII DCs were transfected with 
siRNA against STX3 or a negative control non-silencing siRNA. 24h after the 
transfection, fresh media was put on the cells and incubated for 4h. This media was 
then harvested and basal levels of cytokines or chemokines were assessed using 
specific immunoassays. Results are mean ± SEM of triplicate assays. *p≤ 0.05 and 
**p≤ 0.01 comparing  control versus STX3 siRNA transfected JAWSII DCs as 
determined by a two-tailed t-test. 
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Figure 5.3: Neutralisation of STX3 with STX3 specific monoclonal antibody. 
JAWSII DCs were temporarily permeablised for 15 minutes with SLO (20 μg/ml) 
and which delivered the STX3 neutralising antibody (20 μg/ml). After 4 hours the 
media was then harvested and basal levels of cytokines or chemokines was assessed 
using specific immunoassays. Results are mean ± SEM of triplicate assays. *p≤ 0.05 
comparing control versus STX3 neutralising antibody treated JAWSII DCs as 
determined by a two-tailed t-test. 
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Figure 5.4: Neutralisation of STX3 with STX3 specific monoclonal antibody. 
JAWSII DCs were temporarily permeablised for 15 minutes with SLO (20 μg/ml) 
and which delivered the STX3 neutralising antibody (20 μg/ml).Cells were then 
stimulated with 100 ng/ml LPS for 4 hours. Supernatants were harvested and levels 
of cytokines or chemokines was assessed using specific immunoassays. Results are 
mean ± SEM of triplicate assays. *p≤ 0.05 comparing control versus STX3 
neutralising antibody treated JAWSII DCs as determined by a two-tailed t-test. 
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Figure 5.5: Localisation of STX3 to the Plasma Membrane in JAWSII DCs and 
BMDCs. JAWS II DCs and BMDCs were plated 1x10
6
/ml and stimulated with 5 
µg/ml PGN, 100 ng/ml LPS and 1mM Loxoribine for 1 hour. Immunofluorescent 
indirect double staining of STX3 (Green) and nuclei (red) in TLR 4, TLR7 and TLR 
2 stimulated JAWS II DCs and BMDCs to show localisation of STX3 within the 
cells.  
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Figure 5.6: Schematic representation of secretion of cytokines and chemokines, 
mRNA transcription and localisation of STX3 in JAWS II DCs and BMDCs. 
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IL-12p40 
 
 
 
FIGURE 5.7: Comparison of IL-12p40 secretion from WT and Stx11
-/-
 BMDCs 
following activation with a panel of ligands over a time-course. DCs were 
cultured in r-GM-CSF for seven days and subsequently were plated (1x10
6
 cells/ml) 
and left to rest overnight. Cells were then stimulated with 100 ng/ml LPS and 100 
μg/ml rIL-12, 2 μM CpG, 5 μg/ml PGN or 1 μg/ml PAM. Supernatants were 
recovered after 24 h and assessed for levels of IL-12p40 using specific 
immunoassays. Results are ± SEM of quadruplicate assays. *p≤ 0.05, ** p ≤ 0.01 
and *** p ≤0.001 as determined by a two-tailed t-test. 
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IL-23 
 
 
FIGURE 5.8: Comparison of IL-23 secretion from WT and Stx11
-/-
 BMDCs 
following activation with a panel of ligands over a time-course. DCs were 
cultured in r-GM-CSF for seven days and subsequently were plated (1x10
6
 cells/ml) 
and left to rest overnight. Cells were then stimulated with 100 ng/ml LPS and 100 
μg/ml rIL-12, 2 μM CpG, 5 μg/ml PGN or 1 μg/ml PAM. Supernatants were 
recovered after 24 h and assessed for levels of IL-23 using specific immunoassays. 
Results are ± SEM of quadruplicate assays. *p≤ 0.05, ** p ≤ 0.01 and *** p ≤0.001 
as determined by a two-tailed t-test. 
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IL-27p28 
 
 
 
FIGURE 5.9: Comparison of IL-27p28 secretion from WT and Stx11
-/-
 BMDCs 
following activation with a panel of ligands over a time-course. DCs were 
cultured in r-GM-CSF for seven days and subsequently were plated (1x10
6
 cells/ml) 
and left to rest overnight. Cells were then stimulated with 100 ng/ml LPS and 100 
μg/ml rIL-12, 2 μM CpG, 5 μg/ml PGN or 1 μg/ml PAM. Supernatants were 
recovered after 24 h and assessed for levels of IL-27p28 using specific 
immunoassays. Results are ± SEM of quadruplicate assays. *p≤ 0.05, ** p ≤ 0.01 
and *** p ≤0.001 as determined by a two-tailed t-test. 
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IFN-γ 
 
 
FIGURE 5.10: Comparison of IFN-γ secretion from WT and Stx11-/- BMDCs 
following activation with a panel of ligands over a time-course. BMDCs were 
cultured in r-GM-CSF for seven days and subsequently plated (1x10
6
 cells/ml) and 
left to rest overnight. Cells were then stimulated with 100 ng/ml LPS and 100 μg/ml 
rIL-12, 2 μM CpG, 5 μg/ml PGN or 1 μg/ml PAM. Supernatants were recovered 
after 24 h and assessed for levels of IFN-γ using specific immunoassays. Results are 
± SEM of quadruplicate assays. *p≤ 0.05, ** p ≤ 0.01 and *** p ≤0.001 as 
determined by a two-tailed t-test. 
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MIP-1α 
 
FIGURE 5.11: Comparison of MIP-1α secretion from WT and Stx11-/- BMDCs 
following activation with a panel of ligands over a time-course. BMDCs were 
cultured in r-GM-CSF for seven days and subsequently were plated (1x10
6
 cells/ml) 
and left to rest overnight. Cells were then stimulated with 100 ng/ml LPS and 100 
μg/ml rIL-12, 2 μM CpG, 5 μg/ml PGN or 1 μg/ml PAM. Supernatants were 
recovered after 24 h and assessed for levels of MIP-1α using specific immunoassays. 
Results are ± SEM of quadruplicate assays. *p≤ 0.05, ** p ≤ 0.01 and *** p ≤0.001 
as determined by a two-tailed t-test. 
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MIP-2 
 
FIGURE 5.12: Comparison of MIP-2 secretion from WT and Stx11
-/-
 BMDCs 
following activation with a panel of ligands over a time-course. BMDCs were 
cultured in r-GM-CSF for seven days and subsequently were plated (1x10
6
 cells/ml) 
and left to rest overnight. Cells were then stimulated with 100 ng/ml LPS and 100 
μg/ml rIL-12, 2 μM CpG, 5 μg/ml PGN or 1 μg/ml PAM. Supernatants were 
recovered after 24 h and assessed for levels of MIP-2 using specific immunoassays. 
Results are ± SEM of quadruplicate assays. *p≤ 0.05, ** p ≤ 0.01 and *** p ≤0.001 
as determined by a two-tailed t-test. 
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IL-6
 
FIGURE 5.13: Comparison of IL-6 secretion from WT and Stx11
-/-
 BMDCs 
following activation with a panel of ligands over a time-course. BMDCs were 
cultured in r-GM-CSF for seven days and subsequently were plated (1x10
6
 cells/ml) 
and left to rest overnight. Cells were then stimulated with 100 ng/ml LPS and 100 
μg/ml rIL-12, 2 μM CpG, 5 μg/ml PGN or 1 μg/ml PAM. Supernatants were 
recovered after 24 h and assessed for levels of IL-6 using specific immunoassays. 
Results are ± SEM of quadruplicate assays. *p≤ 0.05, ** p ≤ 0.01 and *** p ≤0.001 
as determined by a two-tailed t-test. 
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IL-10 
 
 
FIGURE 5.14: Comparison of IL-10 secretion from WT and Stx11
-/-
 BMDCs 
following activation with a panel of ligands over a time-course. BMDCs were 
cultured in r-GM-CSF for seven days and subsequently were plated (1x10
6
 cells/ml) 
and left to rest overnight. Cells were then stimulated with 100 ng/ml LPS and 100 
μg/ml rIL-12, 2 μM CpG, 5 μg/ml PGN or 1 μg/ml PAM. Supernatants were 
recovered after 24 h and assessed for levels of IL-10 using specific immunoassays. 
Results are ± SEM of quadruplicate assays. *p≤ 0.05, ** p ≤ 0.01 and *** p ≤0.001 
as determined by a two-tailed t-test. 
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TNF-α 
 
FIGURE 5.15: Comparison of TNF-α secretion from WT and Stx11-/- BMDCs 
following activation with a panel of ligands over a time-course. BMDCs were 
cultured in r-GM-CSF for seven days and subsequently were plated (1x10
6
 cells/ml) 
and left to rest overnight. Cells were then stimulated with 100 ng/ml LPS and 100 
μg/ml rIL-12, 2 μM CpG, 5 μg/ml PGN or 1 μg/ml PAM. Supernatants were 
recovered after 24 h and assessed for levels of TNF-α specific immunoassays. 
Results are ± SEM of quadruplicate assays. *p≤ 0.05, ** p ≤ 0.01 and *** p ≤0.001 
as determined by a two-tailed t-test 
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FIGURE 5.16: Comparison of TLR-4 expression on WT and Stx11
-/-
 BMDCs 
following activation. WT and Stx11
-/-
 BMDCs were differentiated in the presence of 
r-GMCSF for seven days and then stimulated with 100 ng/ml LPS and 100 μg/ml 
rIL-12, 2 μM CpG, 5 μg/ml PGN or 1 μg/ml PAM. Subsequently, cells were washed 
and stained with specific antibodies. Results of flow cytometric analysis and 
corresponding Mean Fluorescence Intensity (MFI) values are shown.  
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FIGURE 5.17: Comparison of CD14 expression on WT and Stx11
-/-
 BMDCs 
following activation. WT and Stx11
-/-
 BMDCs were differentiated in the presence of 
r-GMCSF for seven days and then stimulated with 100 ng/ml LPS and 100 μg/ml 
rIL-12, 2 μM CpG, 5 μg/ml PGN or 1 μg/ml PAM. Subsequently, cells were washed 
and stained with specific antibodies. Results of flow cytometric analysis and 
corresponding MFI values are shown.  
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FIGURE 5.18: Comparison of CD40 expression on WT and Stx11
-/-
 BMDCs 
following activation. WT and Stx11
-/-
 BMDCs were differentiated in the presence of 
r-GMCSF for seven days and then stimulated with 100 ng/ml LPS and 100 μg/ml 
rIL-12, 2 μM CpG, 5 μg/ml PGN or 1 μg/ml PAM. Subsequently, cells were washed 
and stained with specific antibodies. Results of flow cytometric analysis and 
corresponding MFI values are shown. 
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FIGURE 5.19: Comparison of CD80 expression on WT and Stx11
-/-
 BMDCs 
following activation. WT and Stx11
-/-
 BMDCs were differentiated in the presence of 
r-GMCSF for seven days and then stimulated with 100 ng/ml LPS and 100 μg/ml 
rIL-12, 2 μM CpG, 5 μg/ml PGN or 1 μg/ml PAM. Subsequently, cells were washed 
and stained with specific antibodies. Results of flow cytometric analysis and 
corresponding MFI values are shown. 
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FIGURE 5.20 Comparison of CD86 expression on WT and Stx11
-/-
 BMDCs 
following activation. WT and Stx11
-/-
 BMDCs were differentiated in the presence of 
r-GMCSF for seven days and then stimulated with 100 ng/ml LPS and 100 μg/ml 
rIL-12, 2 μM CpG,  5μg/ml PGN or 1 μg/ml PAM. Subsequently, cells were washed 
and stained with specific antibodies. Results of flow cytometric analysis and 
corresponding MFI values are shown. 
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FIGURE 5.21: Comparison of MHCII expression on WT and Stx11
-/-
 BMDCs 
following activation. WT and Stx11
-/-
 BMDCs were differentiated in the presence of 
r-GMCSF for seven days and then stimulated with 100 ng/ml LPS and 100 μg/ml 
rIL-12, 2 μM CpG, 5 μg/ml PGN or 1 μg/ml PAM. Subsequently, cells were washed 
and stained with specific antibodies. Results of flow cytometric analysis and 
corresponding MFI values are shown. 
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FIGURE 5.22 Comparison of CD11c expression on WT and Stx11
-/-
 BMDCs 
following activation. WT and Stx11
-/-
 BMDCs were differentiated in the presence of 
r-GMCSF for seven days and then stimulated. Subsequently, cells were washed and 
stained with specific CD11c antibody. Results of flow cytometric analysis and 
corresponding Percentage fluorescence of CD11c is displayed. ** p ≤ 0.01 
comparing control versus Stx11
-/-
 KO) as determined by a two-tailed t-test. 
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FIGURE 5.23: mRNA expression of (A) STX11 and (B) IFN-γ, WT and STX11-
/-
 BMDCs following activation and (C) a re-cap of IFN-γ secretion from WT and 
Stx11
-/-
 BMDCs following activation. BMDCs were plated 1x10
6
cells/ml and 
stimulated with 100 ng/ml LPS and 100 μg/ml rIL-12, 2 μM CpG, 5 μg/ml PGN or 1 
μg/ml PAM for 6hours. The amount of target mRNA was quantified by reverse 
transcription followed by RT-qPCR using an ABI 7900 HT detection system. mRNA 
target levels were assayed in triplicate (using SYBR green technology) and 
normalised with S18 levels. Fold differences were calculated relative to target levels 
at time zero (assigned value of 1). Results are ± SEM of quadruplicate assays. *p≤ 
0.05, **p≤ 0.01 and ***≤ p 0.001 as determined by a two- tailed t-test comparing 
WT versus Stx11
-/-
 BMDCs. In the case of STX11 *p≤0.05 comparing control vs 
treated groups as determined by one-way ANOVA test.  
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FIGURE 5.24: Comparison of basal TLR4-MD2, CD14 and CD40 expression 
on BMDCs grown in different concentrations of IFN-γ. BMDC were 
differentiated in the presence of r-GMCSF with or without varying concentrations of 
IFN-γ (200pg/ml or 10ng/ml) for three days. Subsequently, cells were washed and 
stained with specific antibodies. Results of flow cytometric analysis and 
corresponding MFI values are shown. BMDCs without IFN-γ (red line) vs. BMDCs 
with varying concentrations of IFN-γ (200 pg/ml or 10 ng/ml) (blue line).   
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FIGURE 5.25: Comparison of basal CD80, CD86 and MHCII expression on 
BMDCs grown in different concentrations of IFN-γ. BMDC were differentiated in 
the presence of r-GMCSF with or without varying concentrations of IFN-γ 
(200pg/ml or 10ng/ml) for three days. Subsequently, cells were washed and stained 
with specific antibodies. Results of flow cytometric analysis and corresponding MFI 
values are shown. BMDCs without IFN-γ (red line) vs. BMDCs with varying 
concentrations of IFN-γ (200 pg/ml or 10 ng/ml) (blue line).  
  
CHAPTER 5                                     FUNCTIONAL ROLES OF STX3 AND STX11 
226 
 
 
CD11c
C
TL LO
M
E
D
0
10
20
30
40
***
***
%
P
a
re
n
t 
P
o
p
u
la
ti
o
n
 
FIGURE 5.26: Comparison of CD11c expression on on BMDCs grown in 
different concentrations of IFN-γ. BMDCs were differentiated in the presence of r-
GMCSF with or without varying concentrations of IFN-γ (200 pg/ml or 10 ng/ml) 
for three days. Subsequently, cells were washed and stained with CD11c antibody. 
Results of flow cytometric analysis and corresponding percentage fluorescence of 
CD11c is displayed. *p≤ 0.05, ** p ≤ 0.01 and *** p ≤0.001 comparing control 
versus IFN-γ treated BMDCs as determined by a two- tailed t-test. 
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FIGURE 5.27: Comparison of IL-12p40 and IL-23 secretion following 
activation with LPS from BMDCs grown in different concentrations of IFN-γ. 
BMDCs were differentiated in the presence of r-GMCSF with or without varying 
concentrations of IFN-γ (200 pg/ml or 10 ng/ml) for seven days. Cells were then 
stimulated with 100ng/ml LPS. Supernatants were recovered after 24h and assessed 
for levels of IL-12p40 and IL-23 using specific immunoassays. Results are ± SEM of 
quadruplicate assays. *** p ≤0.001 comparing control versus IFN-γ treated BMDCs 
as determined by a two-tailed t-test.  
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FIGURE 5.28: Comparison of CD40, CD80, CD86 and MHC II and expression 
on WT and STX11
-/-
 BMDCs following activation with LPS/IL12 
(100ng/ml:100μg/ml) in the presence or absence of IFN-γ neutralising antibody. 
WT and STX11
-/-
 BMDCs were differentiated in the presence of r-GMCSF for seven 
days and then stimulated with LPS/IL12 (100 ng/ml:100 μg/ml). Subsequently, cells 
were washed and stained with specific antibodies. Results of flow cytometric 
analysis and corresponding MFI values are shown.   
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FIGURE 5.29: Comparison of CCR5 expression on WT and Stx11
-/-
 BMDCs 
following activation with 100 ng/ml LPS and 100 μg/ml rIL-12, 2μM CpG, 
5μg/ml PGN or 1μg/ml PAM in the presence or absence of IFN-γ neutralising 
antibody. WT and Stx11
-/-
 BMDCs were differentiated in the presence of r-GMCSF 
for seven days and then stimulated with ligands outlined. Subsequently, cells were 
washed and stained with specific antibodies.  Results of flow cytometric analysis and 
corresponding MFI values are shown.  
  
Control BMDCs 
CTL/LPS:IL-12 
LPS:IL-12 
CpG 
PAM 
CHAPTER 5                                     FUNCTIONAL ROLES OF STX3 AND STX11 
230 
 
 
 
 
 
 
FIGURE 5.30: Comparison of PD-L1 expression on WT and Stx11
-/-
 BMDCs following activation with 100 ng/ml LPS and 100 μg/ml 
rIL-12, 2 μM CpG, 5 μg/ml PGN or 1 μg/ml PAM in the presence or absence of IFN-γ neutralising antibody. WT and Stx11-/- BMDCs 
were differentiated in the presence of r-GMCSF for seven days and then stimulated with LPS (100 ng/ml) and rIL-12 (100 μg/ml). Subsequently, 
cells were washed and stained with specific antibody to PD-L1. Results of flow cytometric analysis and corresponding MFI values are shown.  
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FIGURE 5.31: T-cell Stx11
-/-
 BMDC co culture 
WT and Stx11
-/-
 BMDCs were cultured in r-GM-CSF for seven days and 
subsequently were plated (1x10
6
 cells/ml) and incubated overnight. Cells were then 
stimulated with 100 ng/ml LPS for 4 hours before being co-cultured with CD4
+
 T 
cells (stained with CFSE) for 72 hours. Cells were removed from the plate, washed 
and stained with CD4 antibody and PI and analysed on FACS Aria. The data was 
then analysed using FlowJo analysis software (Treestar). Cells were gated on PI 
negative, CD4 positive cells. CFSE data was plotted and analysed using the 
proliferation algorithm on FlowJo in order to calculate the percentage of divided 
cells, and number of cells in each generation after 72 hours of co-culture. 
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FIGURE 5.32: T-cell Stx11
-/-
 BMDC co-culture 
WT and Stx11
-/-
 BMDCs were cultured in r-GM-CSF for seven days and 
subsequently were plated (1x10
6
 cells/ml) and left to rest overnight. Cells were then 
stimulated with 100 ng/ml LPS for 4 hours before being co-cultured with CD4
+
 T 
cells for 72 h and assessed for levels of cytokines using specific immunoassays. 
Results are ± SEM of triplicate assays. **p≤ 0.01 and ***p≤0.001 comparing WT 
BMDCs versus STX11
-/-
 BMDCs  as determined by a two-tailed t-test.     
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5.4 DISCUSSION  
 
Several studies have addressed the role of SNARE involvement in cytokine release 
from immune cells, however to our knowledge no study has identified the specific 
SNAREs involved in dendritic cell cytokine and chemokine secretion. In this chapter 
we focused on two SNAREs, STX3 and STX11 to elucidate their functional roles in 
dendritic cells. They were identified as candidates as we showed that they were 
significantly up-regulated after immune activation in DCs in vitro and they were also 
expressed in vivo in colitis models of disease. Furthermore they have been 
previously identified as a requirement for secretion of immune mediators from other 
cells of the immune system and in the case of STX11 has been implicated in the 
hyperinflammatory disease, FHL-4 (D'Orlando et al. 2013, Frank et al. 2011). 
 
We firstly looked at STX3 and its role in JAWSII DCs secretion of cytokines and 
chemokines. We depleted the levels of STX3 in two separate ways by means of an 
siRNA specific to STX3 and with the administration of a neutralising antibody. In 
both of these situations IL-6 secretion was significantly down-regulated. MIP-1α was 
also down-regulated when STX3 was depleted by using RNAi. This correlates with 
recent data from mast cells where STX3 was reported to be involved in chemokine 
release from mast cells (Frank et al. 2011). Using confocal microscopy we assessed 
the cellular location of STX3 during activation with TLR ligands in both JAWSII 
DCs and BMDCs, interestingly only in cells where IL-6 was secreted there was a 
translocation of STX3. This data indicates that STX3 has a role in IL-6 secretion 
(and possibly MIP-1α) from dendritic cells and is an important SNARE in dendritic 
cell function.  
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There was not complete abolishment of IL-6 levels from the JAWSII and this may be 
explained as loss of SNAREs can be compensated by other members of the SNARE 
family which have only 30% amino acid similarity (Atlashkin et al. 2003). However 
cytokines such as IL-6 are critical mediators of the autoimmune diseases and IL-6 
implicated in several disease processes. Increased levels of IL-6 have been observed 
IBD, RA, systemic-onset juvenile chronic arthritis (JCA), osteoporsis and psoriasis 
(Ishihara and Hirano 2002). IL-6 blockade has been reported successful in 
autoimmune diseases and with humanized anti-IL-6 receptor antibody in patients 
with RA and JCA was noted to have remarkable clinical effects (Yoshizaki 2009). In 
the past decade IL-6 has been indicated to have a role in differentiation of Th17 
subset with TGF-β, therefore its blockade may potentially improve these diseases at 
the pathogenic initiation phase (Park et al. 2005). Targeted therapeutic of SNAREs 
in inflammatory disease, such as STX3, may be a novel therapeutic tool for secretion 
of cytokines like IL-6. 
 
A STX11 deficient (Stx11
-/-
) mouse was recently developed to investigate the role of 
STX11 played in the immune disease FHL-4. The Stx11
-/-
 mouse model was 
developed by Udo Zur Stadt and were acquired through collaboration with Silvia 
Bulfone-Paus in the Borstel Research Centre, Hamburg, Germany. The data we 
present here suggests that Stx11
-/-
 BMDCs display significant phenotypical 
differences when compared with WT BMDCs. IL-12 family was up-regulated, the 
expression of important cell surface markers were up-regulated and CD11c 
expression was significantly down regulated in Stx11
-/-
 BMDCs compared to WT 
BMDCs. A study by D’Orlando stated that Stx11 deletion did not significantly affect 
the secretion of TNF, IL-6 or IL-12p70 from BMDCs in response to LPS, Poly (I:C) 
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or CpG for 24 or 48 hours (D'Orlando et al. 2013). This correlated with our data in 
terms of TNF-α and IL-6 secretion however was not in agreement with the IL-12 
data. This conflicting data may be accounted for due to the duration of stimulation 
between the studies and the fact that we saw more significant differences were seen 
at early time points, which they do not include in their study. Importantly the study 
did not measure IFN-γ production from BMDCs. This may be for two reasons. The 
fact DCs have only recently been identified as a source of IFN-γ as it conflicts with 
the initial paradigm in which IFN-γ production was restricted to lymphoid cells and 
that inbred mice strains vary in their ability to produce IFN-γ due to the complexity 
of its regulation and subsequently is not always measured from dendritic cells 
(Frucht et al. 2001, Stober, Schirmbeck and Reimann 2001, Schroder et al. 2004). As 
IFN-γ secretion was up-regulated from CTLs and NK cells isolated from Stx11-/- 
mouse we measured its secretion from BMDCs from Stx11
-/-
 mice and WT matched 
controls. We found that IFN-γ was significantly up-regulated from Stx11-/- BMDCs 
compared to WT BMDCs in both unstimulated BMDCs and post TLR stimulation. 
Interestingly we also report that increased mRNA levels of STX11 from WT 
BMDCs correlated with increased expression of IFN-γ mRNA along with secreted 
IFN-γ. IFN-γ has been widely reported as a mediator of dendritic cell maturation, up-
regulating the expression of surface markers MHCII, CD40, CD80 and CD86 
molecules on BMDCs while inducing higher levels of IL-12 (Pan et al. 2004, Xue et 
al. 2013). This up-regulation of basal levels of cytokines, chemokines and surface 
markers in Stx11
-/-
 BMDCs compared to WT BMDCs agrees with previously 
published data on IFN-γ maturation of BMDCs.  
Previous studies have shown that, in the lymph nodes Stx11
-/-
 mice expressed CD11c 
similar levels compared to wild-type expression. This study also reported that 
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compared with wild-type mice, Stx11
-/-
 mice showed no differences in cell number, 
percentages in cell populations, specific cell surface marker expression or activation 
marker expression in lymph nodes or splenic cells (D’Orlando et al., 2013).  
However we saw significant down regulation of CD11c on Stx11
-/-
 DCs and WT 
DCs which interested us. As CD11c has classically been indicated as a DC marker 
we proposed that the phenotype of the Stx11
-/-
 BMDCs was changing. However, a 
recent study by Singh-Jasuja et al., stated that CD11c is down-regulated upon cell 
activation, which would correlate with up-regulation of basal surface marker 
expression of the Stx11
-/-
 BMDCs compared to WT BMDCs. This further supported 
our hypothesis that Stx11
-/-
 DCs become activated during differentiation. Indeed this 
study goes as far as to suggest that down-regulation of CD11c might be used as a 
new activation marker for mouse DCs (Singh-Jasuja et al. 2013). 
As this data indicates that the Stx11
-/-
 BMDCs have a more mature phenotype than 
the WT DCs, it would suggest that some agent is being released from the DC to act 
as a maturation stimulus. In a study looking at the role of STX11 in macrophage 
Offenhauser et al., indicated a novel regulatory role for STX11 by binding to 
SNARE Vti1b in a non-traditional trans-SNARE complex (Offenhaeuser et al. 
2011). Given that IFN-γ has been previously reported to be over expressed from 
CTLs and NK cells in Stx11
-/-
 mice (D’Orlando et al., 2013) as it is from the Stx11-/- 
BMDCs in this study, we proposed that the altered phenotype of Stx11
-/-
 BMDCs is 
due to un-regulated production of IFN-γ due to lack of STX11 regulation. 
To examine whether Stx11
-/-
 BMDCs are maturing during differentiation due to un-
regulated IFN-γ production, we grew WT BMCDs in the presence of rIFN-γ to see if 
this would mimic the Stx11
-/-
 BMDC phenotype. We observed up-regulation of the 
same markers surface markers in unstimlulated cells, up-regulation of the IL-12 
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family post LPS stimulation and down-regulation of CD11c which correlates with 
our Stx11
-/- 
BMDC data. We then added an α-IFN-γ neutralising antibody to the 
Stx11
-/-
BMDC to see if this would restore the phenotype to resemble the WT cells. 
Surface level expression of CD40, CD80, CD86 and MHCII were up-regulated in 
Stx11
-/-
BMDC compared to WT, however with the addition of an α-IFN-γ 
neutralising antibody this decreased surface marker expression to levels similar to 
that of WT BMDCs. We then assessed the expression of CCR5 as immature DCs 
express chemokine receptors which are lost of upon maturation, due to the 
chemokines that are being produced from the maturing DC (Sallusto et al. 1998). 
Thus we wanted to assess the levels of CCR5 on Stx11
-/-
BMDC compared to WT, 
which unsurprisingly was decreased on unstimulated Stx11
-/-
BMDC (suggesting a 
mature BMDC phenotype). Classically LPS/IL-12 stimulation down-regulated 
CCR5 expression on both Stx11
-/-
BMDCs and WT BMDCs, but it was more down-
regulated on Stx11
-/-
BMDCs. Addition of an α-IFN-γ neutralising antibody to the 
Stx11
-/-
BMDC reversed the down-regulation of CCR5 on the Stx11
-/-
BMDCs to WT 
BMDC levels.  
To further test the hypothesis that the phenotype of Stx11
-/-
 BMDCs is due to un-
regulated production of IFN-γ due to lack of STX11 to regulate its secretion, we 
examined the expression of the surface marker PD-L1, T cell proliferation and 
cytokine secretion in a T cell:Stx11
-/-
 BMDC co-culture. We did this as bone marrow 
pre-cursors which are differentiated in the presence of GM-CSF and IFN-γ induce T 
cells hyporesponsiveness (Rongcun et al. 1998). PD-L1 is an inhibitory receptor 
expressed on APCs, such as DCs which regulates tolerance and autoimmunity. 
Expression of PD-L1 has previously been reported to be up-regulated in response to 
IFN-γ in BMDCs (Rojas and Krishnan 2010)We reported an up-regulation of PD-L1 
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expression in Stx11
-/-
 BMDCs and a reversal with IFN-γ antibody. Interestingly there 
were no changes to T cell proliferation, which was in agreement with previously 
published data. This study stated no impairment of Stx11
-/-
 BMDC-mediated 
induction of CD8+ and CD4+ T-cell proliferation data (D'Orlando et al. 2013). 
However the Stx11
-/-
 BMDCs appear to be impaired to prime T cells by inhibition of 
cytokine secretion of IL-2, IL-4 and TNF-α. IL-2 has been reported to be implicated 
in the generation and maintenance of Treg cells. Treg cells have an important 
function in inhibition of the function of antigen presenting cells and effector T cells. 
Due to this function Tregs maintain immune homeostasis, prevent autoimmunity, 
moderate inflammation and minimise tissue damage. Blockade of IL-2 receptor 
completely abrogates suppression (de la Rosa et al. 2004). Therefore a decrease in 
the secretion of this cytokine may impact on T cell function. 
 
Overall this study suggests the STX3 may have a role in the secretion of IL-6 and 
possible MIP-1α from DCs and lack of Stx11 results in DCs with a semi-mature 
phenotype at basal level due to the uncontrolled expression of IFN-γ production, 
indicating a role for both SNAREs in dendritic cell secretion. 
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6.1 GENERAL DISCUSSION 
 
DCs have the ability to link the innate and adaptive immunity. The profile of 
cytokines that they secrete in response to specific pathogens polarize specific Th 
differentiation and thus are a potential target for manipulating the immune system. 
To examine these immune modulating mediators and their potential for targeting in 
inflammatory disease, we established a cytokine secretion model using JAWSII 
DCs. This choice, uncommon in DC research compared to use of primary derived 
DCs, provided us with a homogeneous population that had previously been shown to 
be receptive to transfection with RNAi, which would be beneficial for functional 
studies (Pajtasz-Piasecka et al. 2007) This immature DC cell line has also been 
previously reported to be capable of maturation and subsequently capable of 
stimulating T cells to proliferate (Mackay and Moore 1997). We concluded that 
while similar to primary DCs, JAWSII DCs have significant differences to that of 
BMDCS when stimulated with TLR ligands, and we demonstrated different patterns 
of cytokine and chemokine expression in the JAWSII DCs post activation.  
 
In order to target the cytokines and chemokines that are involved in the pathogenesis 
of many inflammatory diseases, we sought to investigate how they are trafficked out 
of the cell and to identify possible therapeutic targets. The significance of trafficking 
machinery in eukaryotic cells was highlighted recently by the award of the 2013 
Noble Prize for Physiology and Medicine to James Rothman, Randy Schekman and 
Thomas Sudhof. Combined, the discoveries of these researchers have shaped our 
understanding of the building blocks of trafficking networks such as SNARE 
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discovery and its subsequent regulation (Stow 2013). Based on their work, functional 
roles for SNAREs in secretion of critical mediators from immune cells, such as 
TNF-α from macrophage have been identified (stow 2009). Furthermore, it is now 
clear that understanding these complex trafficking pathways and the proteins that 
regulate them will be important in defining their role in inflammatory diseases. 
Indeed to date, their expression in such disease has not yet been investigated. 
 
To investigate the role of SNAREs in DC secretion we firstly examined mRNA 
expression following activation with a panel of TLR ligands. Our objective was to 
identify SNAREs that are up-regulated following TLR activation, which may 
indicate their involvement in the trafficking of cytokines or chemokines that the cell 
secretes in response to the particular TLR ligand. We demonstrate differential 
expression of SNARE mRNA in response TLR ligands. Interestingly, not all 
SNARE expression was modulated. Apart from the obvious lack of involvement in 
functional SNARE complexes in DC secretion, we propose this may be due to other 
reasons. For example, VAMP8 has previously been implicated in DC function 
however we showed that there was no change in its expression (Ho et al. 2008). This 
may be explained by the fact that VAMP8 expression has been reported to be 
regulated by caspases and degraded by microRNA-96 (Ho et al. 2009, Kondkar et al. 
2010). Thus post transcriptional regulation may be involved in SNARE expression. 
It has also been reported that SNAREs involved in membrane fusion are recycled 
many times before being used up (Malsam, Kreye and Soellner 2008), therefore it 
may not be necessary for the cell to turn on transcription. 
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STX3 expression was up-regulated following DC activation. Indeed, STX3 
expression was significantly increased in vivo and in vitro. Of particular interest to us 
was the fact that STX3 expression in JAWSII DCs was up-regulated significantly in 
response to LPS and Loxoribine but not to PGN stimulation. Given our data on the 
cytokines and chemokines that these cells secreted in response to these ligands, we 
were able to correlate expression of STX3 with IL-6 secretion. STX3 was also 
identified to be significantly up-regulated in vivo in colitis models of disease which 
interestingly correlated with increased mRNA expression of IL-6, TNF-α, MIP-1α, 
MIP-2 and MCP in the colon.The concept of SNARE up-regulation paralleled with 
cytokine up-regulation has proven useful in other studies. The novel SNARE 
complex involved in the secretion of TNF-α in macrophage, STX6 and Vti1b was 
also identified in this manner (Murray et al. 2005b).We then went on to prove a role 
for STX3 in IL-6 (and partially MIP-1α) secretion through abolishment of STX3 in 
DCs by means of neutralising antibodies and RNAi, and investigation of subcellular 
STX3 in IL-6 secreting DCs. 
 
IL-6 is a multifunctional cytokine that regulates the immune response, 
hematopoiesis, the acute phase response and inflammation. It has been implicated in 
several disease processes such as IBD, RA, systemic-onset juvenile chronic arthritis 
(JCA), osteoporsis and psoriasis ((Ishihara and Hirano 2002). These studies suggest 
that blockade of IL-6 may represent a potential therapeutic target in inflammatory 
disease. Indeed, administration of an anti-IL-6 monoclonal antibody to patients with 
refractory RA has been shown to improve patient pain in a number of arthritic joints, 
which lasted for two months (Feldmann, Brennan and Maini 1996). Recently, IL-6 
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has been indicated to have a role in differentiation of Th17 subset with TGF-β, and 
its blockade may also be an advantage in Th17-related diseases (Park et al. 2005).  
 
We did observe some evidence to suggest that MIP-1α secretion may also be 
mediated by STX3. This was of interest to us as a previous group identified that 
STX3 and SNAP-23 were required for chemokine release from human mast cells 
(frank et al). MIP-1 proteins are involved in the pathogenesis of diseases such as 
asthma, granuloma formation, wound healing, arthrisis and multiple sclerosis 
(Maurer and von Stebut 2004). MIP-1α has also been indicated in IBD. Systemic 
administration of MIP-1α has been shown to exacerbate colitis in a mouse model, 
increasing the numbers of infiltrating CD4 cells and increased IFN-γ and TNF-α 
levels (Pender et al. 2005). The CCR1 and CCR3 antagonist, UCB35625, has been 
developed which changes the responses of MIP-1α and MCP-4 from eosinophils and 
is currently in clinical trails for the treatment of eosinophil-mediated inflammatory 
disorders, such as asthma (Sabroe et al. 2000).  
 
Given the evidence to show that IL-6 and MIP-1α are involved in the pathogenesis 
of inflammatory disease, and now our findings that STX3 is involved in their 
secretion from DCs, blockade of their secretion from DCs through inhibition of this 
SNARE protein may prove an effective therapy in such diseases. Interestingly in RA, 
which is characterised by up-regulation of pro-inflammatory cytokines, patients have 
been treated successfully with intra-articular Botulinum Toxin (BoNT) A (Feldmann, 
Brennan and Maini 1996, Mahowald, Singh and Dykstra 2006). BoNTs are produced 
by various species of species of Clostridia and cleave specific proteins of SNARE 
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complexs. BoNT/A injections significantly improved joint pain by up to 55%, with 
no immediate or delayed adverse reactions to the injections of toxin which further 
supports our idea that regulation of cytokine secretion by SNARE inactivation may 
yield effective therapies in inflammatory disease (Borodic, Acquadro and Johnson 
2001).  
 
The importance of SNAREs proteins is further highlighted by the disease, familial 
hemophagocytic lymphohistiocytosis type-4 (FHL-4), which is the result of STX11 
protein dysregulation. Patients with this disease present with FHL-4 with symptoms 
including high levels of pro-inflammatory cytokines (IFN-γ, IL-6, TNF and IL-18), 
higher numbers of activated, incorrectly phagocyotsing macrophage and defective 
CTL and NK cells (D'Orlando et al. 2013, Gholam et al. 2011).  
 
For this reason and the fact that we showed STX11 expression to be highly up-
regulated in vivo and in vitro, we identified STX11 as another important SNARE in 
DC secretion. Following TLR2, 4 and 7 activation there was significant up-
regulation of STX11 in JAWSII DCs and during early acute inflammation of DSS its 
expression was up-regulated in parallel with IL-6, TNF-α, IFN-γ, MIP-1α, MIP-2 
and MCP. Furthermore, in the C. rodentium model of colitis, STX11 was up-
regulated in parallel with IL-6, TNF-α, IFN-γ and MCP-1.  To investigate the role of 
this SNARE further, we employed the use of a STX11 deficient mouse model. 
Unlike STX3 where abolishment resulted in suppression of cytokine and chemokine 
secretion, STX11 deficiency resulted in a significant up-regulation of the IL-12 
family and the expression of important cell surface markers and down-regulation of 
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CD11c DC surface marker in un-stimulated Stx11
-/-
 BMDCs compared to WT 
BMDCs. These significant phenotypical changes in un-stimulated resting Stx11
-/-
 
BMDCs compared to WT BMDCs led us to believe that Stx11
-/-
 BMDCs display a 
more mature phenotype than WT BMDCs.  
 
IFN-γ, a known DC modulator, was up-regulated in resting and stimulated Stx11-/- 
BMDCs compared to WT BMDCs. We, in this study, and others show that BMDCs 
grown in IFN-γ have characteristics similar to Stx11-/- BMDCs. Given the fact that 
IFN-γ has previously been reported to be up-regulated in CTLs and NK cells isolated 
from Stx11
-/-
 mouse and as STX11 has been reported to act is a negative regulator by 
binding to the SNARE Vti1b in a non-traditional trans-SNARE complex 
(Offenhaeuser et al. 2011), we proposed that STX11 negatively regulates IFN-γ 
secretion from BMDCs.  
 
To support this hypothesis we demonstrated that STX11 expression was up-
regulated in parallel with IFN-γ expression and secretion in WT BMDCs. This was 
further supported by our data showing the reversal of the Stx11
-/-
 BMDCs phenotype 
with an α-IFN-γ antibody. IFN-γ primed BMDCs have been reported to have an 
impaired ability to prime T cells, therefore we examined a number of parameters 
relevant to this. We showed that expression of PD-L1, a co-inhibitory marker on 
DCs for T cell activation was more highly up-regulated on Stx11
-/-
 BMDCs 
compared to WT DCs. This expression was reversed to normal levels with addition 
of an α-IFN antibody. In a T cell:Stx11-/- BMDC co-culture, proliferation remained 
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unchanged but importantly T cell cytokines such as IL-2, important in the growth 
and proliferation of T cells, were significantly down-regulated.  
 
T cells are reported to be tolerogenic or anergic when they fail to respond to their 
specific antigen (Schwartz 2003). We showed that Stx11
-/-
 BMDCs had increased 
levels of the co-inhibitory marker PD-L1 and the co-cultured T cells showed 
inhibition of cytokine secretion. However, these hyporesponsive T cells did not show 
any signs of inhibition of proliferation or arrested growth, both signs of T cells 
anergy. Hence more work in this area would need to be carried out to fully define the 
consequences of lack of regulated IFNγ in DCs for subsequent T cell activation.  
 
Other work in our lab has pointed to a role for STX11 in T helper cells. We have 
identified differential expression of STX11 in Th1 and Th17 cells.  High levels of 
STX11 and IFNγ in Th17 cells suggested a role for STX11 in Th17 differentiation as 
suppression of IFNγ is necessary for efficient Th17 differentiation. Indeed STX11 
deficient mice were unable to differentiate into a Th17 subset due to the aberrant 
expression of IFN-γ. (DeCourcey, Unpublished). 
 
IFN-γ has been implicated in many inflammatory diseases, indeed we identified it to 
its expressed in two mouse models of disease that we examined. Administration of 
IFN-γ to mouse models of CIA has been shown to accelerate disease onset and 
incidence, and treatment of CIA with an α-IFN-γ antibody resulted in reduced 
severity of disease and lower anti-collagen antibody levels (Chen and Liu 2009). 
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However, this was dependant on the stage of treatment; at later stages of disease 
treatment with this antibody aggravated the arthritis. We have shown that IFN-γ 
treatment can promote the expression of the suppressive molecule PD-L1 and which 
has the ability to antagonize Th17 cell development. This could conversely be a 
treatment of Th17 mediated diseases such as psoriasis, RA, MS, IBD and asthma.  
Subsequently, further investigation of IFNγ role in disease and its regulation in these 
Th17 mediated diseases could provide insight to its therapeutic potential.  
 
It is important to note that secretion of the negative regulator of inflammation, 
Flightless (Flii), a gelsolinsuperafamily protein member has been reported to be 
regulated by Rab7 and STX11 in macrophage (Lei et al. 2012, Dai et al. 2009). It 
does so through a number of intracellular mechanisms including directly interfering 
with the formation of the TLR4-MyD88 signalling complex, resulting in reduced 
activation of NF-κB (Dai et al. 2009, Wang et al. 2006). Lei et al., also suggest that 
Flii is secreted and can bind to LPS acting as a scavenger mopping up excess LPS 
and preventing hyper-activation of the immune system. In the absence of 
extracellular Flii, LPS activation of macrophage leads to increased TNF secretion 
and enhanced macrophage activation. (Lei et al. 2012). Although we didn’t report a 
change in TNF-α expression in the Stx11-/- BMDCs compared to WT BMDCs, Flii’s 
secretion is regulated by STX11 and as FLii is indicated to negatively regulate 
inflammation, it would be interesting to look at Flii expression in the Stx11
-/-
 
BMDCs compared to WT BMDCs.  
 
CHAPTER 6                                                                 GENERAL DISCUSSION 
248 
 
In conclusion we have identified two important SNARE proteins that play key roles 
in DCs. STX3 mediates secretion of IL-6 from DCs. Given the significance of IL-6 
in mediating inflammatory disease, our findings suggest that STX3 could be a 
potential target in such diseases to block secretion of this important cytokine. We 
also provided evidence that STX3 may also play a role in MIP-1α secretion which 
could also provide useful in regulating inflammation. We also present a negative 
regulatory role for STX11 in IFNγ secretion and demonstrate an altered DC 
phenotype in STX11 deficient mice which may have consequences for subsequent T 
cell activation. Further characterisation of SNARE proteins in inflammatory disease 
may uncover a novel group of proteins which can be targeted to regulate 
inflammation.  
The importance of future work into the SNARE complexes is highlighted by the 
award of a Nobel Prize to the initial researchers in this area who identified and 
functionally characterised these proteins and their involvement in trafficking. As 
trafficking underpins nearly all cell functions in particular the secretion of immune 
mediators, it would also be medically important to fully elucidate all steps involved 
in immune trafficking. As this work as identified two SNAREs, STX3 and STX11 
involved in pathways of DC secretion, more work looking at their SNARE partners 
by means of co precipitation, location identification within the post-golgi domain (on 
secretory vesicles or the plasma membrane) would help elucidate the entire 
trafficking pathways of the cytokines or chemokines such as IL-6 and IFN-γ. This 
consequently could be used for therapeutic targets in the treatment of Th17 or Th1 
mediated immune diseases where secretion of these cytokines from DCs contributes 
to the differentiation of T helper cell subsets.   
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APPENDIX A     MEDIA AND BUFFERS 
 
CELL CULTURE MEDIA 
 
COMPLETE α-MEM     500ml 
Non-heat inactivated Foetal Calf Serum (FCS)  10% 
Penicillin/Streptomycin/L-glutamine             100μg/ml:100μg/ml:2mM 
Gentamycin       50μg/ml 
rGMCSF       5ng/ml 
 
 
COMPLETE RPMI 1640     500ml 
Heat inactivated Foetal Calf Serum (FCS   5% 
Penicillin/Streptomycin/L-glutamine             100μg/ml:100μg/ml:2mM 
 
 
10X PHOSPHATE BUFFERED SALINE (PBS) 
Na2HPO4.2H2O      8 mM 
KH2PO4       1.5 mM 
NaCl        137 mM 
KCl        2.7 mM  
Dissolved in dH2O to a  pHof 7.4 
 
 
10 X TRIS BUFFERED SALINE (TBS) pH 7.6 
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NaCl        1.5M 
Trizma Base       0.2M 
Dissolve dH2O pH to 7.6 
 
2N H2SO4 
H2SO4 (36 N)       11.1 ml 
dH2O        88.9 ml 
 
FACS BUFFER  
FCS        2% 
NaN3        0.05% 
EDTA        0.5M 
 
Dissolved PBS and 0.2μM filtered before use 
 
NP-40 LYSIS BUFFER 
Tris HCL (pH 7.5)      50mM 
NaCl        150mM 
Igepal        0.5% 
Protease Inhibitor Cocktail     1% 
Phosphatase Inhibitor Cocktail     1% 
 
 
 
5X SAMPLE BUFFER 
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125 mM Tris           6.25 ml 1M Tris HCl pH 6.8 
10 % Glycerol       5 ml 
2 % Sodium dodecyl sulphate (SDS)    10 ml (10 % (w/v) SDS) 
0.05% (w/v)Bromophenol Blue    0.01 g 
dH2O        28.75 ml 
0.25 M Dithiothreitol (DTT)*    250 μl 1 M DTT  
* Added to 1 ml 5X Sample Buffer just before use 
 
SEPARATING GEL (10% (v/v)) 
Acrylamide/Bisacrylamide (30% stock)    33% w/v 
Tris-HCl pH8.8       1.5M 
SDS         1% w/v 
Ammonium persulpate      0.5% w/v 
TEMED        0.1% v/v 
Dissolved in dH2O 
STACKING GEL 
Acrylamide/Bisacrylamide (30% stock)    6.5% v/v 
Tris-HCl pH6.8       0.5M 
SDS         1% w/v 
Ammonium persulphate      0.5% w/v 
TEMED        0.1% v/v 
Dissolved in dH2O 
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ELECTRODE RUNNING BUFFER  
Tris base         25mM 
Glycine         200mM 
SDS         17mM 
Dissolved in dH2O 
 
50X TAE Buffer  
 
Tris Base         40mM 
Glacial Acetic Acid       20mM 
EDTA          1mM 
Dissolved in dH2O and pH to 8.5 
 
PARFORMALDEHYDE  
Paraformaldehyde        3% (w/v)  
0.1M NaOH        500 ml  
Place in a 70oC shaking water bath until dissolved (15mins). Cool to room 
temperature and pH with HCl to 7.2.  
PERMABLOCK SOLUTION 
Saponin        0.1% (v/v)  
Fish gelatine         0.25% (v/v)  
Sodium Azide        0.02% (w/v)  
PBS          10 ml  
All microscopy solutions were 0.2μM filtered before use. 
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APPENDIX B   PRIMER TEMPERATURE GRADIENTS  
 
FIGURE A: Assay Validation: Primer Temperature Gradient for STX-2. RT-
qPCR was performed using STX-2 primers. Master mix was prepared and split into 
six individual PCR tubes containing cDNA of LPS 100 ng/ml JAWS II DCs. Each 
mix was subjected to different temperatures ranging from 55-65 
o
C degrees.  
 
TABLE A: Assay Validation: Primer Temperature Gradient for all primers. 
RT-qPCR was performed using specific primers. Master mix was prepared and split 
into six individual PCR tubes containing cDNA of LPS 100 ng/ml JAWS II DCs. 
Each mix was subjected to different temperatures ranging from 55-65
o
C degrees 
Primer 
Temperature Gradient 
producing product 
Temperature 
used in RT-qPCR 
SNAP-23 55-63
o
C 60
o
C 
STX-2 55-63
o
C 60
o
C 
STX-3 55-61
o
C 60
o
C 
STX-4 55-63
o
C 60
o
C 
STX-5 55-63
o
C 60
o
C 
STX-6 55-63
o
C 60
o
C 
STX-7 55-63
o
C 60
o
C 
STX-11 55-61
o
C 60
o
C 
STX-12 55-63
o
C 60
o
C 
STX-16 55-63
o
C 60
o
C 
Vti1a 55-61
o
C 60
o
C 
Vti1b 55-61
o
C 60
o
C 
Vamp-1 55-61
o
C 60
o
C 
Vamp-2 59-65
o
C 60
o
C 
Vamp-3 59-65
o
C 60
o
C 
Vamp-4 59-65
o
C 60
o
C 
Vamp-7 55-61
o
C 60
o
C 
Vamp-8 55-65
o
C 60
o
C 
Mip-1α 55-61
o
C 60
o
C 
Mip-2 55-61
o
C 60
o
C 
MCP 55-61
o
C 60
o
C 
IL-6 55-61
o
C 60
o
C 
IFN-γ 55-61
o
C 60
o
C 
S18 55-63
o
C 60
o
C 
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APPENDIX C  STX 3 TRANSFECTION DATA  
 
FIGURE B: Transfection Efficiency: JAWS II were differentiated in the presence 
of r-JAWSII DCs were transfected with siRNA against negative control non-
silencing Cy-3 postivesiRNA. At 24h after the transfection cells were washed and 
read by FACS Aria. Results of flow cytometric analysis and corresponding MFI 
values are shown. Control DCs (grey filled histogram) vs Cy3-postiive transfected 
stimulated DCs (red/blue line). Profiles are shown for a single experiment and are 
representative of three experiments. 
 
 
 
 
 
 
 
FIGURE C: Knockdown Efficiency: JAWS II were differentiated in the presence 
of r-JAWSII DCs were transfected with siRNA against negative control non-
silencing Cy-3 postivesiRNA. At 24h after the transfection cells were lysed and 
immunoblotted for STX-3 (β-actin used as a loading control). Profiles are shown for 
a single experiment and are representative of three experiments.  
CTL         Scram  STX3 #1     STX3#2 
        1nM   1nM           1nM 
STX3 
       
 
β-actin  
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APPENDIX D STX-11 EXPRESSION IN WT AND STX-11
-/- 
 BMDCS 
 
 
 
FIGURE D: mRNA expression of STX-11 in WT AND STX-11
-/- 
 BMDCs. WT 
and STX 11
-/- 
BMDCs were plated 1x10
6/
ml and stimulated with 100ng/ml LPS and 
100μg/ml rIL-12, 2μM CpG, 5μg/ml PGN or 1μg/ml PAM for 6 hours. The amount 
of target mRNA was quantified by reverse transcription followed by RT-qPCR using 
an ABI 7900 HT detection system. PCR products were run out on a 1% agarose gel 
and STX-11 was detected at its respective bp product size. 
 
 
 
 
 257 
 
 
 
 
 
 
 
BIBLIOGRAPHY 
                                                               BIBLIOGRAPHY 
258 
 
Akira, S. and Hemmi, H. 2003. Recognition of pathogen-associated molecular 
patterns by TLR family. Immunology Letters, 85(2), pp.85-95.  
Alex, P., Zachos, N.C., Nguyen, T., Gonzales, L., Chen, T., Conklin, L.S., Centola, 
M. and Li, X. 2009. Distinct cytokine patterns identified from multiplex profiles of 
murine DSS and TNBS-induced colitis. Inflammatory Bowel Diseases, 15(3), 
pp.341-352.  
Atlashkin, V., Kreykenbohm, V., Eskelinen, E.L., Wenzel, D., Fayyazi, A. and von 
Mollard, G.F. 2003. Deletion of the SNARE vti1b in mice results in the loss of a 
single SNARE partner, syntaxin 8. Molecular and Cellular Biology, 23(15), 
pp.5198-5207.  
BALCH, W., DUNPHY, W., BRAELL, W. and ROTHMAN, J. 1984. 
Reconstitution of the transport of protein between successive compartments of the 
golgi measured by the coupled incorporation of N-acetylglucosamine. Cell, 39(2), 
pp.405-416.  
Banchereau, J. and Steinman, R.M. 1998a. Dendritic cells and the control of 
immunity. Nature, 392(6673), pp.245-252.  
Banchereau, J. and Steinman, R. 1998b. Dendritic cells and the control of immunity. 
Nature, 392(6673), pp.245-252.  
Baumgarth, N. and Roederer, M. 2000. A practical approach to multicolor flow 
cytometry for immunophenotyping. Journal of Immunological Methods, 243(1-2), 
pp.77-97.  
                                                               BIBLIOGRAPHY 
259 
 
Bennett, M.K., Garciaarraras, J.E., Elferink, L.A., Peterson, K., Fleming, A.M., 
Hazuka, C.D. and Scheller, R.H. 1993. The syntaxin family of vesicular transport 
receptors. Cell, 74(5), pp.863-873.  
Berndt, B.E., Zhang, M., Chen, G., Huffnagle, G.B. and Kao, J.Y. 2007. The role of 
dendritic cells in the development of acute dextran sulfate sodium colitis. Journal of 
Immunology, 179(9), pp.6255-6262.  
Bhinder, G., Sham, H.P., Chan, J.M., Morampudi, V., Jacobson, K. and Vallance, 
B.A. 2013. The citrobacter rodentium mouse model: Studying pathogen and host 
contributions to infectious colitis. Journal of Visualized Experiments : JoVE, (72), 
pp.e50222-e50222.  
Blanco, P., Palucka, A.K., Pascual, V. and Banchereau, J. 2008. Dendritic cells and 
cytokines in human inflammatory and autoimmune diseases. Cytokine & Growth 
Factor Reviews, 19(1), pp.41-52.  
Block, M., Glick, B., Wilcox, C., Wieland, F. and Rothman, J. 1988. Purification of 
an N-ethylmaleimide-sensitive protein catalyzing vesicular transport. Proceedings of 
the National Academy of Sciences of the United States of America, 85(21), pp.7852-
7856.  
Boismenu, R. and Chen, Y.P. 2000. Insights from mouse models of colitis. Journal 
of Leukocyte Biology, 67(3), pp.267-278.  
Borodic, G.E., Acquadro, M. and Johnson, E.A. 2001. Botulinum toxin therapy for 
pain and inflammatory disorders: Mechanisms and therapeutic effects. Expert 
Opinion on Investigational Drugs, 10(8), pp.1531-1544.  
                                                               BIBLIOGRAPHY 
260 
 
Bostrom, P., Andersson, L., Vind, B., Haversen, L., Rutberg, M., Wickstrom, Y., 
Larsson, E., Jansson, P., Svensson, M.K., Branemark, R., Ling, C., Beck-Nielsen, 
H., Boren, J., Hojlund, K. and Olofsson, S. 2010. The SNARE protein SNAP23 and 
the SNARE-interacting protein Munc18c in human skeletal muscle are implicated in 
insulin Resistance/Type 2 diabetes. Diabetes, 59(8), pp.1870-1878.  
Bustin, S.A., Benes, V., Garson, J.A., Hellemans, J., Huggett, J., Kubista, M., 
Mueller, R., Nolan, T., Pfaffl, M.W., Shipley, G.L., Vandesompele, J. and Wittwer, 
C.T. 2009. The MIQE guidelines: Minimum information for publication of 
quantitative real-time PCR experiments. Clinical Chemistry, 55(4), pp.611-622.  
Cai, D.T., Ho, Y.H.S., Chiow, K.H., Wee, S.H., Han, Y., Peh, M.T. and Wong, S.H. 
2011. Aspirin regulates SNARE protein expression and phagocytosis in dendritic 
cells. Molecular Membrane Biology, 28(2), pp.90-102.  
Carmosino, M., Valenti, G., Caplan, M. and Svelto, M. 2010. Polarized traffic 
towards the cell surface: How to find the route. Biology of the Cell, 102(2), pp.75-91.  
Chan, V.W.F., Kothakota, S., Rohan, M.C., Panganiban-Lustan, L., Gardner, J.P., 
Wachowicz, M.S., Winter, J.A. and Williams, L.T. 1999. Secondary lymphoid-tissue 
chemokine (SLC) is chemotactic for mature dendritic cells. Blood, 93(11), pp.3610-
3616.  
Chen, J. and Liu, X. 2009. The role of interferon gamma in regulation of CD4(+) T-
cells and its clinical implications. Cellular Immunology, 254(2), pp.85-90.  
                                                               BIBLIOGRAPHY 
261 
 
Clary, D.O., Griff, I.C. and Rothman, J.E. 1990. Snaps, a family of nsf attachment 
proteins involved in intracellular membrane-fusion in animals and yeast. Cell, 61(4), 
pp.709-721.  
Collison, L.W., Workman, C.J., Kuo, T.T., Boyd, K., Wang, Y., Vignali, K.M., 
Cross, R., Sehy, D., Blumberg, R.S. and Vignali, D.A.A. 2007. The inhibitory 
cytokine IL-35 contributes to regulatory T-cell function. Nature, 450(7169), pp.566-
U19.  
Creagh, E.M. and O'Neill, L.A.J. 2006. TLRs, NLRs and RLRs: A trinity of 
pathogen sensors that co-operate in innate immunity. Trends in Immunology, 27(8), 
pp.352-357.  
Cua, D.J., Sherlock, J., Chen, Y., Murphy, C.A., Joyce, B., Seymour, B., Lucian, L., 
To, W., Kwan, S., Churakova, T., Zurawski, S., Wiekowski, M., Lira, S.A., Gorman, 
D., Kastelein, R.A. and Sedgwick, J.D. 2003. Interleukin-23 rather than interleukin-
12 is the critical cytokine for autoimmune inflammation of the brain. Nature, 
421(6924), pp.744-748.  
Dai, P., Jeong, S.Y., Yu, Y., Leng, T., Wu, W., Xie, L. and Chen, X. 2009. 
Modulation of TLR signaling by multiple MyD88-interacting partners including 
leucine-rich repeat fli-I-interacting proteins. Journal of Immunology, 182(6), 
pp.3450-3460.  
De Koker, S., Lambrecht, B.N., Willart, M.A., van Kooyk, Y., Grooten, J., Vervaet, 
C., Remon, J.P. and De Geest, B.G. 2011. Designing polymeric particles for antigen 
delivery. Chemical Society Reviews, 40(1), pp.320-339.  
                                                               BIBLIOGRAPHY 
262 
 
de la Rosa, M., Rutz, S., Dorninger, H. and Scheffold, A. 2004. Interleukin-2 is 
essential for CD4(+)CD25(+) regulatory T cell function. European Journal of 
Immunology, 34(9), pp.2480-2488.  
Dearman, R.J., Cumberbatch, M., Maxwell, G., Basketter, D.A. and Kimber, I. 2009. 
Toll-like receptor ligand activation of murine bone marrow-derived dendritic cells. 
Immunology, 126(4), pp.475-484.  
Didierlaurent, A., Ferrero, I., Otten, L.A., Dubois, B., Reinhardt, M., Carlsen, H., 
Blomhoff, R., Akira, S., Kraehenbuhl, J.P. and Sirard, J.C. 2004. Flagellin promotes 
myeloid differentiation factor 88-dependent development of Th2-type response. 
Journal of Immunology, 172(11), pp.6922-6930.  
D'Orlando, O., Zhao, F., Kasper, B., Orinska, Z., Mueller, J., Hermans-Borgmeyer, 
I., Griffiths, G.M., Stadt, U.Z. and Bulfone-Paus, S. 2013. Syntaxin 11 is required 
for NK and CD8(+) T-cell cytotoxicity and neutrophil degranulation. European 
Journal of Immunology, 43(1), pp.194-208.  
Dowling, D., Hamilton, C.M. and O'Neill, S.M. 2008. A comparative analysis of 
cytokine responses, cell surface marker expression and MAPKs in DCs matured with 
LPS compared with a panel of TLR ligands. Cytokine, 41(3), pp.254-262.  
Dziarski, R. 2003. Recognition of bacterial peptidoglycan by the innate immune 
system. Cellular and Molecular Life Sciences, 60(9), pp.1793-1804.  
Egger, B., Bajaj-Elliott, M., MacDonald, T., Inglin, R., Eysselein, V. and Buchler, 
M. 2000. Characterisation of acute murine dextran sodium sulphate colitis: Cytokine 
profile and dose dependency. Digestion, 62(4), pp.240-248.  
                                                               BIBLIOGRAPHY 
263 
 
Farquhar, M.G. and Palade, G.E. 1998. The golgi apparatus: 100 years of progress 
and controversy. Trends in Cell Biology, 8(1), pp.2-10.  
Feldmann, M., Brennan, F. and Maini, R. 1996. Role of cytokines in rheumatoid 
arthritis. Annual Review of Immunology, 14pp.397-440.  
Frank, S.P.C., Thon, K., Bischoff, S.C. and Lorentz, A. 2011. SNAP-23 and 
syntaxin-3 are required for chemokine release by mature human mast cells. 
Molecular Immunology, 49(1-2), pp.353-358.  
Frucht, D., Fukao, T., Bogdan, C., Schindler, H., O'Shea, J. and Koyasu, S. 2001. 
IFN-gamma-production by antigen-presenting cells: Mechanisms emerge. Trends in 
Immunology, 22(10), pp.556-560.  
Galli, S., Kalesnikoff, J., Grimbaldeston, M., Piliponsky, A., Williams, C. and Tsai, 
M. 2005. Mast cells as "tunable" effector and immunoregulatory cells: Recent 
advances. Annual Review of Immunology, 23pp.749-786.  
Gee, K., Guzzo, C., Mat, N.F.C., Ma, W. and Kumar, A. 2009. The IL-12 family of 
cytokines in infection, inflammation and autoimmune disorders. Inflammation & 
Allergy Drug Targets, 8(1), pp.40-52.  
Gholam, C., Grigoriadou, S., Gilmour, K.C. and Gaspar, H.B. 2011. Familial 
haemophagocytic lymphohistiocytosis: Advances in the genetic basis, diagnosis and 
management. Clinical and Experimental Immunology, 163(3), pp.271-283.  
Girolomoni, G., Lutz, M.B., Pastore, S., Abmann, C.U., Cavani, A. and 
Ricciardicastagnoli, P. 1995. Establishment of a cell-line with features of early 
                                                               BIBLIOGRAPHY 
264 
 
dendritic cell precursors from fetal mouse skin. European Journal of Immunology, 
25(8), pp.2163-2169.  
Gorden, K.B., Gorski, K.S., Gibson, S.J., Kedl, R.M., Kieper, W.C., Qiu, X.H., 
Tomai, M.A., Alkan, S.S. and Vasilakos, J.P. 2005. Synthetic TLR agonists reveal 
functional differences between human TLR7 and TLR8. Journal of Immunology, 
174(3), pp.1259-1268.  
Guo, Z.H., Turner, C. and Castle, D. 1998. Relocation of the t-SNARE SNAP-23 
from lamellipodia-like cell surface projections regulates compound exocytosis in 
mast cells. Cell, 94(4), pp.537-548.  
Haase, C., Michelsen, B.K. and Jorgensen, T.N. 2004. CD40 is necessary for 
activation of naive T cells by a dendritic cell line in vivo but not in vitro. 
Scandinavian Journal of Immunology, 59(3), pp.237-245.  
Hamerman, J.A., Ogasawara, K. and Lanier, L.L. 2005. NK cells in innate immunity. 
Current Opinion in Immunology, 17(1), pp.29-35.  
Hartgers, F., Figdor, C. and Adema, G. 2000. Towards a molecular understanding of 
dendritic cell immunobiology. Immunology Today, 21(11), pp.542-545.  
Hay, J. 2001. SNARE complex structure and function. Experimental Cell Research, 
271(1), pp.10-21.  
Higgins, L.M., Frankel, G., Douce, G., Dougan, G. and MacDonald, T.T. 1999. 
Citrobacter rodentium infection in mice elicits a mucosal Th1 cytokine response and 
lesions similar to those in murine inflammatory bowel disease. Infection and 
Immunity, 67(6), pp.3031-3039.  
                                                               BIBLIOGRAPHY 
265 
 
Ho, Y.H.S., Cai, D.T., Huang, D., Wang, C.C. and Wong, S.H. 2009. Caspases 
regulate VAMP-8 expression and phagocytosis in dendritic cells. Biochemical and 
Biophysical Research Communications, 387(2), pp.371-375.  
Ho, Y.H.S., Cai, D.T., Wang, C., Huang, D. and Wong, S.H. 2008. Vesicle-
associated membrane protein-8/endobrevin negatively regulates phagocytosis of 
bacteria in dendritic cells. Journal of Immunology, 180(5), pp.3148-3157.  
Hue, S., Ahern, P., Buonocore, S., Kullberg, M.C., Cua, D.J., McKenzie, B.S., 
Powrie, F. and Maloy, K.J. 2006. Interleukin-23 drives innate and T cell-mediated 
intestinal inflammation. Journal of Experimental Medicine, 203(11), pp.2473-2483.  
Huizing, M., Anikster, Y. and Gahl, W. 2000. Hermansky-pudlak syndrome and 
related disorders of organelle formation. Traffic, 1(11), pp.823-835.  
Ierino, F.L., Mulley, W., Dodge, N., Li, Y.Q., Mouhtouris, E., Christiansen, D. and 
Sandrin, M.S. 2010. Dendritic cells expressing soluble CTLA4Ig prolong antigen-
specific skin graft survival. Immunology and Cell Biology, 88(8), pp.846-850.  
Ishihara, K. and Hirano, T. 2002. IL-6 in autoimmune disease and chronic 
inflammatory proliferative disease. Cytokine & Growth Factor Reviews, 13(4-5), 
pp.357-368.  
Jahn, R. and Scheller, R.H. 2006. SNAREs - engines for membrane fusion. Nature 
Reviews Molecular Cell Biology, 7(9), pp.631-643.  
Jiang, X., Shen, C., Rey-Ladino, J., Yu, H. and Brunham, R.C. 2008. 
Characterization of murine dendritic cell line JAWS II and primary bone marrow-
                                                               BIBLIOGRAPHY 
266 
 
derived dendritic cells in chlamydia muridarum antigen presentation and induction of 
protective immunity. Infection and Immunity, 76(6), pp.2392-2401.  
Jorgensen, T.N., Haase, C. and Michelsen, B.K. 2002. Treatment of an immortalized 
APC cell line with both cytokines and LPS ensures effective T-cell activation in 
vitro. Scandinavian Journal of Immunology, 56(5), pp.492-503.  
Kawai, T. and Akira, S. 2006. TLR signaling. Cell Death and Differentiation, 13(5), 
pp.816-825.  
Kenny, E.F. and O'Neill, L.A.J. 2008. Signalling adaptors used by toll-like receptors: 
An update. Cytokine, 43(3), pp.342-349.  
Kimbrell, D.A. and Beutler, B. 2001. The evolution and genetics of innate immunity. 
Nature Reviews Genetics, 2(4), pp.256-267.  
Kondkar, A.A., Bray, M.S., Leal, S.M., Nagalla, S., Liu, D.J., Jin, Y., Dong, J.F., 
Ren, Q., Whiteheart, S.W., Shaw, C. and Bray, P.F. 2010. VAMP8/endobrevin is 
overexpressed in hyperreactive human platelets: Suggested role for platelet 
microRNA. Journal of Thrombosis and Haemostasis, 8(2), pp.369-378.  
Kondo, Y., Tachikawa, E., Ohtake, S., Kudo, K., Mizuma, K., Kashimoto, T., Irie, 
Y. and Taira, E. 2010. Inflammatory cytokines decrease the expression of nicotinic 
acetylcholine receptor during the cell maturation. Molecular and Cellular 
Biochemistry, 333(1-2), pp.57-64.  
Lacy, P. 2006. Mechanisms of degranulation in neutrophils. Allergy, Asthma, and 
Clinical Immunology : Official Journal of the Canadian Society of Allergy and 
Clinical Immunology, 2(3), pp.98-108.  
                                                               BIBLIOGRAPHY 
267 
 
Laroui, H., Ingersoll, S.A., Liu, H.C., Baker, M.T., Ayyadurai, S., Charania, M.A., 
Laroui, F., Yan, Y., Sitaraman, S.V. and Merlin, D. 2012. Dextran sodium sulfate 
(DSS) induces colitis in mice by forming nano-lipocomplexes with medium-chain-
length fatty acids in the colon. Plos One, 7(3), pp.e32084.  
Lavelle, E.C., Murphy, C., O'Neill, L.A.J. and Creagh, E.M. 2010. The role of TLRs, 
NLRs, and RLRs in mucosal innate immunity and homeostasis. Mucosal 
Immunology, 3(1), pp.17-28.  
Lee, J., Chuang, T.H., Redecke, V., She, L.P., Pitha, P.M., Carson, D.A., Raz, E. and 
Cottam, H.B. 2003. Molecular basis for the immunostimulatory activity of guanine 
nucleoside analogs: Activation of toll-like receptor 7. Proceedings of the National 
Academy of Sciences of the United States of America, 100(11), pp.6646-6651.  
Lei, N., Franken, L., Ruzehaji, N., Offenhaeuser, C., Cowin, A.J. and Murray, R.Z. 
2012. Flightless, secreted through a late endosome/lysosome pathway, binds LPS 
and dampens cytokine secretion. Journal of Cell Science, 125(18), pp.4288-4296.  
Lorentz, A., Baumann, A., Vitte, J. and Blank, U. 2012. The SNARE machinery in 
mast cell secretion. Frontiers in Immunology, 3pp.143.  
Low, S.H., Chapin, S.J., Weimbs, T., Komuves, L.G., Bennett, M.K. and Mostov, 
K.E. 1996. Differential localization of syntaxin isoforms in polarized madin-darby 
canine kidney cells. Molecular Biology of the Cell, 7(12), pp.2007-2018.  
Luckashenak, N., Schroeder, S., Endt, K., Schmidt, D., Mahnke, K., Bachmann, 
M.F., Marconi, P., Deeg, C.A. and Brocker, T. 2008. Constitutive crosspresentation 
                                                               BIBLIOGRAPHY 
268 
 
of tissue antigens by dendritic cells controls CD8(+) T cell tolerance in vivo. 
Immunity, 28(4), pp.521-532.  
Lutz, M., Kukutsch, N., Ogilvie, A., Rossner, S., Koch, F., Romani, N. and Schuler, 
G. 1999. An advanced culture method for generating large quantities of highly pure 
dendritic cells from mouse bone marrow. Journal of Immunological Methods, 
223(1), pp.77-92.  
Macdonald, T.T. 2011. New cytokine targets in inflammatory bowel disease. 
Gastroenterology & Hepatology, 7(7), pp.474-6.  
Mackay, V.L. and Moore, E.E.1997. Immortalized dendritic cells, 3.  
Mahowald, M., Singh, J. and Dykstra, D. 2006. Long term effects of intra-articular 
botulinum toxin A for refractory joint pain. Neurotoxicity Research, 9(2-3), pp.179-
188.  
Malsam, J., Kreye, S. and Soellner, T.H. 2008. Membrane fusion: SNAREs and 
regulation. Cellular and Molecular Life Sciences, 65(18), pp.2814-2832.  
Marcet-Palacios, M., Odemuyiwa, S.O., Coughlin, J.J., Garofoli, D., Ewen, C., 
Davidson, C.E., Ghaffari, M., Kane, K.P., Lacy, P., Logan, M.R., Befus, A.D., 
Bleackley, R.C. and Moqbel, R. 2008. Vesicle-associated membrane protein 7 
(VAMP-7) is essential for target cell killing in a natural killer cell line. Biochemical 
and Biophysical Research Communications, 366(3), pp.617-623.  
Marsh, R.A., Satake, N., Biroschak, J., Jacobs, T., Johnson, J., Jordan, M.B., 
Bleesing, J.J., Filipovich, A.H. and Zhang, K. 2010. STX11 mutations and clinical 
                                                               BIBLIOGRAPHY 
269 
 
phenotypes of familial hemophagocytic lymphohistiocytosis in north america. 
Pediatric Blood & Cancer, 55(1), pp.134-140.  
Martin-Martin, B., Nabokina, S.M., Lazo, P.A. and Mollinedo, F. 1999. Co-
expression of several human syntaxin genes in neutrophils and differentiating HL-60 
cells: Variant isoforms and detection of syntaxin 1. Journal of Leukocyte Biology, 
65(3), pp.397-406.  
Maurer, M. and von Stebut, E. 2004. Macrophage inflammatory protein-1. 
International Journal of Biochemistry & Cell Biology, 36(10), pp.1882-1886.  
McGettrick, A.F. and O'Neill, L.A.J. 2004. The expanding family of MyD88-like 
adaptors in toll-like receptor signal transduction. Molecular Immunology, 41(6-7), 
pp.577-582.  
McGettrick, A.F. and O'Neill, L.A.J. 2010. Localisation and trafficking of toll-like 
receptors: An important mode of regulation. Current Opinion in Immunology, 22(1), 
pp.20-27.  
Means, T.K., Hayashi, F., Smith, K.D., Aderem, A. and Luster, A.D. 2003. The toll-
like receptor 5 stimulus bacterial flagellin induces maturation and chemokine 
production in human dendritic cells. Journal of Immunology, 170(10), pp.5165-5175.  
Michelsen, K.S., Aicher, A., Mohaupt, M., Hartung, T., Dimmeler, S., Kirschning, 
C.J. and Schumann, R.R. 2001. The role of toll-like receptors (TLRs) in bacteria-
induced maturation of murine dendritic cells (DCs) - peptidoglycan and lipoteichoic 
acid are inducers of DC maturation and require TLR2. Journal of Biological 
Chemistry, 276(28), pp.25680-25686.  
                                                               BIBLIOGRAPHY 
270 
 
Mills, K.H.G. 2011. TLR-dependent T cell activation in autoimmunity. Nature 
Reviews Immunology, 11(12), pp.807-822.  
Mollinedo, F., Calafat, J., Janssen, H., Martin-Martin, B., Canchado, J., Nabokina, 
S.M. and Gajate, C. 2006. Combinatorial SNARE complexes modulate the secretion 
of cytoplasmic granules in human neutrophils. Journal of Immunology, 177(5), 
pp.2831-2841.  
Mundy, R., MacDonald, T., Dougan, G., Frankel, G. and Wiles, S. 2005. Citrobacter 
rodentium of mice and man. Cellular Microbiology, 7(12), pp.1697-1706.  
Murphy, C.A., Langrish, C.L., Chen, Y., Blumenschein, C., McClanahan, T., 
Kastelein, R.A., Sedgwick, J.D. and Cua, D.J. 2003. Divergent pro- and 
antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. 
Journal of Experimental Medicine, 198(12), pp.1951-1957.  
Murray, R.Z., Kay, J.G., Sangermani, D.G. and Stow, J.L. 2005a. A role for the 
phagosome in cytokine secretion. Science, 310(5753), pp.1492-1495.  
Murray, R.Z., Wylie, F.G., Khromykh, T., Hume, D.A. and Stow, J.L. 2005b. 
Syntaxin 6 and Vti1b form a novel SNARE complex, which is up-regulated in 
activated macrophages to facilitate exocytosis of tumor necrosis factor-alpha. 
Journal of Biological Chemistry, 280(11), pp.10478-10483.  
Ni, K. and ONeill, H.C. 1997. The role of dendritic cells in T cell activation. 
Immunology and Cell Biology, 75(3), pp.223-230.  
                                                               BIBLIOGRAPHY 
271 
 
Offenhaeuser, C., Lei, N., Roy, S., Collins, B.M., Stow, J.L. and Murray, R.Z. 2011. 
Syntaxin 11 binds Vti1b and regulates late endosome to lysosome fusion in 
macrophages. Traffic, 12(6), pp.762-773.  
Ohtsuka, Y. and Sanderson, I.R. 2003. Dextran sulfate sodium-induced inflammation 
is enhanced by intestinal epithelial cell chemokine expression in mice. Pediatric 
Research, 53(1), pp.143-147.  
O'Neill, L.A.J., Golenbock, D. and Bowie, A.G. 2013. The history of toll-like 
receptors - redefining innate immunity. Nature Reviews Immunology, 13(6), pp.453-
460.  
Pagan, J.K., Wylie, F.G., Joseph, S., Widberg, C., Bryant, N.J., James, D.E. and 
Stow, J.L. 2003. The t-SNARE syntaxin 4 is regulated during macrophage activation 
to function in membrane traffic and cytokine secretion. Current Biology, 13(2), 
pp.156-160.  
Pajtasz-Piasecka, E., Rossowska, J., Szyda, A., Krawczenko, A. and Dus, D. 2007. 
Generation of anti-tumor response by JAWS II mouse dendritic cells transduced with 
murine interleukin 12 genes. Oncology Reports, 17(5), pp.1249-1257.  
Pan, J., Zhang, M., Wang, J., Wang, Q., Xia, D., Sun, W., Zhang, L., Yu, H., Liu, Y. 
and Cao, X. 2004. Interferon-gamma is an autocrine mediator for dendritic cell 
maturation. Immunology Letters, 94(1-2), pp.141-151.  
Park, H., Li, Z., Yang, X., Chang, S., Nurieva, R., Wang, Y., Wang, Y., Hood, L., 
Zhu, Z., Tian, Q. and Dong, C. 2005. A distinct lineage of CD4 T cells regulates 
                                                               BIBLIOGRAPHY 
272 
 
tissue inflammation by producing interleukin 17. Nature Immunology, 6(11), 
pp.1133-1141.  
Parkin, J. and Cohen, B. 2001. An overview of the immune system. Lancet, 
357(9270), pp.1777-1789.  
Pender, S.L.F., Chance, V., Whiting, C.V., Buckley, M., Edwards, M., Pettipher, R. 
and MacDonald, T.T. 2005. Systemic administration of the chemokine macrophage 
inflammatory protein 1 alpha exacerbates inflammatory bowel disease in a mouse 
model. Gut, 54(8), pp.1114-1120.  
Perse, M. and Cerar, A. 2012. Dextran sodium sulphate colitis mouse model: Traps 
and tricks. Journal of Biomedicine and Biotechnology, pp.718617.  
Pickett, J. and Edwardson, J. 2006. Compound exocytosis: Mechanisms and 
functional significance. Traffic, 7(2), pp.109-116.  
Pinchuk, L.M., Lee, S. and Filipov, N.M. 2007. In vitro atrazine exposure affects the 
phenotypic and functional maturation of dendritic cells. Toxicology and Applied 
Pharmacology, 223(3), pp.206-217.  
Pulendran, B. 2004. Modulating vaccine responses with dendritic cells and toll-like 
receptors. Immunological Reviews, 199(1), pp.227-250.  
Puri, N., Kruhlak, M.J., Whiteheart, S.W. and Roche, P.A. 2003. Mast cell 
degranulation requires N-ethylmaleimide-sensitive factor-mediated SNARE 
disassembly. Journal of Immunology, 171(10), pp.5345-5352.  
                                                               BIBLIOGRAPHY 
273 
 
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S. and Medzhitov, R. 
2004. Recognition of commensal microflora by toll-like receptors is required for 
intestinal homeostasis. Cell, 118(2), pp.229-241.  
Rinehart, JJ., Keville, L. 1997. Effects of endotoxin on proliferation of human cell 
precursors. Cytotechnology, 24 (2), pp 153-9.  
Rojas, D. and Krishnan, R. 2010. IFN-gamma generates maturation-arrested 
dendritic cells that induce T cell hyporesponsiveness independent of Foxp3(+) T-
regulatory cell generation. Immunology Letters, 132(1-2), pp.31-37.  
Rongcun, Y., Maes, H., Corsi, M., Dellner, F., Wen, T. and Kiessling, R. 1998. 
Interferon gamma impairs the ability of monocyte-derived dendritic cells to present 
tumour-specific and allo-specific antigens and reduces their expression of CD1A, 
CD80 and CD4. Cytokine, 10(10), pp.747-755.  
Ruedl, C. and Hubele, S. 1997. Maturation of peyer's patch dendritic cells in vitro 
upon stimulation via cytokines or CD40 triggering. European Journal of 
Immunology, 27(6), pp.1325-1330.  
Sabroe, I., Peck, M., Van Keulen, B., Jorritsma, A., Simmons, G., Clapham, P., 
Williams, T. and Pease, J. 2000. A small molecule antagonist of chemokine 
receptors CCR1 and CCR3 - potent inhibition of eosinophil function and CCR3-
mediated HIV-1 entry. Journal of Biological Chemistry, 275(34), pp.25985-25992.  
Sallusto, F., Palermo, B., Lenig, D., Miettinen, M., Matikainen, S., Julkunen, I., 
Forster, R., Burgstahler, R., Lipp, M. and Lanzavecchia, A. 1999. Distinct patterns 
                                                               BIBLIOGRAPHY 
274 
 
and kinetics of chemokine production regulate dendritic cell function. European 
Journal of Immunology, 29(5), pp.1617-1625.  
Sallusto, F., Schaerli, P., Loetscher, P., Schaniel, C., Lenig, D., Mackay, C.R., Qin, 
S.X. and Lanzavecchia, A. 1998. Rapid and coordinated switch in chemokine 
receptor expression during dendritic cell maturation. European Journal of 
Immunology, 28(9), pp.2760-2769.  
Schekman, R. and Orci, L. 1996. Coat proteins and vesicle budding. Science, 
271(5255), pp.1526-1533.  
Schroder, K., Hertzog, P.J., Ravasi, T. and Hume, D.A. 2004. Interferon-gamma: An 
overview of signals, mechanisms and functions. Journal of Leukocyte Biology, 
75(2), pp.163-189.  
Schwartz, R. 2003. T cell anergy. Annual Review of Immunology, 21pp.305-334.  
Shen, T., Chen, X., Chen, Y., Xu, Q., Lu, F. and Liu, S. 2010. Increased PD-L1 
expression and PD-L1/CD86 ratio on dendritic cells were associated with impaired 
dendritic cells function in HCV infection. Journal of Medical Virology, 82(7), 
pp.1152-1159.  
Shiffman, D., Rowland, C.M., Louie, J.Z., Luke, M.M., Bare, L.A., Bolonick, J.I., 
Young, B.A., Catanese, J.J., Stiggins, C.F., Pullinger, C.R., Topol, E.J., Malloy, 
M.J., Kane, J.P., Ellis, S.G. and Devlin, J.J. 2006. Gene variants of VAMP8 and 
HNRPUL1 are associated with early-onset myocardial infarction. Arteriosclerosis 
Thrombosis and Vascular Biology, 26(7), pp.1613-1618.  
                                                               BIBLIOGRAPHY 
275 
 
Shirakawa, R., Higashi, T., Tabuchi, A., Yoshioka, A., Nishioka, H., Fukuda, M., 
Kita, T. and Horiuchi, H. 2004. Munc13-4 is a GTP-Rab27-binding protein 
regulating dense core granule secretion in platelets. Journal of Biological Chemistry, 
279(11), pp.10730-10737.  
Singh-Jasuja, H., Thiolat, A., Ribon, M., Boissier, M., Bessis, N., Rammensee, H. 
and Decker, P. 2013. The mouse dendritic cell marker CD11c is down-regulated 
upon cell activation through toll-like receptor triggering. Immunobiology, 218(1), 
pp.28-39.  
Smith, A.D., Botero, S., Shea-Donohue, T. and Urban, J.F.,Jr. 2011. The 
pathogenicity of an enteric citrobacter rodentium infection is enhanced by 
deficiencies in the antioxidants selenium and vitamin E. Infection and Immunity, 
79(4), pp.1471-1478.  
Steinman, R.M. 1998. Dendritic cells and the control of immunity. Experimental 
Hematology, 26(8), pp.681-681.  
Steinman, R.M. and Cohn, Z.A. 1973. Identification of a novel cell type in 
peripheral lymphoid organs of mice. Journal of Experimental Medicine, 137(5), 
pp.1142-1162.  
Stober, D., Schirmbeck, R. and Reimann, J. 2001. IL-12/IL-18-dependent IFN-
gamma release by murine dendritic cells. Journal of Immunology, 167(2), pp.957-
965.  
Stow, J.L. 2013. Nobel prize discovery paves the way for immunological traffic. 
Nature Reviews.Immunology, 13(12), pp.839-841.  
                                                               BIBLIOGRAPHY 
276 
 
Stow, J.L., Low, P.C., Offenhaeuser, C. and Sangermani, D. 2009. Cytokine 
secretion in macrophages and other cells: Pathways and mediators. Immunobiology, 
214(7), pp.601-612.  
Stow, J.L., Manderson, A.P. and Murray, R.Z. 2006a. SNAREing immunity: The 
role of SNAREs in the immune system. Nature Reviews Immunology, 6(12), pp.919-
929.  
Stow, J.L. and Murray, R.Z. 2013. Intracellular trafficking and secretion of 
inflammatory cytokines. Cytokine & Growth Factor Reviews, 24(3), pp.227-239.  
Sudhof, T.C. 1995. The synaptic vesicle cycle - a cascade of protein-protein 
interactions. Nature, 375(6533), pp.645-653.  
Sutton, R., Fasshauer, D., Jahn, R. and Brunger, A. 1998. Crystal structure of a 
SNARE complex involved in synaptic exocytosis at 2.4 angstrom resolution. Nature, 
395(6700), pp.347-353.  
Taylor, P.C. and Feldmann, M. 2009. Anti-TNF biologic agents: Still the therapy of 
choice for rheumatoid arthritis. Nature Reviews Rheumatology, 5(10), pp.578-582.  
Tchernev, V.T., Mansfield, T.A., Giot, L., Kumar, A.M., Nandabalan, K., Li, Y., 
Mishra, V.S., Detter, J.C., Rothberg, J.M., Wallace, M.R., Southwick, F.S. and 
Kingsmore, S.F. 2002. The chediak-higashi protein interacts with SNARE complex 
and signal transduction proteins. Molecular Medicine, 8(1), pp.56-64.  
Ungar, D. and Hughson, F.M. 2003. SNARE protein structure and function. Annual 
Review of Cell and Developmental Biology, 19pp.493-517.  
                                                               BIBLIOGRAPHY 
277 
 
Villadangos, J.A. and Schnorrer, P. 2007. Intrinsic and cooperative antigen-
presenting functions of dendritic-cell subsets in vivo. Nature Reviews Immunology, 
7(7), pp.543-555.  
Wang, T., Chuang, T., Ronni, T., Gu, S., Du, Y., Cai, H., Sun, H., Yin, H. and Chen, 
X. 2006. Flightless I homology negatively modulates the TLR pathway. Journal of 
Immunology, 176(3), pp.1355-1362.  
Weimbs, T., Low, S.H., Chapin, S.J., Mostov, K.E., Bucher, P. and Hofmann, K. 
1997. A conserved domain is present in different families of vesicular fusion 
proteins: A new superfamily. Proceedings of the National Academy of Sciences of 
the United States of America, 94(7), pp.3046-3051.  
Williams, R.O., Paleolog, E. and Feldmann, M. 2007. Cytokine inhibitors in 
rheumatoid arthritis and other autoimmune diseases. Current Opinion in 
Pharmacology, 7(4), pp.412-417.  
Wong, S., Zhang, T., Xu, Y., Subramaniam, V., Griffiths, G. and Hong, W. 1998. 
Endobrevin, a novel synaptobrevin/VAMP-like protein preferentially associated with 
the early endosome. Molecular Biology of the Cell, 9(6), pp.1549-1563.  
Woska, J.R.,Jr. and Gillespie, M.E. 2011. Small-interfering RNA-mediated 
identification and regulation of the ternary SNARE complex mediating RBL-2H3 
mast cell degranulation. Scandinavian Journal of Immunology, 73(1), pp.8-17.  
Xie, L., de la Iglesia-Vicente, J., Fang, Y. and Mollinedo, F. 2009. Expression and 
subcellular localization of syntaxin 11 in human neutrophils. Inflammation Research, 
58(7), pp.407-412.  
                                                               BIBLIOGRAPHY 
278 
 
Xue, M., Zhu, L., Meng, Y., Wang, L., Sun, H., Wang, F., Wang, E. and Shan, F. 
2013. Detailed modulation of phenotypes and functions of bone marrow dendritic 
cells (BMDCs) by interferon-gamma (IFN-gamma). International 
Immunopharmacology, 17(2), pp.366-372.  
Yan, Y., Kolachala, V., Dalmasso, G., Nguyen, H., Laroui, H., Sitaraman, S.V. and 
Merlin, D. 2009. Temporal and spatial analysis of clinical and molecular parameters 
in dextran sodium sulfate induced colitis. Plos One, 4(6), pp.e6073.  
Yoshizaki, K. 2009. A new therapeutic strategy for autoimmune and chronic 
inflammatory disease based on clinical results using IL-6 blocking therapy with a 
humanized anti-IL-6 receptor antibody. Yakugaku Zasshi-Journal of the 
Pharmaceutical Society of Japan, 129(6), pp.667-674.  
Zapala, L., Drela, N., Bil, J., Nowis, D., Basak, G.W. and Lasek, W. 2011. 
Optimization of activation requirements of immature mouse dendritic JAWSII cells 
for in vivo application. Oncology Reports, 25(3), pp.831-840.  
zur Stadt, U., Schmidt, S., Diler, A.S., Henter, J.I., Kabisch, H., Schneppenheim, R., 
Nurnberg, P., Janka, G. and Hennies, H.C. 2005. Linkage of familial 
hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and 
identification of mutations in syntaxin 11. Human Molecular Genetics, 14(6), 
pp.827-834.  
